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Summary 
The competence of oocytes to mature and undergo fertilization and embryonic 
development is known to be influenced by the conditions under which their 
maturation occurs. Suboptimal maturation in vitro currently limits the use of 
immature oocytes for embryo creation. This project examines the relationship 
between the conditions of in vitro maturation of human oocytes and aspects of their 
subsequent developmental competence through the in vitro creation and analysis of 
research embryos. This work is essential in defining effective and safe conditions for 
the use of human immature oocytes in programmes of clinical treatment to alleviate 
infertility. 
Human immature oocytes were exposed in vitro to various concentrations of meiosis 
activating sterol (FF-MAS), an endogenous mediator of follicle and oocyte function, 
or epidermal growth factor (EOP), in the absence of other hormonal support. Their 
survival and further development relative to controls were measured by assessing the 
proportions maturing, fertilizing by sperm injection (ICSI), and cleaving in vitro. 
Image analysis was used to measure various dimensions of oocytes and embryos 
daily. A pilot study of chromosome and spindle configurations at meiotic metaphase 
was also conducted. 
The major findings of this project are that FF-MAS supplementation of maturation 
medium has different positive effects upon immature oocytes arising from patient 
groups having different endocrine profiles and yielding differing oocyte populations. 
FF-MAS at 30J.lg/ml promotes survival of oocytes from unstimulated patients with 
polycystic ovaries (p<O.02S) and promotes maturation of oocytes from 
gonadotrophin-stimulated patients undergoing ICSI treatment (p<O.OS). A response to 
FF-MAS in terms of oocyte growth was evident in immature oocytes from both types 
of patients (p<O.05). Mature, immature and atretic oocytes from patients with pca 
became significantly different in terms of oocyte diameter when cultured in FF-MAS 
(10 or 30J.lg/ml), contrasting with those cultured in control conditions, or obtained 
from patients undergoing ICSI treatment. However, significant (p<O.OS) enlargement 
of oocyte diameter between oocyte recovery and the day of insemination occurred 
when oocytes from patients undergoing ICSI were cultured with FF-MAS. 
The proportion of mature oocytes fertilized by ICSI was not affected by FF-MAS in 
the maturation culture but there was a non-significant tendency towards an improved 
chance of cleavage when FF-MAS was present. Embryonic development beyond 
early cleavage was not observed, despite conditions supportive of blastocyst 
production from in vivo matured oocytes, suggesting that developmental competence 
remained compromised even in the presence of FF-MAS. A pilot study to ascertain 
whether the incidence of spindle defects or chromosome irregularities in in vitro 
matured metaphase oocytes was influenced by the presence of FF-MAS gave 
equivocal results. 
This project has confirmed that the ongoing development of in vitro matured oocytes 
may be affected by the conditions of their maturation. Specifically it has demonstrated 
for the first time the positi ve effects of FF-MAS upon human immature oocyte 
development in vitro, and provided the first quantitative non-invasive analysis of 
oocyte growth during maturation under various conditions in vitro. 
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Chapter 1 
Introduction 
''The shortage of human immature oocytes for research is the limiting factor in 
developing methods for using them in clinical practice" (Coskun et al., 1998). 
This thesis examines the maturation of human oocytes in vitro under a variety of 
conditions. This topic is important because little is known about human oocytes 
despite their widespread collection and use in infertility treatments. Oocytes are key 
cells, which embody the ovarian reserve of female gametes. They are laid down in 
early development and their quality is critical for embryo formation and the successful 
continuation of the human species. 
In 1935, Pincus and Enzmann for the first time observed in mammals that intact 
oocytes, isolated from antral follicles, proceed through meiotic maturation 
spontaneously. In 1939, Pincus and Saunders liberated rabbit and human oocytes from 
their follicles in vitro and demonstrated how both matured spontaneously in less than 
12 hours. This was originally considered as potentially the most appropriate way to 
obtain mature oocytes for in vitro fertilization (IVF) techniques (Edwards, 1965a). In 
retrospect, the time allowed for maturation of oocytes in vitro, based on the data of 
Pincus and Saunders (1939), was probably inadequate, judging from the work of 
Edwards (1965b). 
In 1966, Edwards et al. made attempts to fertilize human oocytes matured in vitro. 
Since Steptoe and Edwards achieved the first successful human pregnancy from IVF 
in 1978 (Steptoe and Edwards, 1978), assisted reproductive technology has become 
the frontier of both infertility treatment and research (Cha and Chian, 1998). Yet, in 
vitro maturation (IVM) remains a largely unsuccessful approach to the treatment of 
infertility despite its many prospective advantages over timed collection of mature 
oocytes. 
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1.1 Oocyte development 
1.1.1 Overview 
1.1.1.1 Summary of follicular growth 
The development of oocytes that are competent to become functional embryos is a 
prolonged process, starting in fetal life, when a stock of primordial follicles is formed. 
The oocytes are stored arrested at an immature stage of meiotic prophase, and are 
incompetent to develop further unless the follicle grows and provides an environment 
conducive to support full development. Ovulation does not occur until after puberty. 
In the human female, approximately seven million primordial follicles are initially 
formed; at birth this number has declined to 1-2 million primordial follicles, of these 
approximately 400 ovulate throughout the reproductive life, the rest undergoing 
atresia (Baker, 1963; Salha et al., 1998; Hardy et al., 2000). In one menstrual cycle of 
a mature woman, normally only a single dominant follicle achieves ovulation. 
There are three successive steps in the production of a dominant follicle (Salha et al., 
1998) 
• Growth of a daily cohort of primordial follicles. 
• Recruitment of several small antral follicles by waves of pituitary 
gonadotrophins. 
• Selection and maturation of the preovulatory follicle. 
Figure 1.1 provides a diagrammatic illustration of follicular growth in the human. 
Although follicle growth is a continuous process occurring from early infancy until 
the end of the reproductive phase, follicles do not attain ovulatory sizes or produce 
significant quantities of oestrogen during childhood due to the absence of FSH and 
LH stimulation. At puberty, coordinated cyclic gonadotrophin stimulation initiates the 
menses and results in oocyte maturation and ovulation at midcycle (Salha et al., 
1998). 
The mechanism that induces quiescent primordial follicles to commence growth and 
become follicles is not yet clear (Smitz et al., 1999). Growth of a human follicle takes 
at least 85 days from the primary to preovulatory stage (Gougeon, 1990) and 
granulosa cells surrounding the oocyte are in communication with the oocyte via gap 
junctions throughout all stages of follicular development. The zona pellucida is 
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secreted by the oocyte; it separates the oocyte from the surrounding granulosa cells 
and is penetrated by cytoplasmic processes from the granulosa cells, which interact 
with the gap junctions. The gap junctions form at the points where the cytoplasmic 
processes contact the oocyte surface, transferring nutrients and regulatory molecules 
into the oocyte and also between adjacent granulosa cells, providing the basis for 
intercellular communication and potential syncytial coordination of the follicle 
(Downs, 1995). 
At the primordial follicle stage, the oocyte measures approximately 30flm diameter 
(Gosden et ai., 1987). Oocyte growth and increased RNA polymerase activity is 
indicative of follicle growth initiation (Gosden et ai., 1993), and is followed by clonal 
and radial expansion of pregranulosa cells. At the preantral stage, the enlarged oocyte 
is encapsulated by >2 granulosa cell layers in close proximity without an antrum. 
By the antral stage in humans, it is widely believed that the oocyte has largely 
completed its growth, although full maturity is not attained until the completion of 
follicular development and ovulation. During the antral phase of follicular growth, the 
oocyte is embedded in a cumulus oophorus extending on a stalk into the fluid-filled 
antrum, the central cavity inside the developing follicle. The antrum occupies most of 
the volume of a Graafian follicle just prior to ovulation, and may serve to buffer the 
internal environment. At antrum formation a distinction occurs between different 
populations of granulosa cells, the inner cumulus cells continue growing and respond 
to FSH by mucification, whilst the outer mural granulosa cells stop division and 
express P4S0 aromatase and LH receptors (Gosden et al. 1993). 
3 
Figure 1.1 Stages of folliculogenesis in the adult human ovary and level of atresia 
in the eight classes of growing follicles. 
The granulosa cell (gc) numbers and their corresponding estimated follicle diameter 
indicate the limits of each class. 
(Taken from Gougeon, 1986) 
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1.1.1.2 Follicle selection 
The follicle selected to ovulate (dominant follicle) is normally the largest healthy 
follicle with a diameter of 5.5-8.2mm at the start of the follicular phase (Gougeon and 
Lefevre, 1983). Its granulosa cells are most responsive to FSH, and modulation of 
FSH sensitivity may be achieved by local growth factor involvement, for example, a 
timely and selective activation of insulin-like growth factor-l (lGF-1) in the chosen 
follicle, might promote cytodifferentation and proliferation of granulosa cells (Adashi, 
1993). 
The maturing follicle that achieves dominance does so via feedback inhibition of FSH 
secretion from the pituitary gland and increased sensitivity to FSH. The latter, 
combined with the fact that the dominant follicle requires less FSH to maintain 
preovulatory growth than is required to stimulate follicular growth at an earlier stage, 
enables the dominant follicle to inhibit the development of less mature follicles, 
without inhibiting its own growth (Salha et al., 1998). 
1.1.1.3 Maturation of the dominant follicle 
During the follicular phase, the preovulatory follicle increases in size by both cellular 
multiplication and fluid accumulation in the antrum until the ovulatory LH surge. The 
dominant follicle begins to synthesize systemically detectable oestradiol from the 
mid-follicular phase. As follicle maturation occurs, the granulosa cells acquire LH 
receptors in response to FSH stimulation, conferring responsiveness of large follicles 
but not smaller ones to LH. As preovulatory follicular maturation continues, the 
vascularity of the follicle increases, thereby increasing the deli very of gonadotrophin 
to the maturing follicle as well as the systemic availability of its products, notably 
steroids (Zeleznik et at., 1981). 
The preovulatory gonadotrophin surge stimulates oocyte maturation and cumulus 
expansion, meiotic maturation progresses from prophase I to metaphase II (MIl), 
reaching MIl approximately 36 hr after the stimulus (Edwards, 1965b). Alterations in 
the oocyte cytoplasm also occur, including an increased capacity for the release of 
intracellular calcium (Carroll et al., 1996), alteration of mRNA complement for 
fertilization and embryo growth prior to embryonic genome activation (Fulka et al., 
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1998) and peripheral migration of cortical granules (Hartshorne, 1999). Cumulus 
expansion is a result of hyaluronic acid-rich proteoglycan matrix secretion by the 
cumulus cells, causing the dispersal of cumulus cells within the matrix, which are 
ovulated approximately 37 hr after the LH surge along with a mature MIl-arrested 
oocyte. This expanded matrix is a critical factor for reproductive function, since it 
holds the oocyte in position together with its cumulus cells, facilitates follicular 
extrusion and oviductal fimbria capture, facilitates sperm penetration and fertilization 
(Salustri et al., 1996; Matzuk, 2000). Potential roles in communication with the 
oviductal wall via sloughed cumulus cells may also be envisaged. 
1.1.2 Meiosis 
Meiosis is termed cell reduction; it is a form of cell division occurring only in the 
formation of gametes, where the number of chromosomes is reduced to a haploid 
number (in humans, n=23). In addition to halving the chromosome number, meiosis 
serves to promote genetic variation, through the mixing of maternal and paternal 
chromosomes and genes. 
Following several mitotic divisions in the developing fetus, oogonia enter meiosis 
during the early second trimester of pregnancy. Meiosis is comprised of two stages: 
meiosis I and II, as illustrated in Figure Al (Appendix I). 
1.1.2.1 Meiosis I 
Meiosis I begins in the fetal ovary and has a complex extended prophase stage, which 
is divided into four sub-stages (Briggs et al., 1999). 
Prophase I 
• Leptotene- chromosomes condense, and are attached to nuclear membrane. 
• Zygotene- homologous chromosomes align and homologous loci synapse. The 
synaptonemal complex forms, allowing sites for the exchange of genetic 
material (recombination). Bivalents (sets of synapsed homologues) result. 
• Pachytene- shortening and thickening of bivalents, genetic recombination 
occurs between chromatids of paired homologous chromosomes. 
• Diplotene (dictyate stage)- tetrads part, except at chiasmata, the synaptonemal 
complex dissolves. Oocytes remain arrested at this stage for many years prior 
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to ovulation or degeneration. A stable conformation of the nucleus known as a 
germinal vesicle is present in the oocyte. 
All immature oocytes are diploid (2n) with a 4C DNA content. Progress beyond 
diplotene of meiotic prophase I occurs only in maturing oocytes or those in the stages 
of atresia where control of the oocyte by surrounding somatic cells is lost. 
Metaphase I 
A spindle forms at the periphery; chromosomes are randomly aligned on the 
equatorial plate prior to centromere repulsion and chromosome separation. 
Anaphase I 
The chromosomes move to opposite ends of the spindle. 
Telophase I 
Cell division results in the formation of daughter cells. Formation of the secondary 
oocyte with expulsion of first polar body (pb) (containing a set of chromosomes). The 
division is asymmetric due to the peripheral position of the spindle, resulting in a 
minimal reduction in volume of the oocyte. 
1.1.2.2 Meiosis II 
There is no replication of DNA or formation of a nucleus after completion of meiosis 
I, the cell progresses directly to MIl (Veeck, 1991). 
Metaphase II 
A spindle reforms, the 23 chromosomes (each two chromatids) align on the equatorial 
plate. There is a diploid amount of DNA, but a haploid set of chromosomes, as the 
strands have not yet separated. The second meiotic arrest occurs and the oocyte is 
ovulated in this stage. Meiosis II is resumed only upon sperm penetration or 
parthenogenetic activation. 
Anaphase II 
The chromatids split at the centromeres, moving to the opposite ends of the spindle. 
Telophase II 
Asymmetric cell division occurs, a second pb is expelled leaving 23 maternally 
derived chromosomes in the oocyte together with those of the haploid sperm, to form 
the new, genetically unique fertilized oocyte. 
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1.1.3 Key stages of developmental competence 
"It is only by considering all aspects of maturation that the production in vitro of 
mammalian eggs with a developmental potential equivalent to that of in-vivo 
counterparts will be achieved" (Fulka et al., 1998). 
Human oocyte maturation is defined as the reinitiation and completion of the first 
meiotic division from the germinal vesicle (GV) stage (prophase I) to MIl, with 
accompanying cytoplasmic maturation for fertilization and early embryonic 
development (Cha and Chian, 1998). Although the nuclear and cytoplasmic 
programmes can proceed as independent processes, the acquisition of full 
developmental competence is conferred only when the two processes are closely 
integrated (Moor et al., 1998; Fulka et al., 1998). According to Barnes and Sirard 
(2000), the acquisition of developmental competence via reinitiation of meiosis is 
probably a common signaling or differentiation pathway that occurs in the oocyte 
and/or associated granulosa, regardless of whether the oocyte is destined to ovulate or 
degenerate. 
1.1.3.1 Nuclear maturation 
Nuclear maturation refers to the resumption of meiosis from prophase I arrest (PI) 
and the progression of meiosis to its next physiological arrest point (Mm. 
Morphological evidence of resumption of meiosis is the disappearance of the oocyte's 
nucleolus and nuclear (GV) envelope, a process termed germinal vesicle breakdown 
(GVBD) (Eppig, 1996). 
Nuclear maturation can be morphologically evaluated by observation of the extrusion 
of the first pb (Smitz and Cortvrindt, 1999) as illustrated in Figure 1.2. 
Immature oocytes: GVBD MI Mature oocyte: 
Prophase I MIl 
Figure 1.2 Diagrammatic illustration of the morphological features of nuclear 
maturation. 
The GV tends to move to a peripheral location shortly prior to GVBD. 
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Figure 1.3 shows images of oocytes at the various stages of maturation during in vitro 
culture. 
a b 
GV 
d 
Figure 1.3 Images of the stages of human oocyte maturation in vitro. (a) 
Immature oocyte collected from the un timulated ovaries of a patient with peo. A 
germinal vesicle is visible in the centre of the oocyte (OY) and the oocyte has no 
surrounding cumulus cells (b) After one day in culture, the oocyte has undergone 
germinal vesicle breakdown (OYBD) (c) After two days in culture, the oocyte ha one 
polar body and is presumed to be in MIl, the oocyte is injected with a single 
immobilized sperm by the leS} procedure (d) confirmation of fertilization , shown by 
the presence of pronuclear formation (PN) (with aJigned pronucJeoli) and two polar 
bodies (pbs). 
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Many of the proteins that regulate mitosis also regulate meiosis. The G2 to M-phase 
transition in fully-grown oocytes is driven by maturation (or M-phase) promoting 
factor (MPF)- the primary molecule involved in meiotic cell cycle progression (Eppig, 
1996; Fulka et al., 1998; Briggs et al., 1999; Trounson et al., 2(01). 
Maturation (or M-phase) promoting factor (MPF) 
MPF is a serine-threonine kinase protein heterodimer composed of a regulatory 
subunit, cyclin B and a catalytic subunit p34cdC2 ; see Figure 1.4 for diagrammatic 
representation of the molecular structure. 
The two molecules cyclin B and p34cdC2 become associated, and dephosphorylation of 
p34cdC2 occurs on residues tyrosine-15 and threonine-14, catalysed by a phosphatase 
encoded by the cdc25 gene (Gautier et al., 1991; Gabrielli et al., 1992; Izumi and 
Maller, 1993; Eppig, 1996; Fulka et al., 1998; Trounson, 2(01). Active MPF is 
required for the initiation of nuclear maturation and the condensation of metaphase I 
chromosomes, MPF activity is detected before or coincident with GVBD. MPF is 
activated in vivo by the endogenous LH surge at the onset of oocyte maturation. 
Trounson and colleagues (2001) demonstrated the activation of MPF activity in IVM 
studies using human oocytes from unstimulated ovaries, leading them to conclude that 
the activation of MPF in vitro occurs in a manner similar to that for oocytes in vivo. 
Entry into anaphase I correlates with the inactivation of MPF, probably caused by 
proteolytic degradation of the cyclin unit of MPF (Murray et al., 1989). Entry into 
Mil requires a second increase in active MPF activity, c-mos maintains a high level of 
MPF, thereby arresting cell cycle progression until fertilization. Sperm penetration 
and the resultant increase in intracellular Ca2+ levels induce cyclin degradation and 
completion of meiosis (Fulka et al., 1998; Trounson, 2(01). 
To summarize, oocytes acquire competence to complete nuclear maturation in at least 
two sequential steps (Eppig, 1996). 
1. appropriate production and activation of MPF, driving entry into M-phase 
(GVBn and condensation of chromosomes to a prometaphase configuration). 
2. inactivation of MPF, which correlates with entry into anaphase. 
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Thr-16 
o 
Inacti velPre-MPF 
p34Cdc2 
dephosphorylation 
I 
Cdc250 
Active MPF 
Figure 1.4. Diagrammatic illustration of the activation of maturation promoting 
factor (MPF). 
Adapted from Eppig (1996) and Trounson et al. (2001). 
Additional factors, which may affect meiotic progression, include MAP kinase and 
cAMP. 
Mitogen activated protein kinase (MAP) kinase 
MAP kinase is a serine-threonine kinase, alternatively known as extra-cellular 
regulated kinase (ERK) (Trounson, 2(01); that is activated via a protein kinase 
cascade at the onset of oocyte maturation in mouse (Verlhac et aI., 1993), pig (Inoue 
et al., 1995) and Xenopus (Haccard et aI., 1990). MAP kinase, although activated at 
the onset of oocyte maturation in mice (Trounson, 2(01) is not necessarily required 
for OVBD in mice (Sun et aI., 1999b; Trounson, 2(01). 
In human oocytes, p42ERK2 is the main form of MAP kinase (Sun et aI., 1999a; 
Trounson, 2(01). MAP kinase has not been widely studied in human oocytes, 
although it is known to be inactive in immature oocytes, active in mature oocytes and 
there is a decrease in activity after the formation of pronuclei following fertilization 
(Sun et ai., 1999a). Trounson (2001) suggests that MAP kinase may serve a similar 
function during human oocyte maturation to that in other mammalian species, as the 
pattern of activation of MAP kinase in the cell cycle is similar. 
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Cyclic adenosine monophosphate (cAMP) 
cAMP participates in meiotic arrest and may prevent GVBD by the inhibition of MPF 
activation, or by the down regulation of p34cdC2 dephosphorylation. Once cAMP 
decreases below a threshold level, meiosis can resume. 
Two other purines, hypoxanthine and adenosine, have also been shown to prevent 
GVBO in vitro by promoting elevated cAMP levels in the oocyte. It is thought that 
these purines enter the oocyte via the gap junctions. Hypoxanthine prevents the 
degradation of cAMP and adenosine promotes the generation of cAMP by stimulating 
adenylate cyclase, acting as a substrate for cAMP production (Epigg, 1996; Briggs et 
al., 1999). 
In response to the LH surge at ovulation, gap junctions are lost following mucification 
of the granulosa cells, resulting from hyaluronic acid production, this causes a 
decrease in the levels of cAMP, below the threshold required to maintain GV status 
(Briggs et al., 1999). 
1.1.3.2 Cytoplasmic maturation 
Cytoplasmic maturation refers to the processes that prepare the oocyte for 
fertilization, activation, formation of PN and preimplantation development. Similarly 
to nuclear maturation, competence to undergo cytoplasmic maturation is acquired in 
sequential steps by GV-stage oocytes. Although nuclear and cytoplasmic maturation 
occur in synchrony, the acquisition by GV-stage oocytes of competence to undergo 
cytoplasmic maturation is independent of competence to complete nuclear maturation. 
Most deficiencies in oocytes during maturation are believed to be associated with 
cytoplasmic reprogramming rather than with meiotic progression; and the effects of 
cytoplasmic aberrations are normally associated with cleavage, blastulation and the 
peri-implantation stages, rather than early development (Moor et ai., 1998). 
Protein synthesis 
Proteins are synthesized in growing oocytes from both nuclear and mitochondrial 
transcripts for use by the oocyte, for communication with surrounding cells and for 
early embryo development (Briggs et ai., 1999). Oocyte mRNA that will be translated 
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during oocyte maturation is stored in a stable, dormant form until after GVBD 
(Bachvarova, 1985). Moor et al. (1998) suggested that the reduced developmental 
potential in human oocytes matured in vitro might be attributable to abnormal 
cytoplasmic maturation, as well as sub-optimal culture conditions and incomplete 
growth. Trounson (2001) studied the protein content of in vitro matured MIl human 
oocytes, obtained from unstimulated ovaries. A reduced protein content was observed 
compared to in vivo matured MIl oocytes retrieved from stimulated ovaries. The 
proteins not detected in oocytes matured in vitro probably include molecules essential 
for cell cycle regulation and normal embryo development. 
Inositol lipids and calcium 
Sperm binding and fusion promote Ca2+-dependent changes that result in oocyte 
activation. Ca2+ is released from the intracellular stores via an IP3-dependent signal 
transduction mechanism (Homa, 1995). The oocyte's capacity to release intracellular 
Ca2+ is relatively low during the early stages of maturation, but reaches maximum 
sensitivity at MIl (Fujiwara et aI., 1993). The release of Ca2+, essential for oocyte 
activation and pronuclear formation, normally coincides with nuclear maturation 
(Eppig, 1996). 
Glutathione production 
The levels of glutathione in oocytes rise during maturation (Perreault, 1988). 
Glutathione is a reducing agent, which aids sperm decondensation and may playa role 
in the formation of the male pronucleus, as well as potentially protecting from 
pathological oxidation processes and free radicals (Yoshida et aI., 1993; De Matos et 
al., 1996). 
Competence for the release of cortical granules 
Cortical granules control the permeability of the zona pellucida to sperm, occupying a 
peripheral position below the oolemma. The fusion or penetration of a single 
spermatozoon into the oocyte triggers cortical granule release, blocking polyspermy. 
The exocytosis of cortical granules in response to Ca2+ ionophore increases with the 
progression of maturation (Sathananthan and Trounson, 1982; Ducibella, 1996). 
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Follicle size 
The size of the follicle from which the oocyte originates influences its developmental 
capacity, as aspects of developmental competence are acquired during follicular 
growth (Tsuji et al., 1985). 
A significantly higher percentage of human oocytes retrieved during the follicular 
phase of the menstrual cycle from follicles of 9-15mm diameter underwent GVBD, 
than did oocytes collected during the luteal phase from follicles of 3-4mm in diameter 
(60% and 48% respectively). The percentage of oocytes reaching the Mll stage did 
not differ significantly between the two groups (Whitacre et al., 1998). Conversely, a 
minimum follicle diameter of 5mm was reported by Wynn et al. (1998) to be required 
for oocytes capable of in vitro maturation. 
It is possible that follicles of <tOmm in diameter contain developmentally less 
competent oocytes than larger follicles (Dubey, 1995; Trounson et al., 1998). The 
ability of gonadotrophin priming to influence developmental competence is dependent 
on the stage and size of follicle development (Barnes, 2(00). 
Oocyte size 
The human oocyte has a size-dependent ability to resume meiosis and complete 
maturation, with an oocyte diameter of >115/-lm reported to be necessary for the 
progression from GVBD to MIl (Durinzi et at., 1995). 
A better understanding of the minimal requirements for oocyte growth and maturation 
will enable the development of consistent techniques of in vitro culture of follicles 
and in vitro maturation of oocytes. In vitro maturation of human oocytes is currently 
undertaken with limited success, due to our incomplete knowledge of the factors 
controlling developmental competence. 
A better understanding of the development of the oocyte is crucial, because the 
quality of embryos depends on the maternal endowment of RNA and protein 
molecules laid down during oogenesis, their stability and controlled expression. 
Molecular markers of oocyte viability are needed to inform the current morphological 
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assessments of oocyte/embryo quality, which do not provide a reliable indication of 
the prospect of pregnancy (Briggs et aI., 1999). With the continuation of ongoing 
research into these areas worldwide, the resulting knowledge gained and consequently 
increased pregnancy rates; IVM is expected to become a clinically viable technique 
for infertility treatment. 
1.2 In vitro growth of follicles 
Methods for the long-term culture of whole human follicles are at present in their 
infancy; therefore oocytes retrieved from enlarged antral follicles are usually used in 
IVM studies. However, in future, it is likely that the technology for early follicle 
growth in vitro will be combined with that for in vitro maturation of oocytes to extend 
the period of oocyte culture. Hence a brief description of follicle techniques is 
provided here. 
Prospective applications for oocytes obtained from follicular culture include oocyte 
donation, oocyte storage, IVF, animal production technology, support of endangered 
species and in the experimental study of follicular and oocyte development (Gosden et 
al., 1993; Salha et al., 1998; Cortvrindt and Smitz, 2001). 
As yet, no systems permit complete in vitro culture of early follicle stages in large 
animals or humans, although parts of folliculogenesis have been successfully 
reproduced in vitro (Cortvrindt and Smitz, 2001). To date, in vitro culture from 
primordial follicle to live birth has been achieved only in mice (Eppig and O'Brien, 
1996). However, less than 2% of fertilized oocytes developed to blastocyst stage. Of 
190 embryo transfers, only one live birth resulted, which developed severe obesity, 
liver problems and neurological damage nine months later (Eppig and O'Brien, 1998). 
The live birth was achieved following a two-step strategy; first the ovaries (containing 
only newly formed primordial follicles) of newborn mice were grown in organ culture 
for a period of eight days to allow the development of growing oocytes enclosed by 1-
3 layers of granulosa cells. A normal number of primordial follicles initiated growth 
and developed to the secondary follicle stage by day 8, similar to development after 8 
days in vivo. This was followed by isolation of the developing oocyte-granulosa cell 
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complexes, which were cultured for a further 14 days to complete oocyte 
development. 
The total development period of -three weeks corresponds to the estimated time 
required for full growth in vivo (Pedersen, 1970). According to Gougeon (1986), a 
period in excess of six months is required for the equivalent in vivo with human 
primordial follicles, due to the differing growth rates between small and large 
mammals, however it is possible that artificial manipulation in vitro might enable the 
schedule to be hastened. 
Murine follicles are ideal for developing a culture system, since they are small, 
readily available and grow to full size within a short time-span. The formation of 
primordial follicles, which have an oocyte in first prophase of meiosis and a single 
layer of flattened granulosa cells, occurs synchronously within a few days after birth 
in rats and mice (Fortune et al., 2(00). Activation of a few primordial follicles begins 
almost immediately thereafter, yielding the first group of antral follicles around day 
15 postpartum (Hirshfield, 1991). Thus, the timing of follicle formation and the 
initiation of primordial follicle activation in rodents, coupled with an ovarian size that 
allows organ culture of whole ovaries. make them very useful models. 
Interspecies differences make it difficult to transpose techniques between species, 
there are various problems associated with adapting such a system for use with large 
species. In contrast to rodents, follicle formation in ruminants and primates begins 
during fetal development and occurs over a long period of time, so that some follicles 
are activated and leave the resting pool before others have been formed (Henricson 
and Rajakoski, 1959; Russe, 1983). These developmental processes are thus 
protracted and asynchronous in these larger species, making them more difficult to 
study (Fortune et ai., 2(00). The follicles of primates and ruminants have a much 
thicker theca than in rodents, which restricts oxygen and nutrient transport to the 
centre of the follicle, which tends to become necrotic. Removal of the theca externa 
may overcome this problem, as this layer may not be essential for follicle 
development (Gosden et al., 1993). Culture systems using small pieces of ovarian 
cortex obtained from fetal ovaries are used for domestic species and primates. as the 
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larger size of ovaries precludes the whole-ovary culture system used with rodents. 
There are also interspecies differences in regulation and timing of maturation; mouse 
oocytes acquire GVBD competence at an earlier stage of follicular development than 
MIl competence, which is attained only when the oocyte has reached maximum size 
soon after follicular antrum formation (Erickson and Sorensen, 1974; Sorensen and 
Wassarman, 1976). In contrast, at antrum formation, ungulate oocytes (bovine and 
porcine) have not reached maximum size and exhibit low meiotic competence 
(McGaughey et ai., 1979; Motlik et ai., 1984; Motlik and Fulka, 1986). Even after the 
acquisition of maximum oocyte size during antral growth, MIT competence is low and 
increases only with increasing follicular size (Gilchrist et ai., 1995). 
Despite difficulties encountered with for example, the duration of the follicular 
growth span from the primordial to Graafian stage, changes in the nutritional 
requirements of the cells, cellular interactions, morphogenesis and the sheer increase 
in volume associated with antrum formation, human follicle culture is making 
progress. Picton and Gosden (2000) suggest that at present, the best strategy is likely 
to be initiation of follicle growth in situ in slices of ovarian cortex, isolation of the 
follicles or granulosa-oocyte complexes once they have progressed to preantral stages 
for individual culture. Followed by IVM of the oocytes within their cumulus cells 
once full oocyte growth has been achieved. The preservation of cellular interactions 
and the phenotype of follicle cells is likely to increase the chances of succeeding at 
each stage, as these provide the physiological environment in which oocytes develop. 
Culture of intact follicles beyond -500-1 OOOJ.lm in diameter is unlikely to succeed due 
to failure of oxygen diffusion (Gosden et al., 1986). Therefore, beyond this point, 
oocyte isolation or a non-intact follicle culture system, as in mice is likely to be 
essential (Cortvrindt et ai., 1996). 
At present, development of follicles in vivo has produced more immediate prospects 
for clinical application and in animals can restore fertility after re-aggregation and 
grafting (Carroll and Gosden, 1993). Experimentation in sheep, whose ovaries 
resemble those of humans in size and follicle and fibre composition, and in humans, 
has demonstrated the successful autografting of primordial follicles in cortical tissue 
pieces (Gosden et ai., 1994; Nugent et ai., 1997). Growth and maturation of 
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cryopreserved human primordial and primary follicles can be achieved by 
homologous transplantation of the frozen-thawed ovarian tissue (Nugent et al., 1997; 
Smitz and Cortvrindt, 1999), although there was variable survival of the follicles 
within the transplants. No human pregnancies have resulted from these auto 
transplants to date 
The technique of in vitro growth of immature follicles in combination with in vitro 
maturation and cryopreservation, promises to be a powerful technology in assisted 
reproduction. However, over the past decade there has been no real progress in 
applying these techniques for use in animals and humans with follicles that undergo a 
long growth period (Telfer et al., 2(00). Although it is possible to grow primordial 
follicles to pre-antral stages in slices of ovarian tissue, and support antrum formation 
in isolated pre-antral follicles, we are still some considerable way from growing and 
maturing pre-antral follicles to the pre-ovulatory stage in vitro (Hardy et al., 2(00). 
However, Gosden (2000) predicts that eventually it will be possible to produce viable 
embryos from oocytes that have been grown and matured entirely in vitro. This 
achievement will provide the foundations of a technology that not only has important 
practical application but also provides the most valuable model for investigating 
oogenesis. 
1.3 The current state of IVM of human oocytes 
1.3.1 Background 
The final 36 hr of human oocyte formation are critical for the normal functioning of 
the resulting gamete. During this time, oocytes resume meiosis from their prenatal 
arrest in diplotene of meiotic prophase I, and progress to metaphase II. They also 
undergo cytoplasmic maturation (section 1.1.3.2) in preparation for fertilization and 
early embryo development, which is largely dependent upon oocyte constituents until 
after embryonic genome activation, which occurs principally between the 4-8 cell 
stages of embryonic growth (Braude, 1988). 
It has been known for many years that immature human oocytes removed from large 
follicles will mature spontaneously (Pincus and Enzmann, 1935; Edwards, 1965a,b); 
however, the developmental competence of in vitro matured human oocytes is low 
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(Veeck et al., 1983; Barnes et al., 1996; Coskun et al., 1998), probably due to 
disruption of the normal follicular control mechanisms regulating this important stage 
of development. When oocytes are aspirated from antral follicles early in the 
follicular phase, follicular and oocyte growth are incomplete at the time of oocyte 
retrieval, and some follicles may already have initiated the process of atresia. 
Collected oocytes are usually matured in the 48 hr subsequent to retrieval, a shortened 
period of time compared with the natural cycle, in which nuclear maturation follows 
the luteinization signal and cytoplasmic maturation is a progressive phenomenon 
(Cheung et al., 2000; BFS Policy and Practice Sub-Committee, 2(01). It is possible 
that the maturational and developmental anomalies observed in in vitro matured 
oocytes are attributable to their truncated growth phase and thus the inability to 
complete all the necessary transcriptional and translational changes required for 
complete maturation and developmental competence. 
Following the work of Lonergan et al. (1997), Anderiesz et al. (2000) artificially 
extended the pre-maturation growth phase of human and mice oocytes in vitro using 
6-Dimethylaminopurine (DMAP) which reversibly inhibits GVBD. DMAP blocks 
GVBD and cell cycle progression in immature oocytes by inhibiting the post-
translational dephosphorylation of p34cdC2 that triggers MPF activity (Jessus et al., 
1991), but does not interfere with protein synthesis (Rime et al., 1989; Fulka et al., 
1991; Trounson et al., 2001). It was hypothesized that DMAP treatment may 
synchronize nuclear maturational events in oocytes, but there was no evidence of this 
effect in either mouse or human oocytes. DMAP treatment of human oocytes had no 
effect on fertilization or development to the blastocyst stage, but increased the 
developmental capacity of mouse embryos. Anderiesz et al. (2000) concluded that 
lengthening the prematuration growth phase, by temporarily inhibiting kinase activity 
with DMAP, does not directly improve oocyte developmental competence. 
Due to the low developmental competence of in vitro matured oocytes, in vivo 
maturation has been preferred for oocyte preparation for IVF despite the need for 
large doses of exogenous hormones, with their attendant risks and costs (Russell, 
1999). This is in contrast to some animal species where NM is commonly used to 
obtain viable oocytes for research or commercial purposes (Trounson et al .. 1996), yet 
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this is not without problems, as a proportion of the animals thus produced are 
abnormal (Young et al., 1998; Sinclair et al., 2(00). 
The challenge with human Q()Cytes is to provide optimal conditions for IVM by 
mimicking the microendocrine environment of the developing follicle to enable the 
immature oocyte to achieve nuclear and cytoplasmic maturation. When utilising in 
vitro matured oocytes, conditions for fertilization and culture as well as uterine 
receptivity must also be optimal if implantation is to occur (Russell, 1998). IVM is 
particularly challenging in the human because folliculogenesis is a lengthy process 
encompassing many complex changes in the oocyte and its surrounding follicle cells 
(Hardy et al., 2(00) which are known to have a bearing upon later developmental 
competence. Moreover, disruption of these processes may potentially have 
devastating effects upon development. 
The production of embryos in vitro exposes them to hazards not normally encountered 
in vivo, and as a result, there have been unforeseen consequences including the large 
offspring syndrome (LOS), also termed the fetal oversize syndrome (Walker et al., 
1992; Behboodi et al., 1995; Farin and Farin, 1995; Walker et al., 1996; Thompson, 
1997; Young et al., 1998; McEvoy et al., 2000) which has not however been evident 
in human IVF offspring. The birth of grossly enlarged offspring was the first marked 
and unexpected adverse consequence of culturing cattle or sheep zygotes ex utero 
(McEvoy et al., 2000). However, it is also associated with an increased abortion rate, 
increased gestation lengths, physical abnormalities and increased mortality and 
morbidity (Maxfield et al., 1998; Ranilla et al., 1998; Sinclair et al., 1999; Telfer et 
al., 2(00). Altered genomic imprinting is a likely cause of this syndrome (Sinclair et 
al., 2(00); imprinted genes (Le. genes which express only the maternal or paternal 
allele) play key roles in the control of fetal growth (Khosla et al., 2(01) and are 
possible candidates for involvement in livestock LOS (Young and Fairburn, 2000). 
Although there is no published evidence for a human equivalent to the LOS as a 
consequence of embryo production in vitro, it is known that oocytes, zygotes and 
embryos up to and beyond blastocyst stages of development are extremely sensitive to 
their environment, whether natural or artificial, and their normal development can be 
20 
threatened in many ways. Experience from the culture of cattle and sheep embryos to 
the blastocyst stage of development may help to avoid some of these dangers 
(McEvoy et al., 2(00). 
1.3.2 Content of media used for IVM 
The content of the medium used for NM may affect the outcome. A key experiment 
in the 1990s, which re-awakened interest in human NM, used human follicular fluid 
to supplement the culture medium (Cha et al., 1991) but, with the growing preference 
for defined media, the roles of individual factors are now being assessed and the 
inclusion of biological fluids is declining. 
Various hormones included in the culture medium have promoted oocyte maturation 
and subsequent embryo development, for example, epidermal growth factor (EGF, 
G6mez et al., 1993a,b; Goud et al., 1998) or follicle stimulating hormone (FSH, 
Barnes et al., 1996; Durinzi et al., 1997) with or without human chorionic 
gonadotrophin (hCG, Jaroudi et al., 1997; Cha et al., 2000; Liu et aI., 1997). 
Granulosa cells contain mRNA for FSH receptors from very early in follicle 
development (Oktay et al., 1997), whereas LH receptors are induced much later, in 
response to FSH stimulation, and are principally located at the periphery of large 
follicles (Amsterdam et al., 1975). Receptors for the gonadotrophins are lacking on 
oocytes, so any effects observed must be mediated via the attached cumulus cells 
(Hartshorne, 1999). Cumulus cells are highly metabolically active and their steroid 
production may be influenced by hormonal supplementation in vitro (Durinzi et al., 
1997). 
1.3.3 Intracytoplasmic sperm injection (ICSI) in human IVM programmes 
ICSI is the injection of a single spermatozoon into the cytoplasm of the oocyte. There 
is evidence that removing human oocytes from their normal follicular environment 
before luteinization yields oocytes with compromised ability to be fertilized, as 
exemplified by the failure to elicit normal calcium signalling in response to sperm-
oocyte fusion (Herbert et al., 1997). Consequently, intracytoplasmic sperm injection 
(ICSI) has been employed almost universally to achieve fertilization in human IVM 
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programmes (BFS Policy and Practice Sub-Committee, 2(01). ICSI of in vitro 
matured oocytes has increased the likelihood of normal fertilization; overcoming 
problems with zona hardening due to extended culture (Barnes et a/., 1995, 1996; 
Nagy et a/., 1996; Cha and Chian, 1998; Hwang, et aI., 2(00), and failure of the 
cortical reaction probably due to the inadequate peripheral migration of cortical 
granules during maturation. 
1.3.4 Clinical pregnancies resulting from IVM 
The full developmental competence of an oocyte and an embryo can ultimately be 
evaluated only by live births. In 1983, Veeck et al. reported the first live birth 
resulting from successful NM as part of an NF programme in which patients 
received ovarian stimulation drugs. Subsequently, Cha et al. (1991) reported IVM 
with unstimulated oocytes in a donor oocyte programme. 
Following this there have been a number of reports of the successful use of IVM 
resulting in clinical pregnancies (Veeck et al., 1983; Trounson et aI., 1994; Barnes et 
a/., 1995; Nagy et ai., 1996; Edirisinghe et aI., 1997; Jaroudi et ai., 1997; Liu et ai., 
1997; Cha and Chian, 1998; Russell et at., 1998; Thornton et at., 1998; Tucker et at., 
1998; De Vos et a/., 1999; Chian et ai., 1999a,b; Jaroudi et aI., 1999; Mikkelsen et 
ai., 1999; Cha et a/., 2000; Chian et ai., 2000; Mikkelsen et aI., 2000; Smith et aI., 
2000; Abdul-Jalil et a/., 2001;Chian et a/., 2001; Wu et a/., 2(01) however the live 
birth rate associated with NM remains low. Pregnancy rates of approximately 2% 
result from the transfer of up to three embryos, derived from oocytes matured in vitro. 
The simultaneous transfer of many more embryos derived from oocytes matured in 
vitro may result in higher pregnancy rates (Cha et ai., 2(00). 
1.3.5 Role of prior ovarian stimulation in IVM 
To achieve ovarian stimulation for NF, gonadotrophin-releasing hormone (GnRH) 
agonists or antagonists are used to suppress the secretion and release of endogenous 
gonadotrophins from the pituitary gland. Exogenous FSH is administered to induce 
multiple follicular growth and the final phase of oocyte maturation is induced by a 
dose of hCG, to emulate the LH surge. 
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Various protocols including partial or minimal exogenous hormonal stimulation are 
used in preparation for IVM of human oocytes. In preliminary studies of the treatment 
of women for one or three days with recombinant human FSH (rFSH) early in the 
follicular phase, no difference in the recovery rate of oocytes, maturation, fertilization 
or development in culture was demonstrated (Trounson et al., 1998). Mikkelsen et al. 
(1999) confirmed this finding. After the treatment of women with rFSH for three 
days, on days 3-5 of the cycle, no benefit was observed from extending the rFSH pre-
treatment from three to six days to produce follicles >10mm in diameter. 
However, Wynn et al. (1998) administered a truncated course of 600IU rFSH over 
five days (300 IU on day two, 150IU on day four and six). A mean of 7.5 oocytes was 
recovered after rFSH treatment compared with 5.2 oocytes from untreated oocytes. 
After 48 hr in culture, supplemented with FSH and hCG, significantly more oocytes 
completed maturation to MIl following FSH stimulation than in untreated women 
(71.1% and 43.5% respectively). Significantly fewer degenerating oocytes were seen 
both at the time of collection and after 48 hr of culture from patients treated with 
rFSH. 
Suikkari et al. (2000) also investigated the use of minimal ovarian stimulation of 
recruitable follicles, in order to produce competent oocytes for IVM and fertilization. 
In a natural menstrual cycle, serum FSH begins to increase in the late luteal phase, 
therefore, low dose rFSH was administered starting in the late luteal phase in two 
groups of women, those with regular menstrual cycles and women with PCO and 
irregular cycles. In women with anovulatory cycles, a withdrawal bleed was induced 
by using 600mg daily vaginal micronized progesterone for ten days. Low-dose rFSH 
was commenced on the ninth day of progesterone administration. Oocytes were 
retrieved after withdrawing rFSH for two-five days. It was postulated that low dose 
rFSH priming of follicles would support the growth of multiple follicles, thereby 
increasing the number of immature oocytes retrieved for IVM. A good yield of 
immature oocytes (11.2 and 11.5: regular and irregular menstrual cycles, respectively) 
was retrieved in both groups of women, 71 % of viable oocytes reached MIl after 44 h 
in culture and 64% of these fertilized after ICSI. The oocyte maturation and 
fertilization rates did not differ significantly between the two groups of women. 
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Trounson et ai. (2001) suggest that the failure to achieve a substantial improvement in 
the number and developmental competence of oocytes by pre-treatment with FSH 
indicates that maturation in vitro is not limited by the growth phase of follicles in the 
ovaries. Furthermore, there would be no clinical application of FSH pre-treatment 
prior to immature oocyte recovery, unless a very substantial benefit could be 
demonstrated for maturation and development to term. 
The time course of oocyte GVBD and maturation is different between GV oocytes 
retrieved from stimulated and unstimulated ovaries. Data from Cha and Chi an (1998) 
demonstrated that although the final percentages of GVBD (after 27 hr of culture) for 
oocytes derived from stimulated and unstimulated ovaries did not differ (83.3% and 
87.5% respectively), GVBD occurred significantly earlier in oocytes retrieved from 
stimulated ovaries. After 12 h of culture, 80% of GV oocytes from stimulated ovaries 
had undergone GVBD, whereas there was no change in GV oocytes from 
unstimulated ovaries at the same time point. As a result, the completion times for 
nuclear maturation, shown by extrusion of the first pb differed, -75% of oocytes from 
stimulated ovaries reached MIl by 30 hr of culture whereas 75% of oocytes from 
unstimulated ovaries reached MIl by 42-45 hr (Cha and Chian, 1998; Trounson et ai., 
2(01). The final proportions of maturing oocytes derived from stimulated and 
unstimulated ovaries were not different (75% and 77.5% respectively). The exposure 
of the follicles to FSH and hCG in stimulated ovaries prior to oocyte retrieval may 
account for the difference in timing of GVBD. 
Gonadotrophin therapy leads to the growth of multiple follicles, this is reflected in a 
rise of oestradiol concentrations, and therefore oocytes retrieved from stimulated 
ovaries have been subject to a predominantly oestrogenic milieu (Cobo et ai., 1999). 
Furthermore, it has been shown that the addition of oestradiol to oocyte maturation 
medium can directly influence the quality of the maturing oocyte. Whilst no apparent 
effect of oestradiol on either GVBD or further progression of meiosis was observed, 
increased fertilization and cleavage rates were seen after IVM. Oestradiol induces a 
series of transient increases in the intracellular free Ca2+ concentration, which 
contributes to the oocyte's capacity for fertilization and early post-fertilization 
development (Tesarik and Mendoza, 1995). 
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IVM and fertilization have been reported for human oocytes retrieved from cycles 
after the administration of exogenous hCG in vivo (Veeck et al., 1983; Prins et al., 
1987; Dandekar et al., 1991; Toth et al., 1994; Janssenswillen et al., 1995; Nagy et 
al., 1996; Edirisinghe et al., 1997; Farhi et al., 1997; Goud et al., 1998; Thornton et 
ai., 1998; Tucker et at., 1998; De Vos et al., 1999; Chian et al., 1999a,b; Chian et al., 
2000; Cavilla et ai., 2001; Abdul-Jalil et al., 2(01). 
The above studies differ in many aspects, e.g. number of immature oocytes for in 
vitro maturation, time in culture, culture medium used and maturation, fertilization 
and embryo cleavage rates. However, all studies that replaced embryos resulting from 
IVM reported subsequent clinical pregnancies (Veeck et al., 1983; Nagy et al., 1996; 
Edirisinghe et ai., 1997; Thornton et ai., 1998; Tucker et ai., 1998; De Vos et al., 
1999; Chian et ai., 1999a,b; Chian et ai., 2000; Abdul-Jalil et al., 2(01). 
Immature oocytes retrieved after the in vivo administration of exogenous hCG can be 
matured in culture without gonadotrophin or steroid supplement (Veeck et al., 1983; 
Dandekar et al., 1991) but the culture medium usually contains the patient's own 
serum and occasionally granulosa cells recovered from the same follicle or from 
follicles that contained a mature follicle. 
Four of the IVM studies involved cryopreservation (Toth et al., 1994; Edirisinghe et 
ai., 1997; Thornton et ai., 1998 and Tucker et ai., 1998) three of which resulted in 
clinical pregnancies. Results from Toth et al. (1994) demonstrated that prophase I 
oocytes from stimulated IVF cycles are able to survive cryopreservation and resume 
meiosis to achieve full nuclear maturation post-thaw. In addition, cryopreserved 
oocytes retained the same capacity for fertilization and development as control 
(cultured, non-cryopreserved immature) oocytes. Edirisinghe et al. (1997) reported a 
case resulting in alive birth following the transfer of cryopreserved embryos 
generated from ICSI carried out on the second day after oocyte recovery of three in-
vitro matured MI and two GV stage oocytes. All five zygotes were cryopreserved at 
the pronuclear stage, then thawed and cultured for 24 hr prior to the transfer of two 
embryos in a cycle stimulated with low doses of follicle stimulating hormone. 
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In a variation of natural cycle IVF, Thornton et al. (1998) recovered immature GV 
oocytes from follicles secondary to the one dominant follicle after administration of in 
vivo hCG to trigger ovulation. These follicles were ~ 12mm, oocytes were matured in 
standard culture medium or Hams FlO + 50% follicular fluid as described by Cha et 
al. (1991). No significant differences were observed in maturation or fertilization 
rates. Two births resulted, one of the births resulted from one of six transfers of 
cryopreserved embryos derived from oocytes matured in vitro. Chian et al. (1999a,b, 
2000) adopted a similar approach for PCOS patients with irregular menstrual cycles, 
supplementation of the maturation medium with gonadotrophins and serum additives 
yielded good pregnancy rates. 
In 1998, Tucker et al. reported a pregnancy resulting from the cryopreservation of GV 
stage oocytes, followed by successful thawing, IVM and ICSI. A total of 29 oocytes 
were cryopreserved, 16 at Mil and 13 at the GV stage. No Mil oocytes survived the 
thaw procedure, however, three GV oocytes survived, after 30 hr IVM, two oocytes 
had matured, which fertilized after leSI. Tucker et al. (1998) concluded that this 
study proves the feasibility if not the efficiency of using immature oocytes for 
cryostorage, coupling both cryopreservation and IVM. 
In cases of recurrent ovarian hyperstimulation syndrome (OHSS) (or for those at high 
risk of developing OHSS) with clinical IVF, immature oocytes can be retrieved after 
gonadotrophin treatment, but without hCG administration. Jaroudi et al. (1997) 
reported such a case. 
1.3.6 Different stimulation 
For patients wishing to avoid large doses of FSH, or for patients for whom such 
superovulation is unaffordable, retrieval of oocytes from small non-dominant follicles 
in natural ovulatory cycles, after minimal ovarian stimulation with clomiphene citrate 
(Thornton et al., 1998; Trounson et al., 2(01) and subsequent IVM offers an 
alternative option and a chance of achieving pregnancy. 
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1.3.7 Importance of peo 
In 1994, Trounson et ai. developed methods for the recovery of oocytes from the 
ovaries of patients with pca, in which the dominance of a particular follicle fails to 
occur and the cohort of growing follicles accumulates in the cortex. These follicles 
range in diameter from about 3-Smm and remain under an androgen-dominated 
environment due to increased thecal cell secretion of androgens and a blockage of 
aromatization in the granulosa cell compartments (Almahbobi and Trounson, 1996; 
Trounson et a1., 2(01) (Section 1.4). 
In 1996, Barnes et ai. demonstrated significantly lower maturation, fertilization and 
embryo development rates with oocytes recovered from women with pcas, 
compared with those recovered from regularly cycling women without pcas. They 
suggested that the abnormal endocrine environment and stasis of follicular growth in 
pcas patients may disrupt the oocytes, although incipient follicular atresia does not 
appear to reduce the developmental competence of human oocytes (Barnes et ai., 
1996). However, blastocysts have been produced and live births have occurred as a 
result of NM of oocytes from women with pcas (Trounson et ai., 1994; Barnes et 
al., 1995; Cha and Chian, 1995; Chian et al., 1999a,b, 2(01). Furthermore, the higher 
oocyte yield from the increased numbers of antral follicles in such patients may 
potentially compensate for lower individual viability of oocytes (Trounson et aI., 
1996). 
Recent reports of live births following NM treatment of women during unstimulated 
cycles (Cha et ai., 2000; Chian et ai., 2000; Chian et al., 2(01) have emphasized the 
significant potential of NM treatment, especially for women with polycystic ovaries 
(Abdul-Jalil et al., 2(01). NM can be used to achieve pregnancy for women with 
pcas and irregular menstrual cycles, after a withdrawal bleed, induced with 
progesterone, hCG 10-14 days later, followed by oocyte recovery 36 h later (Chi an et 
al., 1999a,b,2(00). 
When performing an immature oocyte recovery in a patient with pca and irregular 
menstrual cycles, it is not known whether the follicles are atretic. Inducing a 
withdrawal bleed causes the endometrium to develop afresh, and feeds back to the 
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pituitary to reduce the levels of FSH. Upon withdrawal of the steroids used to induce 
the bleed, the negative feedback to the pituitary is reduced. Therefore, the FSH level 
starts to rise and a new cohort of antral follicles commence growth. The retrieval of 
these oocytes at late stage of the follicular phase before the LH surge enables oocytes 
to be retrieved from follicles less likely to be atretic, than from patients with pca 
who had not had a withdrawal bleed. 
In 1999(a,b), Chian et al. reported a clinical pregnancy rate of 39% per cycle after 
hCG priming before immature oocyte retrieval and NM in women diagnosed with 
polycystic ovaries. The patients had irregular menstrual cycles and withdrawal 
bleeding was induced by the administration of intravaginal progesterone for 10 days, 
hCG was administered 10-14 days after steroid withdrawal. Transvaginal oocyte 
recovery from antral follicles was performed, and oocytes were matured for 24-48 hr 
in TCM 199 containing 20% patient's own serum, 25mM pyruvic acid and 75mIU/ml 
hMG. Chian et al. (1999a.b) claimed that priming with hCG prior to oocyte recovery 
increased the developmental competence of the immature oocytes, however Trounson 
et al. (2001) argued that no data were provided to show that the oocytes were 
immature after hCG injection. Furthermore. in 2000 Chian et al. demonstrated that 
46% of oocytes were already maturing in hCG-primed patients. and oocytes 
completed meiosis 12-24 h before oocytes from unprimed patients. There was no 
significant difference between final fertilization, embryo development and pregnancy 
rates for hCG primed and unprimed patients (Trounson et al., 2(01). 
Clinical pregnancy rates of 27.1 % (23/85) established from immature oocytes 
retrieved from unstimulated patients with pcas following IVM (Cha et al., 2(01). 
along with data from others (Trounson et al., 1994; Chian et aI., 2(01) suggest that 
women with PCaS-related infertility could be treated with immature oocyte retrieval, 
NM and fertilization. 
The application of human oocyte maturation in vitro remains a suitable alternative to 
surgery or diathermy of ovaries for the establishment of pregnancy in infertile women 
with pcas. It is clear that improvements can be made to the maturation conditions 
for retention of the potential developmental competence of immature oocytes and this 
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aim should continue to be a priority for research on oocyte maturation (Trounson et 
ai.,2(01). 
1.3.8 The expectations and limitations of IVM as a method of treatment 
compared to conventional IVF treatment. 
Immature oocyte retrieval combined with IVM could offer an alternative to the 
current ovarian stimulation protocols used in IVF, however, efficient maturation, 
fertilisation and embryo development are needed before IVM can be applied routinely 
in the treatment of human infertility. 
1.3.8.1 Potential benefits of IVM 
There are many potential benefits of developing an effective IVM programme as an 
alternative clinical strategy to conventional IVF (Wynn et aI., 1998). Approximately 
10-15% of oocytes recovered after ovarian stimulation with gonadotrophins (hMG, 
FSH and hCG) for IVF are immature (Cha and Chi an, 1998) requiring further 
maturation in vitro. IVM might allow such oocytes to be rescued and lead to an 
improvement in fertilization, embryo cleavage and clinical pregnancy rates. IVM 
would therefore, reduce wastage of immature oocytes obtained during routine IVF 
treatment (Van-Steirteghem et al., 1993) and would particularly benefit patients with 
an unsynchronized cohort of follicles who have a high proportion of immature 
oocytes collected after stimulation. 
IVM would minimize the need for gonadotrophin stimulation of the ovary, which may 
even become redundant, hence greatly reducing the cost of IVF treatment (Salha et 
al., 1998). An approximate cost of ovarian stimulation drugs for one cycle of IVF is 
£800-1500. A further reduction of cost would be contributed by the greatly reduced 
ultrasound monitoring required in the absence of gonadotrophin stimulation. 
IVM might particularly benefit patients diagnosed with PCO and coinciding 
infertility. Such patients often over-respond to the standard gonadotrophin stimulation 
normally used for IVF, potentially resulting in OHSS (Rizk and Smitz, 1992; 
MacDougall et al., 1993). Whilst mild OHSS is of little clinical relevance (Rizk and 
Aboulghar, 1999), severe OHSS characterised by massive ovarian enlargement with 
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fluid accumulation in the abdominal and pleural cavities, gross changes in the blood 
chemistry is a life threatening complication with a risk of thrombosis and death 
(Brinsden et al., 1998). The risk of OHSS could therefore be minimized not only for 
high-risk patients (Le. women with PCO) but also for other patients (Smitz et al., 
2(01). NM treatment may therefore be associated with reduced health risks. It may 
also offer increased patient convenience, through reduced need for blood tests, 
ultrasonographic monitoring and avoidance of daily injections, compared with 
conventional IVF treatment in which these are a major factor (Abdul-Jalil et ai., 
2(01). Additionally, side effects reported for ovulation induction treatment such as 
abdominal bloating, nausea and mood swings would not be encountered with NM of 
oocytes from unstimulated cycles. 
The potentially increased variety of sources of oocytes for donation afforded by IVM 
would potentially benefit young women lacking their own oocytes due to premature 
menopause (e.g. Turners syndrome; familial premature menopause) or definitive 
sterility (post-oncotherapy or post-surgery for severe endometriosis). Immature 
oocytes can be recovered from patients undergoing caesarean section (Hwu et al., 
1998) and oophorectomy (Cha and Chian, 1998) and matured in vitro, increasing the 
availability of oocytes for clinical application and research. A combination of 
immature oocyte cyropreservation, IVM and NF could provide the opportunity to 
establish oocyte banks. 
Both immature and mature oocytes can be successfully cryopreserved, however, the 
success of embryo development subsequently is variable and further research is 
required. NM might facilitate immediate collection of oocytes in women with cancer 
or other malignant conditions who cannot spend time undergoing a normal NF cycle 
prior to sterilising chemotherapy, or in whom ovarian stimulation is contraindicated. 
Immature oocyte cryopreservation for subsequent NM has the potential to overcome 
many of the legal and ethical problems associated with embryo cryopreservation. 
'Custody' and disposal of cryopreserved embryos are sometimes problematic if a 
couple divorces or a partner dies. The risks of creating embryos and losing a mother 
are greater if the woman is suffering from cancer and has undergone NF and stored 
embryos to preserve some prospects of fertility (Apperley and Reddy, 1995). 
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However, most patients do not have the time to undergo IVF prior to aggressive 
cancer treatment. The procedure of IVF and subsequent embryo cyropreservation is 
inappropriate for children, and unacceptable to many single women who reject donor 
sperm as an alternative (Oktay and Gosden, 1999). 
NM may also provide a valuable model for investigating the causes of meiotic 
aberrations and aneuploidies, which are common in mature human oocytes (Gras et 
al., 1992; Delhanty et al., 1997; Wynn et al., 1998). 
1.3.8.2 Limitations of IVM 
At present, routine clinical practice relies upon the in vivo environment, augmented 
by drugs, to achieve the optimum follicular response and maturation of oocytes, since 
experience has shown the present unreliability of maturing oocytes in vitro whilst 
retaining developmental competence. The primary problem in oocytes matured in 
vitro is reduced developmental competence, particularly cleavage and development 
beyond the 4-cell stage (Trounson et al., 1994). However, an increase in 
developmental potential may result if the initiation of maturation is triggered in vivo 
(Chian et al., 1999b). 
In a stimulated cycle of IVF, there are an increased number of oocytes and thus an 
increased number of embryos that are available for embryo transfer compared to 
unstimulated IVM. Conventional IVF offers a predictable response over the less 
predictable outcome of oocyte collection and subsequent IVM in natural cycles. 
Asynchrony of the endometrium with the embryo at the time when transfer might 
normally be planned is a potential problem with removing and maturing oocytes at 
various stages of the menstrual cycle. It is anticipated that adequate endometrial 
preparation through steroidal priming with estrogen and luteal supplementation with 
progesterone as demonstrated by Russell et al. (1997) would help produce a receptive 
uterine environment in a short period of time, essential to support the establishment 
and maintenance of a pregnancy. Alternatively, embryos derived from in vitro 
matured oocytes could be cryopreserved and transferred in a later cycle; however, loss 
of viability during cryopreservation may further reduce the chance of pregnancy. In 
donor oocyte programmes, standard hormone replacement schemes are used to 
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overcome endometrial asynchrony and ensure endometrial receptivity (Cha et al., 
1991). 
There are potential risks attached to prolonged culture associated with IVM, not 
encountered with conventional IVF, for example large offspring syndrome (section 
1.3.1), observed in ruminants. Further information is required before confident 
reassurance on this point can be given, although such a syndrome has not been 
observed to date in human IVM offspring. 
Despite the limitations of IVM, the potential benefits of IVM compared to 
conventional IVF, together with the developing knowledge on mechanisms 
controlling follicle and oocyte growth and early embryology suggest that the time is 
right for IVM to be applied with caution in patient treatment. 
1.4 Polycystic ovaries 
1.4.1 Definition and diagnosis 
The term polycystic ovary (PCa), originally known as Stein-Leventhal ovary (Stein 
and Leventhal, 1935), is used to describe the main phenotypic features of the clinical 
state known as polycystic ovarian syndrome (PCaS) in the human (Almahbobi et al., 
1996). In 1935, Stein and Leventhal described the association of enlarged sclerocystic 
ovaries with amenorrhoea, infertility and hirsuitism, due in part to the marked 
heterogeneity of its clinical and endocrine features (Stein and Leventhal, 1935). A 
universally agreed definition of the polycystic ovary or pcas is not available (Balen 
et al., 1999). However, polycystic ovaries are usually enlarged (>9ml) (Franks et al., 
1992), containing in one plane at least ten follicles between 2 and 8mm in diameter, 
arranged peripherally around a dense core of ovarian stroma or scattered throughout 
an increased amount of stroma (Adams et al., 1985; Adams et ai., 1986; Michelmore, 
2(00). 
Surgical procedures such as laparoscopy, laparotomy or wedge resection of the 
ovaries were Originally used to confirm the presence of pca (Swanson et ai., 1981). 
However diagnostic ultrasonography was introduced in the early 1980s (Swanson et 
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al., 1981; Wild et al., 2(00). Transvaginal ultrasonography is now the diagnostic tool 
of choice for ovarian morphological assessment (Zaidi, 2(00). 
PCO describes the morphological appearance of the ovary, whereas PC OS describes 
the clinical condition when polycystic ovaries are found in association with menstrual 
disturbance, most commonly oligomenorrhoea, the complications of 
hyperandrogenism (seborrhoea, acne and hirsuitism) and obesity (Balen et al., 1999). 
Polycystic ovaries can exist without clinical signs of the syndrome, which may be 
expressed over time. 
1.4.2 Incidence 
In 1988, Polson et al. reported a prevalence of polycystic ovaries of 22% in a 
'normal' population. Others (Clayton et al., 1992; Farquhar et al., 1994) have since 
confirmed the prevalence figure to be approximately 20% in the normal adult female 
population. 
The prevalence in patients referred for IVF is not as clear, although a study carried out 
by MacDougall et al. (1994) in 30 patients referred for natural cycle IVF, all with 
regular ovulatory menstrual cycles, found 43.5% had PCO. 
There are few data in the literature, which address the question of the frequency of 
PCO in women who present with anovulatory infertility (Franks et al., 1988). In 1986, 
Adams et al. studied an un selected series of 73 women with amenorrhoea and 75 with 
oligomenorrhoea presenting to a gynaecological endocrine clinic. After ultrasound 
examination of the ovaries as well as endocrine investigation, PCO were found in 
26% of women presenting with amenorrhoea and in 87% of those with 
oligomenorrhea. The diagnosis of PCO was made primarily on the basis of 
ultrasound, with at least one other clinical or biochemical marker in > 90% of cases. 
Adams et al. (1986) concluded that PCO are very common in anovulatory women 
(57%) and are not necessarily associated with hirsuitism or a raised serum LH 
concentration. 
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In 1999, Kousta et al. studied the prevalence of peo in women with infertility and 
compared the endocrine profiles of women with and without peo within infertility 
groups and with control subjects with and without peo. Among 289 couples 
classified into four diagnostic categories, peo were found in 83% (81198) of 
anovulatory patients, 53% (40176) of patients whose partner had sperm dysfunction, 
50% (26152) patients with tubal disease and in 44% (28/63) of patients with 
unexplained infertility. All peo women included in the tubal disease, sperm 
dysfunction and unexplained infertility groups were, by definition, ovulatory and had 
regular cycles. By comparison, peo was found in 28% (19167) of a control group of 
parous volunteers. The prevalence of peo was significantly higher in the tubal 
disease group and in the sperm dysfunction group compared to the control group. 
Although the prevalence of peo appeared to be higher (44%) in women presenting 
with unexplained infertility than that of the control group (28%), the difference was 
not significant. Ovulatory peo women in all four infertility categories had higher 
testosterone concentrations in comparison with peo women of the control group. 
Kousta et al. (1999) suggested that peo might, perhaps through a 
hyperandrogenaemic effect, possibly exert an adverse effect on the endometrium, 
contributing to the causes of subfertility in peo women with regular menses. 
1.4.3 Pathogenesis of PCO 
The exact aetiology of peo remains unknown (Homburg, 1996; Zaidi, 2(00). The 
clinical presentation of women with polycystic ovaries is considerably diverse, 
ranging from an incidental finding of polycystic ovaries on pelvic ultrasonography in 
an asymptomatic subject to the 'classic' symptoms of hyperandrogenic anovulation 
(Franks, 1995; 1997). Those between these extremes may have anovulatory infertility 
without hirsuitism, or hirsuitism with regular, ovulatory menses (Adams et al., 1986; 
Franks, 1989, 1997; Dewailly, 2(00). Endocrine disturbances (elevated serum 
concentrations of LH, testosterone, insulin and prolactin are common in women with 
peos (Balen et al., 1999). 
All groups of women with a polycystic morphology of the ovaries on ultrasonography 
are characterized biochemically by elevated serum concentrations of testosterone, 
regardless of symptoms (Franks, 1991; Franks et ai., 2(00). Although the highest 
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testosterone concentrations are found in women with classic peas. the mean serum 
testosterone concentration is also significantly higher than normal in women with 
pea who have mild or no symptoms (Franks. 1991). As suggested by Franks (1997). 
it is unlikely that there is a single cause of the polycystic ovary syndrome due to the 
heterogeneity of clinical and biochemical features of women with polycystic ovaries. 
It is more likely that pcas represents a complex disorder. caused by genetic and 
environmental factors (Franks, 1997; 2000; Crosignani and Nicolosi, 2001). It appears 
to have its origins during adolescence and is thought to be associated with increased 
weight gain during puberty (Balen and Dunger. 1995; Balen et al., 1999). It is not 
known at what age pca first appear, although Bridges et al. (1993) found that pea 
could be detected as early as the age of 6 years. 
The growing and antral follicles of pca are approximately doubled in number when 
compared with normal ovaries and are found at all stages of development (Goldzieher 
and Green, 1962; Hughesdon, 1982; Goldzieher, 1981; Green and Goldzieher, 1965 
and Almahbobi and Trounson, 1996). Follicular development is arrested prior to 
selection of a dominant follicle (Erickson and Yen. 1984; Gougeon. 1986; Jakimiuk et 
al., 1998). The selection of a follicle which responds to an appropriate signal (FSH) to 
grow, become 'dominant' and ovulate is disturbed in women with pea, resulting in 
multiple small cysts distending the ovary, most of which contain viable oocytes but 
within dysfunctional follicles (Balen, 2(00). 
In 1982, Hughesden suggested that the appearance of PCG was caused by over-
recruitment of follicles into the growing phases and an increase in follicle turnover. If 
this were the case. the supply of primordial follicles would be expected to be 
prematurely exhausted in women with pca. Although, to date, this possibility has not 
been studied in depth, there is no evidence available to indicate that this is the case. 
The mechanism of the increase in the number of follicles in pea remains unknown. 
but it is suggested that follicle growth is abnormal at all stages and that the increase is 
due to prolonged follicle growth in both ovulatory and anovulatory women with pea 
rather than over-recruitment from the primordial stage (Mason. 2000). There may be a 
greater number of follicles in anovulatory women with pea, due to retarded growth 
combining with arrested development and preventing the normal atresia process. 
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Support for this suggestion by Mason (2000) comes from data indicating that the 
majority of structures present in anovulatory women with pea are functional follicles 
rather than atretic cysts. However, similar to the normal ovary, ovulatory women with 
pea have primarily atretic follicles. 
1.4.4 Complications with fertility treatment 
Infertility in patients with pea is caused either by peas (Le. failure to ovulate at a 
normal rate, and/or hypersecretion of LH), or by any other causes of infertility, e.g. 
tubal blockage, male factor (Hull, 1987) or a combination of both. For women with 
pcas (80% of women with anovulatory infertility), ovulation induction is 
appropriate, but IVF may be necessary for other causes. Patients with pcas who 
have failed to conceive after at least six ovulatory cycles are considered to have 
coexisting 'unexplained' infertility (Balen et a/., 1999; Balen, 2(00). 
After treatment with clomiphene citrate to induce ovulation, 10-15% of patients with 
peas remain anovulatory despite receiving incremental doses of clomiphene 
(GUrgan et a/., 1994). Exogenous gonadotrophin therapy, in a programme of gentle 
ovarian stimulation is used for those who fail to respond to clomiphene. 
Laparoscopic ovarian surgery (ovarian diathermy or laser drilling) has replaced 
ovarian wedge resection as the surgical treatment for anovulatory women with peas 
who are resistant to clomiphene (Balen, 2(00). Laparoscopic ovarian surgery is 
performed under general anaesthesia. Laser or diathermy is used depending upon the 
preference of the surgeon and the availability of the equipment. Laparoscopic ovarian 
diathermy using 40 W for four seconds in four places on each ovary or laser drilling 
using a laser via laparoscopy set at 15 W for two seconds in 15 places on each ovary 
can lead to bilateral ovarian activity and ovulation due to a resultant decrease in serum 
androgen (testosterone and androstenedione). This effect is possibly due to 
destruction of the androgen-producing ovarian stroma and drainage of follicles with 
high androgen and inhibin content (Gtirgan et a/., 1994). Immunoreactive as well as 
bioreactive LH concentrations are decreased (Sakata et ai., 1990; Balen and Jacobs, 
1994). Serum FSH concentrations may be increased. It is hypothesized that the 
response of the ovary to injury leads to a local cascade of growth factors and those 
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such as IGF-l, which interact with FSH, result in stimulation of follicular growth and 
the production of the hormone gonadotrophin surge attenuating/inhibitory factor 
(GnSAF/GnSIF) which leads to a decrease in serum LH concentrations (Balen and 
Jacobs, 1991). These procedures have been shown to induce ovulation in > 80% of 
patients, with a normalization of serum LH concentrations and good rates of 
pregnancy (Gjonnaess, 1984; Balen, 2(00). 
Anovulatory peo is the typical form of peos and the most common cause of 
anovulatory infertility; the selection of a dominant growing follicle is blocked 
(Almahbobi and Trounson, 1996). It has been suggested that increased serum LH 
concentrations and increased intra-follicular androgen levels are instrumental in the 
blockage of normal follicular growth (Baird et al., 1977; Yen, 1980; Franks et al., 
1988). A relative lack of FSH may contribute to the persistence of anovulation but is 
unlikely, in isolation, to be a major cause of it (Franks et al., 2(00). 
Hypersecretion of LH. found in 40% of women with peos, is associated with 
menstrual disturbances and infertility. It appears to result in reduced conception rates 
and increased rates of miscarriage in both natural and assisted conception, possibly 
through an adverse effect of LH on oocyte maturation (Adams et aI., 1985; Howles et 
al., 1986; Homburg et al., 1988; Regan et al., 1990; Balen et al., 1993; Balen, 2000). 
Homburg et al. (1988) suggested that when concentrations of LH are high throughout 
the follicular phase rather than just at the time of the physiological surge, LH may 
penetrate the follicle and promote premature maturation of the oocyte, thereby 
resulting in the ovulation of an oocyte that is 'aged'. Such oocytes may be less likely 
to fertilize or may produce embryos that survive poorly and therefore abort (Howles 
et al., 1986; Homburg, 1996). Administration of gonadotrophin-releasing hormone 
agonist (GnRHa) in order to block endogenous gonadotrophin excretion before and 
during gonadotrophin therapy was employed by Homburg et al. (1993) and resulted in 
halving the miscarriage rate in women with peos treated for induction of ovulation 
and ovarian stimulation for IVF. In addition, Ashkenazi et al. (1995) demonstrated 
that the oocytes of patients with peos who were exposed to GnRHa had a 
significantly higher implantation rate than those from patients treated only with FSH 
or HMG in oocyte retrieval cycles (Sengoku et al., 1997). 
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The polycystic ovary often shows a rapid and intense response to stimulation for 
ovulation induction, producing a multifollicular rather than a unifollicular response 
and OHSS is a well-documented complication of induction of ovulation for 
anovulatory infertility or ovarian stimulation in assisted reproduction in women with 
peos (Franks et al., 1988; Armar, et al., 1990; Dor et al., 1990; Smitz et al., 1991; 
MacDougall et al., 1992; MacDougall et al., 1993; Almahbobi and Trounson, 1996; 
Ludwig et al., 1999; Agrawal, 2(00). 
OHSS is an iatrogenic complication of ovulation induction by gonadotrophins and 
arises from an excessive ovarian response. The syndrome is characterized by leakage 
of fluid from the intravascular compartment, with accumulation of protein rich fluid 
in the peritoneal and eventually pleural cavities, resulting in hypotension and a 
decrease in renal blood flow and volume of urine. VEGF and other cytokines are 
pivotal in the pathogenesis of OHSS (Risk and Aboulghar, 1999; Agrawal, 2(00). 
There are several explanations for the 'explosive' nature of the polycystic ovarian 
response. Firstly, there are many partially developed follicles in the polycystic ovary, 
which are readily stimulated to give rise to the typical multifollicular response. Thecal 
hyperplasia provides large amounts of substrate (androstenedione and testosterone), 
for oestrogen production. Aromatase, under the influence of FSH, acts on the large 
amounts of substrate to produce increased amounts of intraovarian oestrogen. The 
increased numbers of ovarian follicles in peo are increasingly sensitive to FSH, 
resulting in multiple follicular development (Balen, 1999). 
Zaidi (2000) suggested that increased ovarian stromal blood flow within the 
polycystic ovary might help to explain the increased ovarian responsiveness that 
women with peo show in response to administration of gonadotrophins. Vascular 
endothelial growth factor (VEGF) is normally confined to the blood vessels in the 
ovary and is responsible for the invasion of the Graafian follicle by blood vessels after 
ovulation. VEGF is expressed as a result of the LH surge and is an intermadiate in the 
formation of the corpus luteum (Ferrara et al., 1998). VEGF is involved in the 
pathophysiology of OHSS and is widely expressed in theca cells in the increased 
stroma of polycystic ovaries. The unifollicular response of the normal ovary is 
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enabled by diversion of blood flow within the ovaries, first from the non-dominant to 
the dominant ovary and, second, from cohort follicles to the dominant follicle 
resulting in diversion of FSH away from the cohort follicles, permitting them to 
undergo atresia (Balen et al., 1999). Agrawal et al. (1998) suggested that the 
widespread distribution of VEGF within the stroma of the polycystic ovary might 
result in a failure of diversion of blood flow away from the cohort follicles to the 
leading follicle, leaving many small and intermediate sized follicles, which remain 
ready to respond to gonadotrophin stimulation. 
1.5 Epidermal growth factor (EGF) 
1.5.1 Discovery 
Cohen et al. first described EGF in 1962, and isolated it from mouse submaxillary 
glands. Human EGF was subsequently isolated from human urine (Starkey et al., 
1975; Cohen and Carpenter, 1975) based on its ability to inhibit gastric secretion and 
was initially called urogastrone (Gregory, 1975; Gregory and Willshire, 1975; Oka et 
aI., 1983). 
1.5.2 Structure and Synthesis 
Human EGF is a member of the peptide growth factor family (Cooke et al., 1987) and 
is a single polypeptide chain of 53 amino-acid residues; it is a relatively small 
molecule (-6 kDa), likely to traverse easily through the zona of human oocytes to 
exert its effect directly on the oocyte (Goud et al., 1998). EGF was first characterized 
and sequenced in 1972 (Savage et al., 1972). Since the discovery of EGF, more than 
300 EGF-like sequences have been identified, mostly as domains of larger proteins 
(Barnham et al., 1998). These proteins have been associated with a wide range of 
functions, including blood coagulation, fibrinolysis, neural development and cell 
adhesion (Campbell and Bork, 1993; Barnham et al., 1998). 
EGF and EGF-like molecules contain three disulphide bridges. Other cornmon 
structural features are two anti parallel beta-sheets, consisting of a larger triple-
stranded beta sheet where residues at the N-terminus contribute a small third strand, 
and a smaller two-stranded beta-sheet near the C-terminus of the molecule. The three-
disulphide bridges anchor the amino-terminal strand and loop, as well as the C-
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terminal domain containing the smaller sheet, to the surface of the major beta-sheet 
(Bamham et al., 1998). 
BOF is derived from a precursor of 1,217 amino acids that includes at least seven 
BOF-like sequences; mRNA for prepro-BOF has been identified in the primordial 
follicles of the newborn female, demonstrating that the ovary has the capability to 
synthesize the precursor message for BOF (RaIl et ai., 1985). BOF is synthesized in 
small human antral follicles (Westergaard et al., 1990) 
The gene coding for BOF has been localized to human chromosome 4, region q25-27 
(Morton et at., 1986). It shows mitogenic effects in a variety of mesodermal and 
ectodermal tissues and is involved in regulating cell proliferation in mammals (Reeka 
et ai., 1998). In the ovary, BOF may regulate the function of follicular development 
(Das et al., 1991; Lonergan et at., 1996; Ooud et ai., 1998; Qu et al., 2000). BOF has 
been previously suggested to playa role in oocyte maturation in vitro (Oomez et al.. 
1993a; Singh et ai., 1997; Ooud et ai., 1998). 
TOF-a consists of 50 amino-acid residues and has 35-40% homology with EOF 
(Fisher and Lakshmanan, 1990). Like BOF, TOF-a is a potent angiogenic agent (Yeh 
et al., 1993); it modulates granulosa cell steroidogenesis and participates in follicular 
maturation (Reeka et al., 1998). Both peptides are secreted as large inactive 
precursors, which become biologically active following proteolytic cleavage. Despite 
being products of unlinked genes that are independently regulated, TOF-a and EOF 
both bind to a single EOF receptor, a 170-kDa transmembrane glycoprotein with 
tyrosine kinase activity, located on the surface of cells (Oill et ai., 1990). 
The BOF receptor is found in a wide range of adult tissue types; liver parenchymal 
cells, fibroblasts and many different epithelial cells all express the EOF receptor 
(Wiley et al., 1992). In 1992, Wiley et al. hypothesized that there may be a 
heterogeneous population of EOF "receptors" that share a common epitope(s), but 
differ in structure, binding activities and participation in cell membrane events during 
pre-implantation development. The BOF receptor belongs to the family of tyrosine 
kinase growth factor receptors. The EOF-receptor gene is located on human 
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chromosome 7 in the p13-q22 region (Kondo et aI., 1983). It consists of an 
extracellular ligand binding domain, a single transmembrane region and a cytoplasmic 
intrinsic tyrosine kinase domain (see Figure 1.5). EGF, TGF-a, vaccinia virus growth 
factor and other ligands bind to the extracellular domain of the EGF receptor and 
cause autophosphorylation of five intracellular tyrosine kinases. Autophosphorylation 
provides anchoring sites for SH2 and phosphotyrosine binding proteins, which in tum 
lead to stimulation of intracellular Ca2+ mobilization and many signal transduction 
pathway targets including mitogen-activated protein (MAP) kinases, protein kinase-C 
(PKCs) and phospolipase C-y. The autophosphorylation also enables other substrates 
to gain access to the receptor's kinase active site (Panvera, 2(01). 
The EGF receptor is present in the ovary and the corpus luteum (Kban-Dawood, 
1987; Pellicer et aI., 1992; Maruo et al., 1993), in the endometrium (Imai et al., 
1995), on the oocytes of human primordial (Qu et al., 2(00), primary and pre-antral 
follicles (Maruo et aI., 1993; Tamura et aI., 1995) and granulosa cells of antral 
follicles (Reeka et al., 1998). 
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Figure 1.5 Linear view of the EGF receptor protein. 
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Domain 
Functional domains are indicated; zigzag lines indicate cysteine-rich regions. 
(Taken from Gill, 1990). 
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1.6 Meiosis activating sterol (MAS) 
1.6.1 Discovery 
In 1985, Westergaard et al. suggested that resumption of meiosis in the preovulatory 
oocyte is triggered by meiosis-inducing substances (MIS) in follicular fluid, and 
furthermore follicular MIS may be a factor in determining the success of IVF and 
early embryonic development. 
After many years of work, Byskov et al. (1995) discovered an active substance, which 
was termed meiosis-inducing sterol in view of its action to induce resumption of 
meiosis in vitro as demonstrated in hypoxanthine-arrested cumulus enclosed and 
denuded mouse oocytes. Spent media from cultured human and bull testes contained 
the active substance that initiated meiosis in germ cells from fetal mouse testes, which 
had been cultured for 6 days in the spent medium (Byskov et al., 1998). Human 
follicular fluid obtained after stimulation with gonadotrophins was found to have a 
similar effect. 
Two naturally occurring sterols, which induce meiotic resumption of both naked and 
cumulus-enclosed mouse oocytes in vitro have been characterized: FF-MAS (4,4-
dimethyl-5<x-cholesta-8,14,24-trien-3~-01) a trienol, extracted from human 
preovulatory follicular fluid, and T-MAS (4,4-dimethyl-5<x-cholest-8,24-diene-3~-01) 
a dienol extracted from bull testicular tissue (Byskov et al., 1998). 
Sterols are synthesized by most eukaryotic organisms and are present in the lipid 
bilayer of cell membranes where their main function appears to be the modulation of 
membrane fluidity. In animals, cholesterol is the major sterol (Mercer, 1993). 
Cholesterol biosynthesis is directly affected by gonadotrophins (Leonardsen et al., 
2(00); hCG has been shown to inhibit cholesterol biosynthesis in ovine ovarian 
follicles in vitro (Douglas et al., 1978) and FSH increases the synthesis and stores of 
cholesterol in porcine granulosa cells (Baranao and Hammond, 1986). Endogenous 
gonadotrophin-stimulated steroidogenesis by the pre-ovulatory follicle affects enzyme 
activity involved in sterol and steroid synthesis; progesterone upregulation is the most 
well characterized effect (Gore-Langton and Armstrong, 1994; Leonardsen et ai., 
2(00). Within the preovulatory follicle, timely resumption of oocyte meiosis has been 
42 
hypothesized to arise from the combined effect of an altered sterol biosynthesis by the 
granulosa and cumulus cells, resulting in the accumulation of MAS, and a direct 
transfer of MAS from the cumulus cells to the oocyte via the gap junctional 
complexes. If this altered enzyme activity is not induced in the cumulus cells, 
exogenous MAS is probably immediately converted to cholesterol and other steroids 
(Leonardsen et ai., 2000). 
Intact connections between cumulus cells and the oocyte of mouse cumulus-enclosed 
oocytes are essential for FSH (Dekel and Beers, 1978; Downs et ai., 1988; Byskov et 
al., 1997) and forskolin (Guoliang et a/., 1994) to initiate the production of meiosis-
activating substance by the cumulus cells (Leonardsen et ai., 2(00), however they are 
not required for its action upon mouse oocytes (Byskov et ai., 1995). 
In 1998, Byskov et al. hypothesized that resumption of oocyte meiosis is the result of 
oocyte-dependent FSH-induced FF-MAS production by the cumulus cells which, 
when transferred to the oocyte, overcomes follicular inhibition of meiosis. 
1.6.2 Structure and Synthesis. 
FF-MAS and T-MAS are naturally occurring C-29 lipids. MAS are intermediates in 
the cholesterol biosynthetic pathway and are therefore present in all cells, which 
produce cholesterol de novo and from lanosterol. However, MAS accumulate only in 
the gonads (Byskov et al., 1998). T-MAS is the main type of MAS found in adult 
mammalian testes with trace amounts of FF-MAS. In human pre-ovulatory follicular 
fluid, FF-MAS is present at a concentration of approximately 1.3IJM and T-MAS at 
about half of this concentration (Byskov et a/., 1999). Figure 1.6 shows structural 
diagrams of FF-MAS and T-MAS. 
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Figure 1.6 Structural diagrams of FF -MAS and T -MAS. 
MAS were isolated and purified in three consecutive HPLC steps and all fractions 
were tested for any meiosis-activating effect on hypoxanthine-arrested mouse 
cumulus enclosed and naked oocytes. Mass spectrometry and nuclear magnetic 
resonance were employed to characterize the molecular structure of closely related 
MAS molecules. FF-MAS and T-MAS are very similar with respect to molecular 
structure and in their effects in bioassays, suggesting that a family of MAS may exist 
(Byskov et aI., 1998). 
FF- MAS and T-MAS are synthesized by cytochrome P450 14a-demethylase (P450-
14DM), which converts lanosterol to FF-MAS and sterol ~14-reductase (~14R), 
reduces FF-MAS to T-MAS (Schroepfer et al., 1982) (Figure 1.7). 
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Figure 1.7. MAS intermediates in the biosynthesis of cholesterol from lanosterol. 
The enzymes are indicated in italics (Modified from Byskov et al., 1998). 
Several studies have been carried out using purified or synthetic FF-MAS to evaluate 
its effectiveness in stimulating GVBD in meiotically arrested oocytes. Leonardsen et 
al. (2000) showed that blockade of the enzyme ~14-reductase, using an inhibitor 
(A Y9944; a drug used to lower plasma cholesterol by inhibiting enzymes involved in 
cholesterol biosynthesis) in hypoxanthine-arrested mouse cumulus-oocyte complexes 
resulted in the accumulation of endogenously produced FF-MAS in the cumulus cells 
and the resumption of oocyte meiosis. The same effect was not observed in naked 
oocytes, leading Leonardsen et al. (2000) to propose that MAS biosynthesis occurs in 
the cumulus cells of cumulus-oocyte complexes (COC) and not in the oocyte itself, 
and that this may be responsible for resumption of meiosis in oocytes in vivo. 
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Blocking downstream metabolism of FF-MAS with A Y9944-A 7 stimulated GVBD of 
COC in a dose-dependent manner, but not denuded oocytes. Concentrations of 5, 10 
and 25fJmoi AY9944-A7 1"1 increased GVBD in COC significantly compared with 
the controls. At 5 and IOJlglml, FF-MAS induced a significant dose-related increase 
in the percentage of GVBD in naked oocytes, however 5Jlglml, FF-MAS had no 
effect on COC, whereas IOJlglml, FF-MAS significantly stimulated percentage of 
GVBD. 
Alternatively, Downs et al. (2001) proposed that induction of meiotic maturation by 
inhibitors of enzymes situated downstream of FF-MAS in the sterol biosynthetic 
pathway, such as AY9944 (as used by Leonardsen et ai., 2(00) may be acting by 
preventing accumulation of inhibitory downstream metabolites, for example 
cholesterol. This is a plausible consideration, since A Y9944 has an additional site of 
action on ~7-reductase that produces cholesterol from 7-dehydrocholesterol. Indeed, 
cholesterol was shown to augment the inhibitory effect of dbcAMP in both cumulus-
enclosed and denuded oocytes in a dose-dependant fashion. 
Ketoconazole another widely used enzyme inhibitor, inhibits the Cytochrome P450-
14DM enzyme, which converts lanosterol to FF-MAS in vitro (Yoshida et ai., 1996). 
In 1998, Tsafriri et ai. reported no effect of ketoconazole (a potent inhibitor of sterol 
synthesis) on oocyte maturation in the rat, both in in vivo gonadotrophin-stimulated 
oocytes and spontaneously maturing oocytes in vitro. Stimulation of P450-14DM by 
gonadotrophins opposes an inhibitory effect by ketoconazole on this enzyme in the 
living animal (Byskov et al., 1999). Spontaneous meiotic maturation and FSH-
induced maturation are mediated by different intracellular pathways (Coticchio and 
Flemming, 1998). Similarly, it has been suggested that FSH-induced maturation is 
mediated by the generation of a stimulatory signal, which overcomes an inhibitory 
input from the follicle, however; spontaneous maturation does not require a 
stimulatory signal (Downs et ai., 1993). There is a similar difference between MAS-
induced and spontaneous maturation, which may explain how rat oocytes mature 
spontaneously despite an inhibitory action of ketoconazole on MAS biosynthesis. 
(Leonard sen et ai, 2(00). When ketoconazole was tested on FSH-induced maturation 
by Downs et ai. (2001) it was found to have inconsistent effects on meiotic 
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resumption. Mouse cumulus enclosed oocytes (CEO) were cultured 17-18 hr in 
medium containing either 300IJM dbc-AMP ± FSH or 4 mM hypoxanthine ± FSH. In 
dbcAMP-arrested mouse CEO, ketoconazole totally eliminated FSH-induced 
maturation (significant inhibition at 5IJM); but only minor suppression of meiotic 
induction occurred in hypoxanthine-arrested CEO, and considerably higher 
concentrations of ketoconazole (30IJM) were required for this effect. This led Downs 
et al. (2001) to suggest that the effect of ketoconazole on meiotic maturation is 
unrelated to FF-MAS levels. 
The signalling pathways for FF-MAS during resumption of oocyte meiosis have not 
yet been clarified. The MAS receptor has not yet been identified, although Janowski 
et al. (1996) observed FF-MAS to be a ligand for the orphan nuclear receptor LXR-Cl, 
and demonstrated transactivation of the receptor by several oxysterols, including FF-
MAS. However, results by Grondahl et al. (1998) found that none of these oxysterols 
or cholesterol were active in inducing resumption of meiosis in hypoxanthine-arrested 
mouse oocytes, and consequently no correlation was observed between meiosis 
stimulation and LXR-a activation. This led Grondahl et al. (1998) to conclude that it 
is not likely that the LXR-a represents the MAS receptor responsible for resumption 
of meiosis in oocytes. However, a putative nuclear MAS receptor could have 
similarities at least in the ligand-binding domain to LXR-a (Grondahl et al., 2000). 
According to Paerge et al. (2001) specific binding of FF-MAS is predominant at the 
oolemma of denuded oocytes, suggesting the existence of a plasma membrane-
associated molecule with affinity for FF-MAS (i.e., a putative FF-MAS receptor). 
In 2000, Grondahl et al. set out to elucidate whether the MAS-induced oocyte 
maturation-signalling pathway involved transcription or translation. This was 
determined by culturing arrested immature mouse oocytes with either the protein 
synthesis inhibitor cycloheximide or the heteronuclear RNA inhibitors: a-amanitin or 
actinomycin D. They demonstrated that protein synthesis was essential for 
maintaining the oocyte's responsiveness to MAS-induced resumption of meiosis 
however; transcription was not required. It was suggested that either a certain level of 
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protein synthesis is essential for the MAS signalling pathway, or that a rapid receptor 
turnover makes it essential with an ongoing de novo protein synthesis inside the 
oocyte (Grondahl et al., 2000). 
1.7 Project aims and objectives 
IVM of human oocytes has considerable scope for improvement, both in relation to 
the technique itself and the pregnancy rate after transfer of embryos resulting from 
IVM of oocytes. Such improvements could result in major benefits for a range of 
patients facing infertility treatment. However, these must be based upon an improved 
understanding of the events controlling oocyte development, particularly in the final 
pre-fertilization stage, known as maturation. 
Various factors are known to affect oocyte maturation, having effects expressed at 
different times after exposure, although an optimal culture system for human IVM is 
yet to be developed. A successful IVM protocol that is inexpensive both in labour and 
materials whilst overcoming one of the factors currently limiting oocyte maturation in 
vitro, namely poor subsequent developmental competence, will provide a major 
breakthrough in ART. 
This project aimed to provide a sound basis of scientific information gained through 
methods compatible with the clinical application of IVM, in order to provide evidence 
to inform and facilitate the eventual clinical application of IVM. This project sought 
to address the specific issue of developmental competence of embryos arising from in 
vitro matured oocytes, which has, to date, limited the use of immature oocytes in 
human infertility treatment. Throughout this project, factors having the potential to 
affect developmental competence in various ways have been assessed using human 
oocytes, since the extrapolation of data from animals to humans in this field has 
proven unreliable. The government's regulatory authority licensing research and 
treatment of infertility (HFEA) considered the available information worldwide in 
humans and animals to be insufficient information upon which to base a clinical trial, 
requiring further evidence of the safety and efficacy of the process before permitting 
its application in the UK. This project was designed in order to make a direct 
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contribution to this process and has been broadly welcomed for its focus on human 
material. 
The project aimed to assess specific factors affecting in vitro maturation of human 
oocytes in relation to the developmental competence of the resulting embryos. These 
were: 
• The origins of the oocytes in terms of donor characteristics and exposure to 
ovarian stimulation. 
• The effects of supplementation of in vitro maturation culture media with EGF 
or FF-MAS, both demonstrated in animal studies to have a positive role in 
oocyte maturation. 
• The size, growth and other visible features of oocytes at collection and during 
maturation in vitro, 
• The normality of chromosome and spindle development during in vitro 
maturation. 
In order to assess developmental competence, some in vitro matured oocytes were 
inseminated to create human research embryos using the technique of injecting a 
single sperm from a known fertile donor, with the intention of minimizing male factor 
biases in embryo development, thus enabling the female, oocyte-derived contribution 
to be determined. The normality of fertilization and cleavage of the resulting embryos 
was assessed using standard clinical embryological criteria based on morphology as 
well as image analysis enabling a quantitative evaluation of the oocyte and embryo 
database. This has been the first UK licensed project permitted to create and culture 
human embryos specifically for research purposes. 
The outcome of this research project has been an improved understanding of the 
patient groups who may be suitable for eventual IVM treatment, together with 
information on the embryological parameters of IVM. A number of original 
observations have been made, including the following important findings: The 
potential of FF-MAS as a natural stimulator of oocyte maturation has been confirmed 
in humans, as anticipated from previous studies in mice, and the ongoing growth of 
human oocytes associated with further development during maturation culture has 
been presented for the first time. One research paper has been published and a further 
submission is in preparation. This work has brought the goal of clinical application of 
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in vitro maturation closer and has contributed novel data to the literature on human 
oocytes. 
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2.1 Media preparation 
Chapter 2 
Materials and Methods 
All media preparation was carried out in laminar air flow cabinets using aseptic 
technique. The media were filtered through sterile 0.22Jlm filters (Millipore Corp., 
Bedford, UK) and equilibrated with 5% CO2 in air at 37°C before use. The 
compositions of the media used are presented in Appendix II. 
2.1.1 5% w/v Human serum albumin (hSA) 
20% w/v hSA (lmmuno Ltd, Thetford, Norfolk, UK) was diluted 1:3 with sterile 
water for injection (Fresenius, Kabi Ltd, Warrington, UK) to give a working 
concentration of 5% w/v, filtered and stored at 4°C. 
2.1.2 Earle's balanced salt solution (EBSS) 
EBSS (Gibco, Life Technologies, Paisley, UK) was used for equilibrating the mineral 
oil (Sigma, Poole, Dorset, UK) and for diluting the hyaluronidase (Scandinavian IVF 
Science, Gothenburg, Sweden) when stripping cumulus cells prior to ICSI. 
EBSS was prepared in bulk weekly from lOx concentrate (Gibco), supplemented with 
sodium pyruvate (0.22mmol/l, Sigma), penicillin (lOOU/ml) and streptomycin 
(lOOJ.lglml) at 285mOsm and containing 10% v/v of a 5% w/v injectable preparation 
ofhSA (Immuno Ltd). 
This medium was pre-tested using a mouse '2 cell to blastocyst' biotoxicity assay 
(performed by H. Baker as indicated in acknowledgements). 
2.1.3 Phosphate buffered saline (PBS, Gibco) 
PBS was used to dilute Hoechst 33258 (Sigma) for fluorescent staining of chromatin 
(2.5.3) and to dilute the monoclonal anti-a-tubulin antibody for the fluorescent 
labelling of tubulin (2.7.1). 
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2.1.4 FoUicle flushing medium 
2.1.4.1 Patients undergoing transvaginal oocyte retrieval for leSI treatment 
Oocytes were collected transvaginally under ultrasound guidance into prewarmed 
Ham's FlO medium (lCN Biomedicals, Thame, UK) supplemented with heparin 
(3IU/ml, Unihep, Leo Laboratories Ltd, Buckinghamshire, UK), which was also used 
for flushing the follicles. 
2.1.4.2 Patients undergoing laparoscopic oocyte retrieval 
Follicle flushing medium was prepared on the morning of oocyte retrieval for patients 
having PCO who were undergoing a voluntary additional procedure of oocyte 
retrieval during the course of laser drilling or diathermy operations. 
Hams FlO medium (lCN Pharmaceuticals Ltd) was supplemented to produce final 
concentrations of 20mmoVl HEPES, 3IU/ml heparin (Leo Laboratories Ltd) and 0.5% 
hSA (lmmuno Ltd). Sterile IOml plastic tubes (Falcon; Fahrenheit Laboratory 
Supplies, Milton Keynes, UK) were prepared for aspirate collection, containing 2ml 
of follicle flushing medium and the tubes were maintained at 37°C in a thermostatic 
hot-block (Grant, Cambridge, UK). 
The remaining medium in a 250ml flask (Falcon, Fahrenheit Laboratory supplies) was 
taken to theatre in a portable incubator (Cell Trans 4016 Transport Incubator; 
Labotect, Hunter Scientific Ltd, Essex, UK) at 37°C to be used for flushing the oocyte 
collection needle. 
2.1.5 In vitro maturation (IVM) medium 
NM medium was prepared on the morning of oocyte retrieval. The medium 
comprised Medium 199 diluted from M199 2x (Gibco) supplemented with sodium 
pyruvate (O.23mM, Sigma), penicillin G (50lU/ml) and streptomycin (50J.1g/ml, 
Gibco) and 0.5% filtered hSA (lmmuno Ltd). The final osmolarity was 326 ± 
0.8mOsm. 
Tissue culture dishes (40 x 12mm: Nunclon, Life Technologies, Paisley, Scotland) 
containing 2ml NM medium were pre-equilibrated in a humidified incubator at 37°C 
containing 5% C02 in air, ready to receive isolated immature oocytes for randomised 
allocation to further culture. 
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2.1.6 Sperm storage medium 
Cryopreserved donor semen was used for ICSI procedures. After performing a semen 
analysis according to standard procedures, the liquefied semen was gradually mixed 
with an equal volume of test yolk buffer cryoprotectant medium (Rochford Medical 
Ltd, Buckinghamshire, UK) within one hour of production. Mixing was carried out 
slowly to minimise the osmotic shock to the spermatozoa. I ml volumes of the semen 
cryoprotectant mixture were loaded into 1.5ml labelled cryovials (Camlab, 
Cambridge, UK) and placed into the vapour-freezing vessel, and the vessel was 
suspended in liquid nitrogen vapour in the neck of a liquid nitrogen storage tank. 
After 15 minutes, the vials were quickly transferred into a cooled labelled cryocane 
(Camlab); a cane sleeve was used to cover the cane, which was immersed in liquid 
nitrogen. 
2.1.7 Hyaluronidase 
For cumulus-corona removal, hyaluronidase lOX (in commercially prepared 
bicarbonate and HEPES buffered medium containing hSA: Scandinavian IVF 
Science, Gothenburg, Sweden) was diluted 1:2 in prepared EBSS (2.1.2), gassed with 
C02 incubated at 37°C for 30 min. Immediately prior to use, 50111 of the 
hyaluronidase dilution was added to a lOO1l1 drop of EBSS + 0.5% hSA in a prepared 
tissue culture dish (Falcon, Fahrenheit) with six 1001J I drops of medium under -7ml 
paraffin oil (Ovoil; Scandinavian IVF Science) previously pre-equilibrated overnight 
at 37°C containing 5% C02 in air before use to give an approximate final 
concentration of 80 IU/ml. 
2.1.8 Minimal essential medium (MEM) 
HEPES-buffered MEM (Sigma) supplemented with 10% vlv of a 5% wlv solution of 
hSA was used for ICSI (2.4.3). MEM contained earles salts, 25mM HEPES and 
sodium bicarbonate, without L-glutamine. 
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2.1.9 Embryo Culture medium 
2.1.9.1 PI medium with gentamycin (preimplantation stage one; Irvine Scientific, 
Santa Ana, CA). 
This commercially purchased medium was used for the culture of embryos in the EGF 
study. It is a synthetic, defined medium for in vitro procedures. It was purchased in 
IOOml bottles. 
PI medium is bicarbonate based and is modified synthetic human tubal fluid (HTF), it 
lacks glucose and inorganic phosphates, contains sodium citrate (O.15mg/I), taurine 
(O.05mM) and gentamycin (1OIlg/ml). pH 7.1, 292 mOsm. 
It was supplemented with 10% synthetic serum substitute (SSS, Irvine Scientific) and 
used for culture up to the 8-cell stage according to the manufacturers instructions. 
Tissue culture dishes (60 x 15mm: Falcon, Fahrenheit) were set up with six 100,..1 
drops of medium under -7ml of paraffin oil (Ovoil; Scandinavian IVF Science) and 
pre-equilibrated at 37°C containing 5% C02 in air before use. 
2.1.9.2 SI and S2 medium (Scandinavian IVF Science) 
These commercially purchased sequential media were used for the culture of embryos 
in the MAS study. Such sequential media were developed to take into account the 
changes in embryo physiology and requirements occurring as the embryo develops 
from the zygote to the blastocyst. S 1 is a physiological salt buffer containing hSA, 
low glucose and essential amino acids intended to support embryo cleavage to 8 cells 
i.e. pre-compaction. 
S2 is Gardner's "blastocyst culture medium" (Gardner et al., 1998), it contains a 
higher concentration of glucose along with various non-essential amino acids believed 
to be appropriate for embryo development from 8-cell compaction onwards. S I and 
S2 media were purchased in 20ml volumes. Table A6 shows the composition of S I 
and S2 media, the amounts of each component were not given, as they remain a 
commercial secret although the concentrations are presented in descending order 
down the table. 
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Tissue culture dishes (Falcon, Fahrenheit) were set up with six lOO1l1 drops of 
medium under -7ml of paraffin oil (Ovoil; Scandinavian IVF Science) according to 
the manufacturer's instructions. S2 dishes were made up early on the day of use using 
pre-gassed oil. 
2.1.9.3 Gl and G2 medium (Scandinavian IVF Science) 
In February 1999, a media change was made and 01.2 and 02.2 replaced SI and S2 
respectively. SI and S2 were withdrawn by the company in favour of 01.2 and 02.2, 
and were unavailable for five months, until S2 was subsequently made available again 
as "CCM", due to numerous requests to the company by various groups. 
Tissue culture dishes (Falcon) were set up with six looJlI drops of medium under 
-7ml paraffin oil (Ovoil; Scandinavian IVF Science) according to manufacturers 
instructions. 
2.1.10 Pre-equilibration of mineral oil used in ICSI procedure 
20ml HEPES buffered MEM (Gibeo) (minus serum) was added to a 250ml flask 
(Falcon, Fahrenheit) containing looml of mineral oil (Sigma). C02 was used to gas 
the media via a flamed glass Pasteur pipette. The flask was stored with a loosened lid 
at 37°C with 5% C02 in air, for at least four hrs prior to use. Thus ensuring that the 
mineral oil was at the correct pH and temperature. 
2.2 Oocyte maturation in vitro 
2.2.1 EGF 
2.2.1.1 EGF preparation and culture system 
Human recombinant EGF (Calbiochem-Novabiochem Ltd, Nottingham, UK) was 
used. Sterile 10mM acetic acid was used as the vehicle as recommended by the 
manufacturer. Final concentrations of 0.1, 1, IOng/ml EGF and control (no EOF) were 
set up by addition of llll of each stock to lOO1l1 IVM medium drops in tissue culture 
dishes with non-adherent surface (Falcon, Becton-Dickinson, NY) with -7ml paraffin 
oil overlay (Ovoil, Scandinavian IVF Science). The final concentration of acetic acid 
in all drops of medium including controls was 101lM, which produced no alteration in 
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pH. Dishes were pre-equilibrated at 37°C in an atmosphere of 5% C02 in air on the 
morning of oocyte retrieval, which took place in the afternoon. Up to three oocytes 
were co-cultured in each drop 
2.2.2. FF -MAS 
2.2.1.1 FF -MAS preparation and culture system 
FF-MAS was purified from human follicular fluid by high-performance liquid 
chromatography (HPLC) and detected using a photo-diode array system (Waters, 
Copenhagen) as described by Byskov et al. (1995) and Baltsen and Byskov (1999). 
(Performed by Mogens Baltsen, as indicated in the acknowledgements). 
FF-MAS was stored at -20°C in n-heptane under N2 in glass vials. Before use, a 
stream of nitrogen gas was used to evaporate the heptane from a known quantity of 
MAS, which was dissolved in a known volume of absolute ethanol (EtOH). 
Calculated volumes were added to prepared IVM media in sterile, washed glass tubes 
to final concentrations of 10 and 30J,1g/ml (24.4 and 73.2J,1M). EtOH alone, treated in 
the same manner, was added to controls. All wells contained a final concentration of 
0.5% EtOH. FF-MASlEtOH was added to the cultures - Ihr before oocyte retrieval. 
FF-MAS remaining in EtOH was evaporated to dryness and redissolved in n-heptane 
for storage at -200C under N2. 
Volumes of l00J,11 IVM medium containing the various concentrations of FF-MAS 
were set up in a sterile 96 well plate (Nunclon), which also contained medium in the 
surrounding wells to increase humidity and reduce evaporation. Cultures were housed 
in a humidified incubator (37°C, 5% CO2 in air). An oil overlay was not used, in order 
to avoid oil phase extraction of FF-MAS. Control experiments demonstrated that the 
osmolarity of cultures maintained under these conditions varied by <1 % after 24 hr. 
Up to 4 oocytes were co-incubated in each well. 
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2.3 Source and collection of oocytes 
2.3.1 peo patients 
2.3.1.1 Recruitment of patients 
These patients were attending gynaecology or infertility clinics at the Walsgrave 
Hospital. Patients having symptoms of PCO (Adams et al., 1986) and who were 
undergoing treatments which required a laparoscopy, were invited to participate in the 
study. The procedure for oocyte retrieval and the nature of the study was explained 
during the consultation, and patients wishing to participate provided written consent, 
in accordance with protocols approved by Coventry Research Ethics Committee. Only 
two patients approached regarding the study, declined to participate. 
Inclusion criteria were: (i) PCO diagnosed primarily by the ultrasound appearance of 
the ovaries, but additionally by a history of oligomenorrhoea or amenorrhoea, and 
blood hormone measurements potentially including androgen, LH elevation; (ii) no 
drug therapy for infertility in the four months before surgery; and (iii) requiring 
diagnostic laparoscopy and/or laser drilling of the ovaries. Laparoscopy was 
scheduled irrespective of the stage of the menstrual cycle. 
2.3.1.2 Theatre Procedure 
Oocyte retrieval procedures were carried out in the afternoon in theatres on the same 
site but separate from the main embryology laboratory. A previously described 
technique (Trounson et ai., 1994) was followed using a purpose-designed 170 needle 
(Cook IVF, Letchworth, UK) and a laparoscopic approach. All visible follicles were 
individually punctured and aspirated using 80-100mm Hg suction. Measurement of 
follicular diameter was not possible by direct laparoscopic inspection since the 
follicles were relatively small «10 mm) and the stroma was dense as expected in 
women with PCO (Adams et aI., 1985). The fluid was collected into the IOml sterile 
plastic tubes containing follicle-flushing medium prepared in the morning (2.1.4.2). 
The aspirates were transported to the embryology laboratory in a portable incubator 
(Cell Trans 4016 Transport Incubator, Labotect). The oocyte aspiration procedure 
took -40 minutes and the journey <10 min. 
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2.3.1.3 Oocyte identification 
Follicular aspirates were placed into an Em-Con filter of 75J..lm pore size (lmmuno 
Systems, Spring Valley, WI, USA) which had been pre-rinsed with warmed follicle 
flushing medium. The aspirates were flushed with 250ml of follicle flushing medium 
to remove contaminating blood cells and the filter retentate was transferred to sterile 
dishes (Falcon, Fahrenheit). 
Oocyte-cumulus masses and free oocytes were identified using a dissecting 
microscope (Leica Microsystems Ltd, Milton Keynes, UK), equipped with a heated 
stage at 37°C, and transferred to the prepared tissue culture dishes (Nunclon) 
containing 2ml pre-equilibrated IVM medium. 
2.3.1.4 Cumulus grading 
The level of cumulus cover surrounding the oocyte was graded subjectively from 0-3, 
where 0 = devoid of cumulus; 1 = partially covered zona; 2 = completely covered 
zona; 3 = substantial multi-layered cumulus cover (Figure A2, Appendix III). 
2.3.1.5 Oocyte viability and maturity assessment 
An oocyte was considered to be viable if it had an intact oolemma, a light coloured 
cytoplasm and a regular-appearing spherical shape. In previous experiments using the 
fluorescent vital stains, carboxy-fluorescein diacetate (CFDA) and propidium iodide 
(PI), these features had been confirmed as identifying viable oocytes. Where possible, 
it was recorded whether a germinal vesicle (aV) was present in the ooplasm, and any 
other features of oocyte morphology. Oocytes obscured by tightly surrounding 
cumulus cells (cumulus enclosed; CE) were presumed to contain a av. The initial 
assessment of maturity was performed -2 hrs after oocyte retrieval. Oocytes, which 
were clearly atretic on collection, e.g. dark cytoplasm and irregular shape, were noted 
before discarding. 
Images of oocytes were collected daily via a video link on an inverted high power 
microscope (Olympus IX 70) employing Hoffman optics and Image Pro-plus software 
(Media Cybernetics). 
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2.3.1.6 Oocyte allocation 
Individual viable oocytes were randomly allocated to either one of the four 
concentrations of EGF in the EGF study or one of three concentrations of FF-MAS in 
the FF-MAS study using tables of random numbers. The dishes of oocytes were 
incubated at 37°C under 5% CO2 in air and examined again after 23-24 hr. 
2.3.2 ICSI patients 
2.3.2.1 Recruitment 
Women undergoing ICSI at the Centre for Reproductive Medicine, Walsgrave 
Hospital were approached in advance of oocyte retrieval with information about the 
study. Women wishing to participate gave written consent prior to the oocyte retrieval 
using information sheets and consent forms approved by Coventry Research Ethics 
Committee. Approximately 80% of patients approached, agreed to participate. In the 
event of consent, any immature oocytes among the cohort collected for ICSI treatment 
were used in this study. 
2.3.2.2 Theatre Procedure 
Patient preparation, oocyte retrieval and embryological procedures were performed 
using the centre's standard protocols for ICSI (Garello et ai., 1999). 
2.3.2.3 Oocyte identification and randomisation 
Any immature oocytes identified when oocytes were stripped of cumulus in 
preparation for ICSI were randomly allocated to FF-MAS treatment groups using 
random number tables and the plates were incubated at 37°C under 5% C02 in air in a 
humidified incubator. Thereafter, they were treated identically to oocytes from 
patients with PCO. Oocytes were considered immature if they contained a germinal 
vesicle (GV) or had undergone germinal vesicle breakdown (GVBD) but had not 
released a polar body (pb). 
2.3.2.4 Oocyte maturity assessment for ICSI 
Oocytes displaying a GV were considered to be arrested at prophase I of meiosis. 
Those lacking a GV and a pb were considered to have undergone GVBD. Those 
having a pb were considered mature MIl and subjected to ICSI. Invasive analysis to 
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confirm the stage of meiosis was performed by chromatin staining of all non-matured 
and unfertilised oocytes as described in section 2.5.3. 
2.3.3 Collection of mouse oocytes 
Mouse oocytes were used for fluorescent labelling of tubulin and chromatin. Female, 
Fl, B6/C3 mice at -8 weeks of age were superovulated by intraperitoneal injection 
with 6-12 IV of pregnant mares serum gonadotrophin (PMSG; Intervet Laboratories 
Ltd, Cambridge), followed by an injection of 6-12 IV hCG (Intervet Laboratories Ltd) 
intraperitoneally 48 hrs later (Carried out by Animal House Personnel). 
48 hrs after the administration of the hCG injection, the mice were killed by cervical 
dislocation. Prior to killing the mice, two 35 mm dishes (Nunclon) and a conical tube 
each containing 1 ml HEPES buffered Earle's were set up and kept at 37°C on a heated 
microscope pad. The conical tube was kept in a humidified incubator (37°C, 5% C02) 
with the lid loose until use. All dissection equipment was sterilised with 70% alcohol 
and flaming and laid on sterile tissues until use. After killing the mice, the abdomen 
of the mouse was swabbed with 70% alcohol, before tearing the skin open between 
the fore and hind limbs. A cut was then made through the peritoneum to expose the 
abdominal cavity, and locate the two uterine horns. The oviducts, some ovarian tissue 
and about 5mm of the uterus from each side was dissected out and placed into the 
culture dish with HEPES buffered Earle's. 
Under the dissecting microscope, the bursa was gently torn and the ovarian tissue 
removed using sterile forceps and scissors. The uterus tissue was cleanly cut where it 
joined the oviduct, the coils of the oviduct were teased apart and the clean oviduct 
was moved to a new culture dish. This procedure was repeated for the other oviduct 
so the two clean oviducts from the same mouse were in a dish together. The oviducts 
were torn at the swollen points to release the oocyte- cumulus complexes, which were 
then transferred into the conical tube containing HEPES buffered Earle's. The tube 
was then transported in a transport incubator (37°C) to the Centre for Reproductive 
Medicine where it was kept in a humidified incubator (37°C, 5% CO2) with the lid 
loose until use. 
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Oocytes were stripped of cumulus using the protocol described in 2.4.2, although the 
time left in hyaluronidase was -60 seconds. 
2.4 ICSI 
2.4.1 Sperm preparation 
Two different methods were employed to recover motile spermatozoa from the frozen 
ejaculates of two known fertile sperm donors, due to the different characteristics of 
their samples. The semen samples were frozen in test yolk buffer cryoprotectant 
medium (Rochford Medical Ltd), section 2.1.6. 
Donor 1 sample contained quite a high proportion of immotile sperm and a large 
degree of cellular debris. 
Donor 2 sample contained spermatozoa with good motility; therefore the swim-up 
technique was employed. 
Donor 1- Density gradients composed of Sil-Select (silane-coated colloidal silica in 
HEPES-buffered EBSS; Fertipro) upper layer (40%) and lower layer (80%) were 
used, followed by a swim-up procedure. 
1ml of 40% upper layer was placed in a sterile 14ml conical tube (Falcon), using a 
sterile syringe and needle; 1ml of 80% was carefully layered below the 40% layer. 
0.5ml EBSS supplemented with 0.5% hSA was added to an aliquot of thawed 
ejaculate. Approximately 1ml of the semen mixed with EBSS + 0.5% hSA was then 
layered gently on top of the density gradient using a sterile Pasteur pipette and the 
tube was centrifuged at 460g for 10 min. 
The supernatant was then removed, and the pellet gently resuspended in 1ml EBSS + 
0.5% hSA. 
Swim-up: 
The sperm suspension was then transferred to a new sterile round-bottomed tube 
(Falcon) and centrifuged at 460g for 5 min. The supernatant was immediately 
removed from the top of the sample to just above the pellet which was then gently 
overlaid with -200/l1 EBSS + 0.5% hSA. The sample was left at RT for 30 min to 
allow motile spermatozoa in the sample to "swim up". The supernatant (containing 
motile spermatozoa) was then removed from the tube without disturbing the pellet; 
and transferred to a new 5ml sterile tube (Falcon). 
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After examination of a lOfJI aliquot on a Mackler chamber, an appropriate aliquot 
(-lfJl) was transferred to a 5fJI droplet of HEPES buffered MEM (minimal essential 
medium; Gibco) on the pre-prepared ICSI dish (which contained droplets for oocytes 
and PVP, see section 2.4.3) prior to the ICSI procedure. 
Donor 2- -0.5ml of frozen ejaculate was thawed at RT in a 5ml sterile tube (Falcon); 
Iml EBSS + 0.5% hSA was added to the thawed ejaculate before centrifuging at 460g 
x 5 min. The supernatant was removed and discarded, l00fJl of EBSS + 0.5% hSA 
was added to resuspend the pellet, and a further l00fJl of EBSS + 0.5% hSA was 
carefully layered on top. The sample was incubated at 37°C, 5% CO2 in air for 30 min 
to allow motile spermatozoa to swim up. 
Prior to the ICSI procedure, a IfJI aliquot was gently removed from the top layer and 
transferred to a 5fJI droplet of HEPES buffered MEM on the pre-prepared ICSI dish. 
2.4.2 Removal of Cumulus cells 
Where present, the cumulus and corona radiata of oocytes were removed by 
incubation in EBSS supplemented with 0.5% hSA containing hyaluronidase (80 
IV/ml; Scandinavian NF Science) for -30 seconds. The oocytes were transferred to 
droplets of EBSS with 0.5% hSA under paraffin oil overlay (Ovoil). The corona cells 
were removed by mechanical aspiration using a fine hand drawn sterile Pasteur 
pipette with a diameter of -150fJm. Oocytes were washed in EBSS with 0.5% hSA 
through several 1 OOfJ I droplets under oil and the maturational status observed under 
an inverted microscope at 200x magnification. 
2.4.3 ICSI reagents and set up 
Microinjection dishes (50 x 9mm: Falcon 1006) were prepared in advance. Six 5fJI 
drops of HEPES buffered MEM supplemented with 0.5% hSA were placed towards 
the centre of the dish. One of these for sperm incubation and the remainder for up to 
five oocytes, one per drop. A 5fJI drop of 10% polyvinylpyrrollidone (PVP) (lCSI-
100, Scandinavian IVF Science) was placed in the centre of the six drops. The drops 
were overlaid with -5ml pre-warmed mineral oil (Sigma), pre-washed with HEPES 
buffered MEM (Figure 2.1). 
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Mature oocytes, identified by the presence of a polar body were injected with 
spermatozoa according to the Centre's established ICSI protocol (Garello et al., 1999) 
Prior to performing ICSI on the oocytes in this study, ICSI practice was undertaken to 
achieve standards required for ICSI license application to the HFEA. After learning 
how to set up the micromanipulators used for ICSI, consent was obtained from 
patients to use any oocytes that failed to fertilize during their treatment (surplus to 
patients' requirements) to practice the injection of latex beads into oocytes. 50 one 
day-old unfertilised oocytes were injected over a period of time with latex beads and 
survival was recorded the following day after injection. A survival rate of 82% was 
achieved. 
5111 drops of HEPES buffered 
MEM + 0.5% hSA. 
Drops overlaid with mineral oil 
to maintain correct temperature 
and pH. 
5111 drop PVP. 
Figure 2.1 Diagram of microinjection dish as seen from above, used for ICSI 
procedure. 
Low sided microinjection dish used was 50 x 9mm (Falcon 1006). 
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2.5 Embryo culture 
2.5.1 Embryo culture media 
After injection, oocytes were transferred individually to lOOjJl drops of either PI 
medium with gentamycin (Irvine Scientific), Sl or G1.2 medium (Scandinavian IVF 
Science) as described in section 2.1.9. Dishes containing embryo culture media were 
pre-equilibrated at 37°C in an atmosphere of 5% CO2 in air for I day before use. The 
oocytes were checked for fertilization 14-18 hrs post-injection using standard 
procedures of pronuclear assessment. Oocytes having two pronuclei and two polar 
bodies were considered to be normally fertilized. If embryos were still cleaving on 
day 3, they were transferred to S2 or G2.2 medium. 
2.5.2 Morphological evaluation of embryo quality 
Zygotes and cleaving embryos were observed and moved to fresh drops daily. The 
number and size of cells and degree of fragmentation were recorded. A grading 
system devised by Veeck (1990) was used to score embryo quality. This assessment 
of embryo quality relates to the symmetry of cleavage, degree of fragmentation and 
the rate of cleavage. Grade 1 represents an ideal morphology. 
Gradel: Embryo with blastomeres of equal size, no cytoplasmic fragments 
Grade 2: Embryo with blastomeres of equal size, minor cytoplasmic fragments or 
blebs. No more than 10% fragmentation of blastomeres 
Grade 3: Embryo with blastomeres of distinctly unequal size, No more than 50% 
fragmentation of blastomeres. 
Grade 4: Embryo with blastomeres of equal or unequal size, major cytoplasmic 
fragments (more than 50%) and numerous blebs. 
Grade 5: Embryo with few or no recognizable blastomeres. major cytoplasmic 
fragmentation. 
Grade 6: Embryos are non-viable, with lysed, contracted or dark blastomeres. 
Computerized photographic images were collected each day until the embryos 
arrested or degenerated. 
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2.5.3 Fluorescent staining of chromatin 
All oocytes that failed to mature or fertilize and all arrested embryos were stained 
with Hoechst 33258 (Sigma) to visualise chromatin to show the meiotic stage of the 
oocytes or the nuclear profile of blastomeres. 
Stock Hoechst, 1 mglml in sterile water for injections (B Braun Medical Ltd, 
Sheffield, UK) was prepared in advance and stored in the dark (wrapped in aluminium 
foil) at 4°C. For staining, a 11100 dilution was prepared in phosphate buffered saline 
(PBS; Gibco). Oocytes/embryos were stained by incubation in 2ml prepared stain in a 
tissue culture dish at 37°C (on a warm stage) in the dark under aluminium foil for 
approximately 10 min and moved to fresh PBS at 37°C. Oocytes/embryos were 
viewed by placing in a small drop (-20IlI) PBS on a slide with gentle compression 
under a coverslip supported by Vaseline pillars at the comers. The slides were viewed 
on a fluorescence microscope (Olympus B071) using a DAPI-filter. Fluorescent 
microscopic images were collected via video link and Image Pro-plus software 
(Media Cybernetics). 
2.6 Chromosome spreading 
Immature oocytes donated by patients undergoing ICSI treatment were cultured with 
colcemid (Sigma) at a final concentration of 10Ilglmi in EBSS + 0.5% hSA in a 
prepared tissue culture dish (Falcon, Fahrenheit) having six l001l1 drops of medium 
under -7ml pre-equilibrated paraffin oil (Ovoil; Scandinavian IVF Science) Dishes 
were preincubated overnight at 37°C with 5% C02 in air before use, and oocytes were 
incubated for 4-6 hrs at 37°C, under 5% C02 in air before fixing and spreading. 
Chromosome spreading was performed according to a modification of the air-drying 
technique (Tarkowski, 1966). Briefly, oocytes were placed in 1% w/v sodium citrate 
solution (BDH, Merck Ltd, Poole, Dorset, UK) at RT for ten minutes. Oocytes were 
then placed in a micro drop of the 1 % w/v hypotonic sodium citrate medium in the 
middle of a grease free slide and gradual fixation was performed by adding a drop of 
freshly prepared fixative: ethanol (BDH): glacial acetic acid (Sigma) solution (v/v, 
3:1). Blowing on the slide aided the air-drying procedure. 
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Fixed preparations were stained with 4% Giemsa (BDH) in 0.1 M phosphate buffer 
(pH 7.2) in a coplin jar (BDH) for five minutes, then washed in O.1M phosphate 
buffer (pH 7.2) alone. When chromosomes were observed, the slide was de stained 
with ethanol and stained with -20~Jl mounting medium containing 4'-6-diamidino-2-
phenylindole at a concentration of 1.5/lglml (DAPI~ Vectorlabs, USA). 
Fluorescence microscopy using a Zeiss Axioskop fluorescence microscope 
(Oberkochen, Germany) equipped with a DAPI (Zeiss 487909) selective filter set and 
a 50W mercury lamp was used to obtain the DAPI fluorescence. Images were taken 
using a cooled CCD camera (Photometrics) coupled with a Smartcapture image 
acquisition and analysis system (Vysis/Applied Imaging). 
2.7 Immunocytochemistry 
2.7.1 Fluorescent labelling of tubulin and chromatin 
Tubulin and chromatin were identified in mouse and human oocytes. In vivo matured 
oocytes that had failed to fertilize were obtained from consenting patients undergoing 
NF and used as control oocytes. Oocytes were fixed using a modification of the 
method of Battaglia et al. (1996a). Briefly, oocytes were fixed at RT for 45 min in 
PBS (Gibeo) containing 16% w/v formaldehyde (TAAB Laboratories equipment Ltd, 
Berkshire, UK) and 0.01 % Triton X-IOO (Sigma). They were then washed in PBS 
containing 2% bovine serum albumin (BSA; Sigma) for at least 60 min. 
The antibody employed to detect spindles was a monoclonal anti-a-tubulin antibody 
raised in mice and specific for human, monkey, murine and a variety of other species. 
It was supplied as solution in O.OIM PBS, pH 7.4, containing 1% BSA and 15mM 
sodium azide as a preservative, ready labelled with fluorescein isothiocyanate 
conjugate (FITC), isomer I (Sigma clone DM I A). The antibody was applied at a 
concentration of 1 :200 in PBS containing 0.1 % Tween 20 (polyoxyethylenesorbitan 
monolaurate~ Sigma) for 30 min at RT. After washing in PBS, the oocytes were 
mounted in PBS on a slide and stained with -20/l1 mounting medium containing 4' -6-
diamidino-2-phenylindole at a concentration of 1.5/lglml (DAPI; Vectorlabs, USA) to 
localize chromatin; the coverslip was then placed on slide. The fixing and staining 
procedures were carried out at RT with the oocytes free in suspension. 
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Fluorescence mIcroscopy using a Zeiss Axioskop fluorescence microscope 
(Oberkochen, Germany) equipped with fluorescein (Zeiss 487902) and OAPI (Zeiss 
487909) selective filter sets and a SOW mercury lamp were used to obtain the FITC 
localization patterns and DAPI fluorescence simultaneously. Images were taken using 
a cooled CCD camera (Photometrics) coupled with a Smartcapture image acquisition 
and analysis system (Vysis/ Applied Imaging). Paired and separate images were taken 
to examine the co-localization oftubulin and chromatin. 
2.8 Image analysis 
2.8.1 Set up and measurements 
In this study, daily throughout culture, light microscopic images of all oocytes and 
embryos were routinely collected using an image analysis package (Image pro-plus, 
Media Cybernetics) linked via a video camera to an inverted microscope (Nikon) with 
Hoffman contrast optics. The store of images collected for each oocyte and patient 
was analysed to show whether any measured parameter correlated with the in vitro 
culture conditions employed and/or the subsequent development of the 
oocyte/embryo. Trial measurements were performed as a control to check the 
reliability of measuring (Table 7.1). For the trial, ten oocytes (from patients 
undergoing treatment in the CRM) were each measured ten times on the day of oocyte 
retrieval. 
The image analysis package was used to measure various parameters of the oocyte or 
embryo, these were mean diameter of oocyte, mean diameter of oocyte + zona, mean 
zona thickness, and perivitelline space (PVS) (Figure A3, Appendix IV). 
2.8.2 Oocyte diameter 
The mean diameter of an oocyte was calculated by measuring the mean length of 
diameters as far as the oolemma at two-degree intervals and passing through the 
object's centroid. 
2.8.3 Oocyte + zona diameter 
This assessment was performed as for oocyte diameter, but extending the diameter 
measurement to the outer surface of the zona pellucida. It therefore included both the 
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oocyte and its zona pellucida, and incorporated differences in perivitelline space and 
zona thickness. 
2.8.4 Zona peUucida thickness 
The image analysis software generated a mean zona pellucida thickness measurement, 
after measuring the zona thickness at 2J.lm intervals. 
2.8.S Perivitelline space (PVS) 
The image analysis software generated a measurement of the PVS by calculating the 
minimum and the maximum distance between the inner zona and the oolemma and 
calculating a mean PVS from this. This measurement could be assessed in one plane 
only and is therefore an estimate, which may vary depending upon the orientation of 
the oocyte. 
2.9 Statistics 
Scatter plots of oocyte yield (viable and atretic) according to patient age; weight, BMI 
or days since last menstrual period were assessed for correlation using regression 
analysis. P values < 0.05 were considered significant. Student's t-test was used to 
compare the numbers of viable oocytes from the two patient groups. 
The proportions of GV and GVBD oocytes maturing or undergoing atresia in the 
presence or absence of EGF were compared using pxq contingency table with chi-
squared test (X2) (Campbell, 1989). 
The proportions of oocytes surviving, maturing or becoming atretic in groups exposed 
to different concentrations of FF-MAS were compared using pxq contingency table 
with X2 test. The extent of maturation in vitro of oocytes collected at the GV and 
GVBD stages and cultured with or without FF-MAS within both patient groups was 
tested for statistical significance using X2 test. The extent of oocyte maturation 
according to the amount of cumulus cover at recovery of oocytes from patients with 
pca was tested for significance using pxq contingency table with X2 test. 
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The measurements for each individual oocyte over several days of assessment were 
compared, according to the treatment which the oocyte received and the outcome of 
attempted maturation and fertilization in vitro, to observe whether there were 
correlations between these measurements and the oocyte's subsequent development. 
In this way, normal and threshold values were identified for various features of oocyte 
development. 
For oocytes retrieved from patients with pea, diameters of oocytes with dense 
cumulus cover at collection were compared with oocytes with less or no cumulus 
cover using pxq contingency table with X2 test. 
Within both patient groups the following tests were performed: oocytes diameters on 
day 0 were compared according to the outcome of in vitro culture (mature, immature, 
atretic) and tested for statistical significance using the Kruskall-Wallis test (Campbell, 
1989). For each patient group, oocyte diameters were compared between day of 
oocyte retrieval and day 0 of oocytes that became atretic, within each culture 
condition using the Mann-Whitney V-test (Campbell, 1989). Oocyte growth during 
culture (from day of oocyte retrieval to day 0) for those oocytes that matured was 
tested for statistical significance using the non-parametric sign test (Campbell, 1989), 
according to the conditions of culture to which oocytes were exposed. For the 
difference in growth between oocytes maturing in 3011 glml MAS and in control, a 
two-sample t-test was performed. 
The difference in mean diameter of oocytes + zona between the day of oocyte 
retrieval and day 0 within each culture group was tested for statistical significance 
using the Mann Whitney V-test. A pxq contingency table with X2 test was performed 
on oocyte + zona data on day of oocyte retrieval and on day 0 for those measuring 
140-151Jlm and 152-175Jlm and the ability of the oocytes to mature in vitro. The 
same test was also performed on oocyte + zona data on day of oocyte retrieval and on 
day 0 for those measuring 140-157Jlm and 158-175Jlm. A Mann Whitney V-test was 
performed on the zona pellucida thickness of oocytes on day+ 1 of those that fertilized 
and those that failed to fertilizelbecame atretic for both patient groups. 
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A one-tailed T -test was performed on oocyte diameters on day of collection from the 
two patient groups. A Mann Whitney V-test was performed on oocyte + zona 
diameters on the day of collection from the two patients groups. 
Additionally for oocytes donated by patients undergoing ICSI, non-parametric 
statistical analyses (Mann Whitney V tests) were applied to determine if there were 
any significant differences in oocyte diameter between oocytes that matured within 
23-24 hr and those that matured within 40-48 hr. This was performed for oocytes 
within each culture group, and using pooled data (all culture groups combined). A 
Kruskall Wallis test was also performed on oocytes diameters of all those maturing 
within 23-24 hr within the different culture groups, and on all those maturing within 
46-48 hr within the different culture groups. 
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3.1 Introduction 
Chapter 3 
Patient data 
Immature oocytes were retrieved from two patient groups: unstimulated patients 
having PCO undergoing treatments which required a laparoscopy; and patients 
undergoing ICSI treatment, which included ovarian stimulation according to a 
standard 'long' down-regulation protocol. The study was approved by Coventry 
Research Ethics Committee and licensed by the Human Fertilisation and Embryology 
Authority. 
Oocyte function is known to be related closely to the environment of the follicle, and 
the health of the somatic cells that surround and nourish the oocyte. The origin of the 
oocytes used to study oocyte maturation may therefore influence their subsequent 
viability and developmental competence. This chapter presents basic information 
about the patients who donated oocytes to this study, including their ages, aetiology of 
infertility, outcome of treatment and other parameters that may have had a bearing 
upon the quality of their oocytes. 
For the patients with PCO, this information has been related to the oocyte yield of the 
unstimulated oocyte collection procedure. Since patients undergoing ICSI treatment 
received ovarian stimulation, predictive information would not be expected to arise 
from oocyte yield and this approach has not been taken. 
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3.2 PCO patients 
3.2.1 Clinical details of patients 
The clinical details of patients with peo are presented in tables 3.1 and 3.2 according 
to whether their oocytes were used in the EGF or MAS series of experiments 
respectively. 
Table 3.1 Clinical details of patients with polycystic ovaries (peO) who donated 
immature oocytes for culture with or without EGF. 
Patients (n) 
Patient age (years)C 
Menstruation 
8 
31.8 ± 5.8 (25-37) 
o 
6 (days since LMP: 37.3 ± 14.9, range 16-55) 
Regular (28-35d) 
Oligomenorrhoeic 
Amenorrhoeic (2o)a 
Weight (kg) 
2 (days since LMP: 304 ± 257.4, range 122-486) 
72.9 ± 19.3 (51-96) 
Body mass index (BMI)b 
No of oocytes collectedc 
Live 
Atretic 
30.5 ± 7.6 (25-45) 
5.8 ±5.9 
5.1±4.7 
(1-19) 
(0-11) 
a 20 Amenorrhoea is defined as no menstruation for >3 months. 
b BMI calculated as body weight (kg) divided by height (M2). 
C Data are mean ± SD, with range in parentheses. 
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Table 3.2 Clinical details of patients with polycystic ovaries (PCO) who donated 
immature oocytes for culture with or without FF-MAS. 
Patients (n) 
Patient age (years) C 
Menstruation 
Regular (28-35d) 
Oligomenorrhoeic 
Amenorrhoeic (20) a 
Data not recorded 
Weight (kg) 
Body mass index (BMO b 
No of oocytes collected C 
Live 
Atretic 
19 
27.9 ± 3.8 (22-35) 
3 (days since LMP: 21.3 ± 5.8, range = 18-28) 
10 (days since LMP: 25.9 ± 26.8, range = 3-96) 
5 (days since LMP: 192.2 ± 33.8, range =154-241) 
1 
75.3 ± 19.9 
30.4 ± 7.0 
6.7 ±4.0 
5.1 ± 4.3 
(44-115) 
(15.5-44) 
(1-19) 
(0-14) 
a 20 Amenorrhoea is defined as no menstruation for >3 months. 
b BMI calculated as body weight (kg) divided by height (M2). 
C Data are mean ± SO, with range in parentheses. 
A comparison of tables 3.1 and 3.2 revealed no significant differences between the 
groups in terms of patient age, weight, BMI or number of live or atretic oocytes 
collected. The PCO patient group has therefore been presented as a cohort of 27 
patients for the subsequent analyses in this chapter. 
23% (5/26) patients became pregnant as a result of surgery; one patient was 
undergoing surgery to decrease hirsuitism and was sterilized after the oocyte 
collection. 
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3.2.2 Relationship between age and number of oocytes collected. 
Figure 3.1 shows scatter plots of the numbers of viable and atretic oocytes collected 
from unstimulated peo ovaries according to the age of the patient. The figure shows 
no significant correlation between age and number of oocytes collected, whether 
viable or atretic. 
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Figure 3.1 Scatter plots of the number of (a) viable and (b) atretic oocytes 
retrieved from unstimulated polycystic ovaries according to the age of the 
patient. 
No significant correlations were present (a) r = 0.092 (b) r = 0.064. 
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3.2.3 Relationship between days since last menstrual period (LMP) and the 
number of viable and atretic oocytes collected. 
Figure 3.2 presents a scatter plot of the numbers of viable and atretic oocytes retrieved 
from unstimulated patients with peo according to the time that had elapsed since 
their last menstrual period. The apparent positive correlations between these 
parameters in terms of viable and atretic oocytes were not significant and may have 
occurred because of a single outlying observation for each, skewing the distributions. 
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Figure 3.2 Scatter plots of the number of (a) viable and (b) atretic oocytes 
according to the number of days since the last menstrual period (LMP). 
No significant correlations (a) r = 0.471 (b) r = 0.359. 
75 
3.2.4 Relationship between patient weight and the number of viable and atretic 
oocytes collected. 
Extremes of weight are known to affect fertility, and a tendency towards obesity may 
occur in women with peD. Fertility may be enhanced in obese women with peDS by 
a loss of weight (Jansen, 1995). Figure 3.3 presents the scatter plots of the numbers of 
viable/atretic oocytes retrieved from women with peD in relation to their weight in 
kg. 
Although this study group included a range of obese and non-obese women, no 
significant associations between weight and viable or atretic oocyte yield were 
observed. 
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Figure 3.3 Scatter plots of the number of (a) viable oocytes and (b) atretic 
oocytes retrieved according to the weight of patients with PCO, 
No significant correlations, (a) r = 0.252 (b) 0.124 
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3.2.5 Relationship between patient body mass index (8MI) and the number of 
viable and atretic oocytes collected. 
BMI is an index of obesity; it is calculated as body weight (kg) divided by height 
(M2). A BMI <20 kglm2 is considered underweight and >30 kglm2 is considered obese 
(Balen et al., 1999). Figure 3.4 presents the scatter plots of the numbers of viable and 
atretic oocytes retrieved from women with peo in relation to their BMI. No 
significant associations between BMI and viable or atretic oocyte yield were 
observed. 
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Figure 3.4 Scatter plots of the number of (a) viable oocytes and (b) atretic 
oocytes retrieved according to the BMI of PCO patients. 
No significant correlations, (a) r = 0.061 (b) 0.048. 
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3.3 ICSI patients 
3.3.1 Clinical details of patients 
Table 3.3 presents the clinical details of all the patients included in this study who 
were undergoing ICSI treatment. They were recruited between September 1998 and 
April 2001, during which time ICSI procedures at the CRM remained unchanged. The 
data in table 3.3 indicate rates of successful pregnancy that are consistent with the 
IVFIICSI programme of the CRM over this period. A total of six patients had partners 
diagnosed with azoospermia. Of these, three patients had epididymal sperm used and 
three had testicular sperm used for the therapeutic ICSI procedure, which did not 
affect their success in terms of oocyte fertilization and pregnancy. 
Table 3.3 Clinical details of patients undergoing intracytoplasmic sperm 
injection (ICSI) treatment who donated immature oocytes for culture 
with or without FF-MAS, chromosome assessment or for culture with 
or without FF-MAS for spindle analysis. 
Patients (n) 57 
Patient age (years)a 32.9 ± 3.7 
No. of previous ICSI attemptsa 0.8 ±.0.9 
Total no. of oocytes collecteda 15.2± 6.2 
Fertilization rate (2PN)b 63.5% 
Ongoing pregnancy rate 29.6% 
Pregnancy losses Ie 
No. of cleaving embryos frozen 2.2 ± 2.4 
No. of 2PN frozen 0.9 ± 2.5 
No. of immature oocytes 2.2 ± 1.5 
donated to study 
a Data are mean ± SO, with range in parentheses. 
b Oocytes with 2 PN/ oocytes injected 
C For one cycle, all embryos frozen 
(27-40) 
(0-3) 
(5-28) 
(16/54 c, d) 15 deli vered 
(1- 6) 
d Two cycles resulted in OHSS, therefore no embryo transfer 
e Biochemical pregnancy 
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Table 3.4 presents the principle identifiable causes of infertility of the patients who 
donated immature oocytes via the ICSI programme. While these pertain to the results 
of treatment presented in table 3.3, they are less relevant for the subsequent 
experimental work on immature oocytes, in which fertile donor sperm was used to 
promote consistency of interpretation. 
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Table 3.4 Aetiology of infertility for patients (n=57) undergoing ICSI treatment 
who donated immature oocytes for this study. 
Aetiology No. of 
Cause 
of infertility patients 
(S factor: 
Teratozoospermia 
Azoospermia 
Oligozoospermia 
Primary (10) 36 ~ factor: 
Ovarian 
Tubal 
6 & ~ factor: 
Failedllow fert: 
CS factor: 
Teratozoospermia 
Azoospermia 
Oligozoospermia 
Failed vasectomy 
Secondary (2°) 21 reversal 
~ factor: 
Ovarian 
Tubal 
6 & 5f factor: 
Failedllow fert: 
a Anovulatory and teratozoospermia 
b Endometriosis and teratozoospermia 
Definition of terms (WHO. 1999): 
Mean no. of 
No. of years of 
patients involuntary 
infertility 
20 
3 
3 
5.0±2.8 
1 
4 
2a,b 
3 
7 
3 
5 
1 
4.0 ± 2.4 
2 
1 
1 
l a 
0 
Teratozoospermia-Reduced levels of normally shaped sperm «15% normal) 
Azoospermia-Total absence of sperm 
Oligozoospermia-Reduced sperm numbers «20 x 106/ml) 
Range 
1-12 
1-12 
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3.4 Discussion 
The patients having polycystic ovaries, who donated oocytes during gynaecology 
operations comprised one group, regardless of which part of the study their oocytes 
were used in, as shown in tables 3.1 and 3.2. 
The mean number of viable oocytes collected from this group of patients with PCO 
was 6.4 ± 4.6. This was lower than the means of 13.8 and 13.1 obtained from 
anovulatory and ovulatory PCO patients (collected in the follicular phase) 
respectively by Trounson et al. (1994), but more comparable to the average of 8.1 per 
patient reported by Coskun et al. (1998). Coskun et al. (1998) recovered immature 
oocytes from 17 patients at risk for ovarian hyperstimulation syndrome, ten of the 
patients had polycystic ovaries. Immature oocytes were recovered trans vaginally with 
reduced aspiration pressure, one day after the last hMG injection, hCG was not 
administered. Russell et al. (1997) retrieved a similar figure of approximately 11 
oocytes from unstimulated patients whose endometrial priming started in either the 
early or midfollicular phase. 
Both Coskun et al. (1997) and Russell et al. (1997) collected the oocytes 
trans vaginally under ultrasound guidance; therefore all of the visible antral follicles 
were aspirated. Trounson et al. (1994) also collected the oocytes transvaginally under 
ultrasound guidance, except in 19 % (8/42) of patients, for whom laparoscopic oocyte 
retrieval was performed, due to the difficult puncture of small follicles as a result of 
ovary mobility. In comparison, the oocytes collected from PCO patients in this study 
were all collected laparoscopically; therefore follicles were rarely clearly visible prior 
to aspiration, the patients had received no gonadotrophin priming and the laparoscopy 
was scheduled irrespective of the menstrual cycle. This may explain both the reduced 
number of oocytes retrieved and the collection of atretic oocytes (mean number of 5.1 
± 4.3 atretic oocytes per PCO patient). In a study of immature oocyte retrieval in 37 
patients with varying diagnoses including tubal disease, endometriosis, anovulation, 
male factor and unexplained, Russell et al. (1997) reported a mean of 2.1 atretic 
oocytes per patient when oocyte retrieval was scheduled between day 9 and day 12. 
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The appearance of the atretic oocytes in the present study was characteristically dark 
indicating that they had been atretic for some time, rather than damaged during the 
aspiration procedure. 
The small follicles associated with polycystic ovaries are neither atrophic nor 
apoptotic (Homburg et al., 1996) but may persist longer than normal at this stage. 
They became arrested in the small antral stage following apparently normal 
development up to a size of 6-8mm, the size at which dominant follicle selection 
would normally take place (Fauser, 1994). The effects which such persistent follicles 
may have upon oocyte viability is uncertain since they are highly responsive to FSH 
stimulation and may result in viable mature oocytes in assisted conception procedures. 
Due to the small size of follicles present in polycystic ovaries, the technique of oocyte 
retrieval is one of the pivotal factors for success (Cha et al., 2000). Using an US-
guided transvaginal oocyte aspiration technique, either 10-13 days after spontaneous 
menses in those peas patients with some menstrual function or 10-13 days after 
withdrawal bleeding induced by 1M injection of progestin, Cha et al. (2000) reported 
the recovery of 13.6 ± 7.5 oocytes per patient, with a range of 3-34. The induction of 
a withdrawal bleed, which effectively "restarts" follicle development by promoting 
endogenous FSH secretion, may have assisted in the achievement of a high yield of 
oocytes. 
The presence of small antral follicles responsive to FSH in the luteal phase is thought 
to determine the number of recruitable oocytes in the following menstrual cycle 
(Gougeon and Testart, 1990), therefore an increase in FSH levels in the late luteal 
phase would possibly allow more follicles to continue their growth in the following 
menstrual cycle (Suikkari et al., 2000). Suikkari et al (2000) reported the mean 
recovery of 11.2 viable oocytes from women with regular menstrual cycles and a 
mean of 10 viable oocytes from women with pea and irregular cycles, after low-dose 
FSH priming of follicles starting in the late luteal phase. The women with peo in this 
study received no gonadotrophin priming and so the pool of follicles for aspiration 
may have been smaller. 
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In contrast to the reports cited above, preliminary studies of the pretreatment of 
women with FSH early in the follicular phase showed no difference in the recovery 
rate of oocytes (Trounson et al., 1998; Mikkelsen et al., 1999), although improved 
maturation was observed (Wynn et al., 1998). 
The number of oocytes available to be collected would be expected to reduce as the 
ovarian reserve declines with advancing age, as evidenced by rising basal FSH levels 
(Cha and Chian 1991 Cha et al., 1991; Whitacre et al., 1998) and the symptoms of 
PCO may ameliorate with increasing age. However, Figure 3.1 demonstrates no 
significant correlation between age and the number of oocytes collected, whether 
viable or atretic. The underlying condition of PCO, where many antral follicles persist 
may account for the observed numbers of oocytes failing to decrease significantly 
with increasing age, as might otherwise be expected. 
Barnes et al. (1996) reported the retrieval of a larger number of oocytes from 
irregularly cycling and anovulatory patients compared to regularly cycling women 
(16.5 and 4.9 respectively), which related to the relative ease of aspiration from the 
peripherally located antral follicles in PCO. Among patients with PCOS, Cha et al. 
(2000) retrieved a similar number of oocytes from women with oligomenorrhea and 
amenorrhea. Almahbobi et al. (1996) proposed that ovulatory PCO is an intermediate 
form of the syndrome, which may lead, when expressed severely to anovulatory PCO. 
In this study, the time elapsed since LMP did not show any significant correlations 
with the numbers of viable or atretic oocytes retrieved. It had been expected that the 
time elapsed since the LMP may correlate with an increasing number of atretic 
oocytes as a result of follicle aging, however, this supposition was not confirmed. 
Obese women with PC OS hypersecrete insulin, which stimulates ovarian secretion of 
androgens, and is associated with hirsuitism, menstrual disturbance and infertility 
(Balen et al., 1999). It is known that weight loss can lead to regular menstrual cycles 
and spontaneous pregnancies by producing a more favourable ovarian environment 
for follicle growth through a lower insulin and insulin-like growth factor (lGF)-I 
concentration (Franks, 1989; Pasquali et al., 1989; Kiddy et al., 1990, 1992 and Elting 
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et al., 2(00). In this study, no significant associations between weight or BMI and 
viable or atretic oocyte yield were observed (Figure 3.3 and 3.4 respectively). 
In conclusion, no specific characteristics of the PCO patients in this study were 
predictive of the numbers of oocytes retrieved; specifically patient age, time since the 
LMP, weight and BMI did not show significant correlations with either viable or non-
viable oocytes. This may be related to the pathological "PCO" ovary, where large 
numbers of antral follicles are present at any age, potentially tending to equalize any 
differences in accessible follicle numbers due to underlying age or other factors 
related to the ovarian reserve. 
The patients undergoing ICSI treatment and donating immature oocytes appeared 
representative of infertility patients, who would normally undergo this treatment 
having a predominance of male factor indications. The mean age of patients in this 
study (32.9 ± 3.7) is similar to the mean age of patients attending the CRM for 
infertility treatment, which is -34 years. The mean total number of oocytes collected 
per patient (15.2 ± 6.2) appeared generally higher than the mean number of oocytes 
normally collected for infertility patients undergoing oocyte collection at the CRM, 
which is -10 oocytes. Patients in this group had clearly responded well to stimulation, 
as might be anticipated from the relatively low incidence of ~ factor indications for 
treatment, and also from the observation that their oocyte cohort included one or more 
immature oocytes. These would be expected to arise from smaller or less mature 
follicles and might suggest a tendency towards OHSS or PCO amongst some of these 
patients. The pregnancy rate shown in table 3.3 was similar to the ICSI pregnancy rate 
of infertility patients at the CRM over the same period. The number of immature 
oocytes donated by patients undergoing ICSI ranged from 1-6 and might indicate that 
a proportion of follicles failed to develop fully in response to the ovarian stimulation. 
The exogenous gonadotrophic drugs used to stimulate the growth of several follicles 
concurrently may compromise oocyte development in comparison with natural cycles 
(Bnien et al., 1995). The immature oocytes obtained in this study after follicular 
stimulation have been exposed to supraphysiological concentrations of 
gonadotrophins in vivo yet still failed to mature, they may therefore be of inherently 
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reduced quality or the immature oocytes may have been developing normally but 
retrieved from small follicles with reduced gonadotrophin sensitivity. Alternatively, 
they may have arisen from otherwise normal follicles, which did not receive the same 
hormonal stimulus as others, perhaps due to a limited blood supply. However, such 
oocytes have been previously shown, in certain cases to have the potential for full 
embryonic developmental (Cha and Chian, 1998). 
No patient undergoing ICSI who donated oocytes to this study had immature oocytes 
retrieved only. This is a rare occurrence with few previous case reports (Hartshorne et 
aI., 1999). Patients donating oocytes in this study had a mean of 11.4 ± 5.6 mature 
oocytes collected that could be used for their treatment, and their donation of 
immature oocytes to this study had no effect upon their treatment. 
While the collection of oocytes from patients undergoing infertility treatment or 
suffering pathological conditions is not ideal for research, the extremely limited 
availability of human oocytes for study required such an approach to be taken. Fresh, 
in vivo matured oocytes are reserved for patients' own use, and are therefore not 
accessible as control material, without interfering with the patient's chances of a 
successful outcome. It is hoped that if IVM can be optimized, then further 
understanding of the processes involved in oocyte and embryo development could be 
gained from the increased availability of fertile oocytes that would arise as a result. 
Additional sources of such immature oocytes might include patients undergoing 
laparoscopic sterilization, caesarian section, or ovariectomy. However, these would 
also have concerns, such as the likelihood of prior steroidal contraception, an acyclic 
endocrine environment, or advanced age associated with a low ovarian reserve or 
malignancy potential respectively. There therefore remains no optimal source of 
oocytes, however, a through understanding of the patient populations from which 
starting material is sourced is essential in interpretation of experimental results. 
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Chapter 4 
Addition of EGF to culture of oocytes from PCO patients 
4.1 Introduction 
A number of peptide growth factors have been implicated as ovarian regulators of 
follicular development and steroidogenesis. These factors include, for example, 
epidermal growth factor (EGF), transforming growth factor-alpha (TGF-a), fibroblast 
growth factor (FGF), insulin-like growth factor-type I (IGF-I), platelet-derived growth 
factor (PDGF) and transforming growth factor-beta (TGFP) (Yeh et al., 1993). 
EGF is present in human follicular fluid at concentrations ranging between 0.60-
2.42nglml (Westergaard et al., 1990). Serum concentrations of EGF range between 
0.7 and 2.Onglml in humans (Hofmann et al., 1990; Westergaard and Andersen, 1989; 
Westergaard et al., 1990). 
In 1990, Westergaard et al. studied EGF concentrations in small antral follicles 
«6mm in diameter) of pregnant women and reported concentrations of EGF in the 
follicular fluid of these follicles to be several times higher than those in serum. In 
addition, a significant decline in the levels of intrafollicular EGF from 4.7 to 
l.4nm01ll was observed with increasing follicle size from 1-6mm. This decrease in 
intrafollicular EGF seen with follicular growth appears to continue until the 
preovulatory stage (Westergaard et al., 1990). In a previous study of EGF 
concentrations in follicular fluid aspirated from preovulatory follicles (> 14mm 
diameter) by Westergaard and Y ding-Andersen (1989), the EGF concentration in 
follicular fluid ranged between 0.1-0.4nmol/1, corresponding to approximately 50% of 
that in serum. This led Westergaard et al. (1990) to conclude that intrafollicular EGF 
is specific to small antral follicles and may be synthesized by the granulosa and/or 
theca cell layers of these follicles. 
Data obtained in the mouse model by Almahbobi et al. (1995) also suggested that in 
normal conditions, the decrease in the concentrations of EGFrrGF-a is a necessity for 
late follicular maturation. 
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EGF has been implicated in the condition of polycystic ovaries (pea), due to its 
potent inhibition of FSH-induced aromatase activity (Franks et aI., 1988; Mason et 
al., 1990). Franks et al. (1987, 1988) have suggested that EGF in small follicles may 
be responsible for a lack of follicular responsiveness to FSH in women with 
polycystic ovary syndrome. These women exhibit a significantly higher level of EGF 
in follicular fluid obtained from Graafian follicles than women with normal ovaries. It 
is possible that pea may be caused by a disruption in the regulatory mechanisms of 
EGFffGF-a production and activity, resulting in a reduction in oestradiol 
concentration and an accumulation of androgens. The persistence of EGF activity, in 
conjunction with the subsequent lack of oestradiol, would inhibit LH receptor 
formation on granulosa cells. As a result, growth and development of the dominant 
follicle would be inhibited, leading to anovulation (Almahbobi et al., 1995). Most of 
the follicles in patients with pea are not atretic (Almahbobi et al., 1996) and 
furthermore follicular atresia, at least in its early stages, does not appear to reduce the 
developmental competence of human Q()Cytes (Barnes et aI., 1996). 
Interestingly, and in contrast to the above data on the potential aetiology of pea, EGF 
plays a positive role in various mammalian culture systems supporting oocyte 
maturation (Goud et al., 1998). The promotion of oocyte nuclear maturation by EGF 
has been demonstrated in humans (Das et al., 1991; G6mez et aI., 1993a,b), mice 
(Das et al., 1991; Downs et al., 1989; De La Fuente et al., 1999), cattle (Kobayashi et 
al., 1994; Lorenzo et al., 1994; Lonergan et al., 1996; Park et al; 1997; Reiger et al., 
1998), and pigs (Singh et al., 1993; Ding and Foxcroft 1994; Grupen et al., 1997). In 
addition, EGF has also been shown to promote oocyte cytoplasmic maturation in the 
same species (humans: Goud et al., 1998, mice: Das et al., 1991; De La Fuente et al., 
1999; cattle: Kobayashi et al., 1994; Lonergan et al., 1996; Park et al; 1997; Reiger et 
al., 1998; pigs: Ding and Foxcroft 1994; Singh et al., 1997; Wang and Niwa, 1995; 
Grupen et a/., 1997; Abeydeera et al., 1998). 
EGF is a potent stimulator of oocyte maturation in the mouse (Dekel and Sherizly, 
1985; Pellicer et al., 1989 and Downs 1989), and in combination with 
gonadotrophins, EGF promotes nuclear maturation in oocytes obtained from intact 
preantral follicles cultured to the antral follicle stage (Boland and Gosden, 1994; 
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Smitz et al., 1998). Positive effects were observed at ~5nglml. EGF also induces 
nuclear maturation in human immature unstimulated oocytes (Das et aI., 1991; 
Pellicer et al., 1992; Gomez et aI., 1993b). 
In 1998, Goud et al. studied the role of cumulus cells and EGF (2nglml) in the culture 
medium on IVM of human GV oocytes obtained after gonadotrophin stimulation for 
ICSI. EGF was shown to have a direct action on both cumulus-intact and cumulus 
denuded oocytes during IVM. Furthermore, retention of the attached cumulus cells 
helped to achieve higher rates of cytoplasmic maturation indicated by the higher 
cleavage rates after fertilization. More recently, EGF (2nglml) in combination with 
FSH present during the first 24 hours of culture of human mature oocytes has been 
shown to augment the implantation rates of the resulting embryos, even though the 
positive effects were not evident during pre-implantation development (Yding-
Anderson et aI., 1999). 
Limited data are available on the role of EGF in IVM of human oocytes in the 
presence and absence of cumulus cells and in terms of its effects on embryonic 
competence. The culture system used for IVM is one of the most important factors in 
regulating the proportion and quality of oocytes maturing in vitro (Goud et al., 1998). 
As yet, the optimal culture conditions and culture media components for human IVM 
have not been determined. This would be essential before introduction to clinical use. 
New developments in human assisted conception are sometimes based upon 
experience with other mammalian species and this approach is favoured in the work 
up of new techniques by the regulatory authorities. Therefore it was decided to assess 
the effects of EGF in a human IVM culture system, using similar conditions to those 
previously used in animal systems. 
The effect of supplementation of the IVM culture medium with EGF was investigated 
in human immature oocytes obtained from unstimulated ovaries from women with 
PCO. The EGF concentrations used (O.I-IOng/ml) were similar to those shown to be 
effective in previous studies (Das et al., 1991; Gomez et al., 1993a,b; Goud et al., 
1998). The nuclear and cytoplasmic maturation of the cultured oocytes was judged 
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from their capability to undergo GVBD, polar body extrusion, fertilization and early 
cleavage after ICSI. 
4.2 Aims 
To collect immature oocytes from patients without recent history of ovarian 
stimulation or fertility drugs, having polycystic ovaries coincident with diagnostic 
laparoscopy or laser drilling. 
To culture immature oocytes, in order to assess the effects of EGF upon oocyte 
maturation in vitro. 
To inseminate in vitro matured (metaphase II) oocytes with known fertile donor 
sperm using ICSI in order to assess any effects of EGF on fertilization, cleavage and 
embryo development. 
4.3 Patients and oocytes 
4.3.1 Patients 
For this study, a total of 46 viable immature oocytes were collected from eight pca 
patients with unstimulated ovaries. Clinical details of the patients are presented in 
Chapter 3, Table 3.1. 
4.3.2 Oocytes 
The viable oocytes collected were randomly allocated to four groups: 0 (control), 0.1, 
1.0 and IOng/ml EGF for a period of 48 hrs. Oocytes were considered mature if there 
was evidence of a polar body visible by Hoffman microscopy. All mature oocytes 
were subjected to ICSI with donor sperm as described in Chapter 2, section 2.4.3. 
4.4 EtTect of EGF on survival and maturation 
Figure 4.1 shows the results of EGF exposure in terms of oocyte survival and 
maturation, according to the concentration of EGF present in the culture medium used 
for IVM. The apparent increase in survival with increasing EGF concentration did not 
reach statistical significance, 73% survival in vehicle ranging to 89% in I Ong/ml 
EGF. The proportion of surviving oocytes which matured, was -50% in all the EGF 
culture concentrations. 
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Figure 4.1 In-vitro maturation of immature oocytes (n=46) collected from 
patients (n=8) with polycystic ovaries and cultured with or without epidermal 
growth factor (EGF). 
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The oocytes collected were at the GY and GYBD stages in equal proportions. Figure 
4.2 shows the maturation in vitro of oocytes collected at the GY and GYBD stages. It 
was notable that in the absence of EGF, none of the five GV oocytes matured to MIL 
whereas in the pre ence of EGF a total of nine of the 19 GV oocytes matured to MIL 
This represented a significam difference (0.025 < p < 0.05). However, the proportion 
of maturing GY oocytes wa unrelated to the concentration of EGF. There was no 
significant difference between the proportions of GYBD oocytes maturing to Mil 
with or without EGF. All oocytes that matured produced polar bodies on the second 
day of IYM culture (40-48 hr). Once the oocytes had matured, there were no visible 
differences among the group, for example in the size of the oocyte and the size of the 
polar body between the different culture groups. 
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Figure 4.2 Maturation of germinal vesicle (GV) and germinal vesicle breakdown 
(GVBD) oocytes from patients with polycystic ovaries (PCO) in the presence or 
absence of epidermal growth factor (EGF). 
n= number of oocytes in each group. 
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Figure 4.3 shows the incidence of atresia occurring in vitro after the collection of 
apparently viable oocytes. There was no significant difference between atresia levels 
with or without EGF, or between GV and GVBD oocytes in each culture condition 
(with or without EGF). 
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Figure 4.3 Proportions of germinal vesicle (G V) and germinal vesicle breakdown 
(GVBD) oocytes becoming atretic in vitro after collection from patients with 
polycystic ovaries (PCO) and cultured in the presence or absence of EGF. 
n= number of oocytes in each group. 
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4.5 Effects of EGF on fertilization and embryo development 
Table 4.4 presents the proportions of maturing oocytes fertilized by ICSI, resulting in 
formation of two pronuclei and those subsequently cleaving in vitro. Statistical tests 
were not performed in view of the small amount of data available for analysis. 
Table 4.4 Fertilization and cleavage rates of in-vitro matured oocytes arising 
from polycystic ovaries (PCO) patients. 
Epidermal growth factor (ng/ml) 
0 
Fertilization * 3/3 
Cleavage** 2/3 
* 2pn oocytes / oocytes surviving ICSI 
** Cleaving embryos / 2pn oocytes 
0.1 1.0 
2/5 2/5 
212 112 
10 
114 
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There were no particular difficulties encountered with the ICSI procedure. 2 cases of 
abnormal fertilization were observed at the highest EGF concentrations (1.0 and 
IOng/ml): fragmented pronuclei were seen in an oocyte matured in 1.Ong/ml EGF and 
3 pronuclei were seen in an oocyte matured in IOng/ml EGF. Only one polar body 
was seen in the case of triploid fertilization, so it is likely that retention of the second 
polar body occurred during oocyte meiotic maturation, leading to the formation of 
two maternal pronuclei and one paternal pronucleus resulting in a digynic embryo. 
The most advanced embryo observed reached 6 cells (O.lng/ml EGF). 
Failure of cytokinesis was observed in two embryos (oocytes matured in vehicle and 
O.1ng/ml EGF). One 2-cell embryo had five nuclei, all five nuclei were in the larger 
cell and no chromatin was seen in the smaller cell and a 3-cell embryo contained four 
nuclei in one cell indicating nuclei division without cell division (karyokinesis) and 
one nucleus each in the other two cells. The other embryos each had one nucleus per 
cell as would be expected for normal development. 
It is usual for some oocytes to become damaged during the ICSI procedure itself, 
normally amounting to approximately 9% (Tarlatzis and Bili, 1998), unless the 
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oocytes are particularly fragile. In this series, 25% of oocytes that matured without 
EGF (control) underwent atresia compared to 13% in the combined EGF culture 
groups. This did not represent a significant difference. 
4.6 Effect of cumulus cells on oocyte development 
Figure 4.4 shows the extent of oocyte maturation according to the amount of cumulus 
cell cover at oocyte recovery. There were no significant differences in the proportions 
of oocytes maturing to MIl, or becoming atretic, according to whether they were or 
were not surrounded by cumulus cells. The small numbers of oocytes available may 
have limited interpretation, however, as there were tendencies towards improved 
maturation and reduced atresia in the presence of cumulus cells. 
95 
a 
c 
5 
4 
,.-.. 
c 
'-' 
<IJ 3 ~ 
.. 
>. 
8 2 
... 
0 1 
0 
o ~ Z 
5 
4 
~ 3 
.... 
>. 8 2 
... 
o 
~ 
o 
0 cum 1-3 
Cumulus cover 
T 
o cum 1-3 
Cumulus cover 
b 
5 
4 
,.-.. 
5 
<IJ 3 ~ 
>. (J 2 0 
0 
... 
0 1 
0 
Z 0 
d 
5 
4 
C 
'-' 
~ 3 ; 
->. g 2 
... 
0 
Q 1 ; 
Z 
o . 
Key: [ • Immature • Mil • Atretic 
I 
0 cum 1-3 
Cumulus cover 
o cum 1-3 
Cumulus cover 
Figure 4.4 Levels of cumulus cover on oocytes on day-2 recovered from patients 
with polycystic ovaries (peO) and cultured in a) vehicle, b) O.lnglmJ EGF, c) 
1.0nglmJ EGF, d) lOnglmJ EGF. 
0= devoid of any cumulus/no more than 10 scattered cells; I = partial cover; 2= 
complete cover; 3= substantial multilayered cover. 
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4.7 Discussion 
The results obtained in this study generally did not indicate significant effects of EGF 
(at concentrations of 0.1, I and IOnglml) used alone, in the absence of gonadotrophins 
on in-vitro survival and maturation of human oocytes. One significant response was 
evident, where EGF at all concentrations combined had a positive effect upon 
maturation of GV oocytes (0.025 < P < 0.05). 
A limiting factor in this experiment was the relatively low number of oocytes 
available (n=46), resulting in few fertilization and cleavage stage embryos for study. 
In view of the few significant results or trends, this part of the study was abandoned 
early in favour of pursuing the more fruitful work assessing the role of FF-MAS, 
presented in the next chapter. However, this was the first study that included the 
creation of embryos for research to be approved in the UK, and the establishment of 
methods and collection of oocytes from nine patients is a substantial number in this 
field, and the data adds to the pool of information available. 
Das et al. (1991) performed a preliminary study using eight human GV oocytes and 
observed 100% maturation after 48 hrs culture with 5nglml EGF compared to 0% 
maturation (and signs of degeneration in one oocyte) in control. Subsequently, G6mez 
et al. (l993b) used physiological and supraphysiological concentrations of EGF 
similar to those used in my experiments. Three patient groups were used in their 
study: patients who had received no ovarian stimulation (24 oocytes obtained), 
patients at risk of developing OHSS and therefore having their stimulated cycles 
cancelled (8 oocytes) and patients undergoing HMG-hCG stimulation for NF (93 
oocytes). After 48 hrs culture of oocytes (n=24) obtained from non-stimulated 
ovaries, a significant difference (p < 0.01) was observed between the percentage of 
Mil oocytes in control (19.2%) and in I Onglml EGF (54.8%), although at a 
physiological concentration of 2nglml EGF there was no significant difference. 
Concentrations of 2 and IOng/ml EGF induced a borderline significant (p = 0.07) 
increase (12.5% and 12.9% respectively) on the number of oocytes reaching MIl at 24 
hrs when compared to control (0%). In my experiments, no oocytes reached MIl after 
24 hrs in culture, in agreement with Das et al. (1991). 
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The reasons for these differences might include the patient source; oocytes obtained 
from non-stimulated ovaries in the study by G6mez et al. (1993b) were obtained from 
22 women undergoing gynaecological surgery for a number of benign disorders. All 
of these patients had spontaneous and regular menstruation, and were scheduled for 
surgery on days 7-10 of the menstrual cycle, which is likely to include a lower 
proportion of oocytes from atretic or persistent follicles than in my study. In my study 
oocytes were collected from mainly (75%) oligomenorrhoeic patients, therefore 
collection of oocytes was scheduled irrespective of the stage of the menstrual cycle. 
Secondly, different methods were employed to obtain the oocytes. Pieces of ovary 
were removed surgically, and follicles punctured, compared with my study where 
follicles were aspirated in vivo. Moreover, only oocyte-cumulus complexes were used 
in their study, whereas all viable oocytes obtained were used in my study, including 
those without cumulus cells. 
In 1998, Goud et ai. studied the role of cumulus cells and BGF supplementation of the 
culture medium on the IVM of human GV oocytes obtained after gonadotrophin 
stimulation for ICSI. All oocytes obtained from follicular aspirates were treated with 
0.1 % hyaluronidase for 1-2 min to visualize the presence of a GV. 121 oocytes from 
38 patients were completely denuded of cumulus cells and cultured with or without 
EGF (2ng/m1). Cumulus cells were retained on 191 GV oocytes (n=54 patients), 
which were cultured with or without EGF (2ng/ml). More oocytes with intact cumulus 
reached Mil by 30 hrs compared to nude oocytes, although EGF supplementation of 
the medium did not affect maturation of oocytes cultured with intact cumulus cells 
when compared to maturation in control medium lacking EGF. However, EGF did 
have a significant effect on promoting the maturation of nude oocytes (p < 0.003). 
They concluded that cytoplasmic maturation of human oocytes in vitro could be 
improved with maintenance of cumulus cells during culture and supplementation of 
the maturation medium with EGF. Also that the effect of EGF appears to be 
synergistic with gonadotrophins in the cumulus-intact oocytes. 
In a study on meiotic progression in mouse follicle-enclosed oocyte culture, Smitz et 
al. (1998) observed a stimulatory effect of HCG and EGF (2:: 5nglml) on completion 
of the first meiotic division, whereas EGF alone up to a dose of 5Ong/ml overrode the 
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somatic inhibitory stimuli in fewer than half of the cultured follicles. After studying 
the effects of EGF on nuclear and cytoplasmic maturation of mouse oocytes grown in 
vivo or in vitro, De La Fuente et al. (1999) concluded that gonadotrophins in vivo 
increase the sensitivity or responsiveness of cumulus cell-enclosed oocytes to EGF, 
thereby promoting both nuclear and cytoplasmic maturation. However, oocyte-
granulosa cell complexes grown in vitro become responsive to EGF without 
gonadotrophin treatment. The relationship between EGF and gonadotrophin control in 
respect of oocyte maturation is therefore uncertain in human oocytes and warrants 
further investigation. 
Goud et al. (1998) did not observe a positive effect of EGF on the fertilization of the 
in vitro matured human GV oocytes without cumulus cells cultured with EGF. 
However, a significant positive effect (p<O.05) of EGF on fertilization was observed 
in GV oocytes obtained from the same source but cultured with cumulus cells intact. 
No differences, for example in oocyte size, or size of the polar body were observed 
between the different culture groups. It is known that the size of a polar body can 
reflect the degree of peripheral movement of the spindle at MIT, and disorders in 
spindle positioning may relate to immaturity of oocytes. Inward displacement of the 
spindle results in a pb of atypically large size. Oocytes with very small pbs. are 
associated with reduced fertilization and increased aneuploidy, since chromosomes 
destined for the first pb may remain entirely in the oocyte or be incompletely expelled 
(Veeck, 1999). 
No significant effect of EGF on fertilization and cleavage was observed in my 
experiments, although the numbers of oocytes were low. However, cleaving embryos 
were achieved in all culture conditions confirming that the oocytes matured in vitro 
were capable of fertilization and the initial stages of embryo development, despite the 
absence of gonadotrophin stimulation in vitro. Early cleavage events are known to be 
predominantly under maternal control from inherited mRNAs (Braude et al., 1988) 
and developmental competence is acquired sequentially as particular stages of oocyte 
development are reached (Eppig et al., 1994) 
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Reduced developmental competence of human oocytes matured in vitro has been 
reported previously (Trounson et al., 1994) and cleavage and development beyond the 
third cleavage division remains a problem with IVM. Cleavage arrest could result 
from inadequate cytoplasmic maturation, as aberrations in cytoplasmic maturation are 
more likely to cause embryonic demise in later stages of preimplantation development 
(Moor et al., 1998). My data, though limited, suggest that EGF did not overcome this 
problem. 
Although my results did not achieve significance, they tended to support the 
conclusion that the presence of cumulus cells was beneficial for maturation, and that 
EGF supplementation of the medium did not significantly affect maturation of 
oocytes cultured with intact cumulus cells. It is interesting to note that at a 
concentration of I.Ong/ml EGF (the closest to the 2ng/ml used in Goud's study) there 
was an increased number of nude oocytes reaching MIT when compared to nude 
oocytes in all other culture conditions. At this concentration only, the number of 
oocytes reaching maturation was higher for nude oocytes than for those with cumulus 
cell cover. These data confirm previous suggestion (Goud et ai., 1998) that EGF may 
be capable of acting on oocytes directly, rather than in a manner mediated by the 
cumulus. The relatively small EGF molecule is likely to traverse easily through the 
zona of human oocytes, to exert its effect directly on the oocyte (Shalgi et ai., 1973; 
Goud et al., 1998). 
In conclusion, my data do not indicate a significant effect of EGF on oocyte survival, 
maturation or development in vitro, however the size of the data set is limited. In view 
of the lack of significant results in this pilot study and the limited supply of human 
oocytes, further experiments on EGF were not undertaken. However, future directions 
of this research could have included, for example, increasing the numbers of oocytes 
in each group to assess whether significant effects upon maturation or fertilization 
according to EGF concentration became evident and also assessing 
co-supplementation of EGF with gonadotrophins which are known to stimulate 
maturation via cumulus cells. In addition, a comparison with oocytes that had been 
exposed to some in vivo stimulation might provide information on the relevance of 
follicular viability. 
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ChapterS 
Effects of FF -MAS during in vitro maturation culture 
S.l Introduction 
In this part of the project, I sought to assess the effects of FF-MAS upon maturation 
of human oocytes in vitro, and to test the developmental competence of the matured 
oocytes in terms of their fertilization and embryo development. Oocytes from both 
patients with PCO and patients undergoing ICSI treatment were used as described in 
chapter 2, section 2.3. The effects of this compound were considered particularly 
interesting, as it is believed to be one of the endogenous factors involved in oocyte 
maturation in vivo, and its potential role in human oocytes had not previously been 
explained, despite evidence of efficacy in mice (Byskov et al., 1995, 1999; Hegele-
Hartung et al., 1999). 
Meiosis activating sterol (FF-MAS: 4,4-dimethyl-5a-cholesta-8,14,24-trien-313-0l) is 
an intermediary occurring naturally in the biosynthetic pathway between lanosterol 
and cholesterol. It is present in human pre-ovulatory follicular fluid at concentrations 
of -1.3JJmoVl (Byskov et al., 1995). It activates meiotic resumption of both cumulus-
enclosed and cumulus-denuded mouse oocytes in vitro (Byskov et al., 1995, 1999; 
Hegele-Hartung et al., 1999). FF-MAS is synthesized by cumulus cells of intact 
oocyte-cumulus-complexes in response to FSH stimulation (Byskov 1998) and the 
concentrations of FF-MAS in pre-ovulatory follicular fluid samples are correlated 
with the ability of the associated oocyte to fertilize and cleave (Byskov et al., 1998). 
Grondahl et al. (1998) and Ruan et al. (1998) have demonstrated the specificity of FF-
MAS as an inducer of meiosis when compared to a series of related sterol compounds. 
Hegele-Hartung et al. (1999) showed the ability of FF-MAS to stimulate GVBD in 
both cumulus-enclosed and denuded mouse oocytes in the presence of inhibitors such 
as hypoxanthine, isobutylmethylxanthine and dibutyryl cAMP (dbcAMP), which 
normally maintain meiotic arrest. Conflicting results from Downs et al. (2001) 
demonstrated failure of FF-MAS at a concentration of 3JJg/ml to induce GVBD in 
denuded mouse oocytes, when meiotic arrest was maintained with dbcAMP (300jJM). 
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However, in a parallel hypoxanthine-treated set of denuded oocytes FF-MAS at the 
same concentration was stimulatory. 
Downs et al. (2001) hypothesized that the use of different culture medium may have 
influenced the efficacy of FF-MAS as a meiosis-inducing agent. However they 
concluded that the medium type did not account for their inability to demonstrate FF-
MAS-stimulated maturation in dbc-AMP arrested oocytes. It was speculated that the 
positive action of FF-MAS on cumulus-enclosed oocytes is contingent on culture 
conditions, due to FSH inducing meiotic resumption in a high percentage of cumulus-
enclosed oocytes, where FF-MAS had failed. Evidence lending support to this theory 
came from the results of glucose removal from medium, where a subsequent 
inhibitory effect of FF-MAS on GVBD in hypoxanthine-arrested cumulus-enclosed 
mouse oocytes was observed; leading Downs et al. (2001) to acknowledge that this 
change in culture medium could have altered sterol processing by the cumulus cells 
and thereby its influence on meiosis. 
Downs et al. (2001) also studied the kinetics of maturation induced by FF-MAS; 
long-term exposure (l2hr) to the sterol was required for meiotic maturation. Slow 
maturation kinetics (>6hr) were observed in denuded mouse oocytes cultured in 4mM 
hypoxanthine ± 3J.lglml FF-MAS, oocytes were assessed for GVBD at 3,6 and 12 hr. 
The proportion of oocytes undergoing GVBD in the FF-MAS treated group was 
significantly different only at the 12hr time point. In the superovulated mouse model, 
GVBD is initiated between 1.5-2 hr post heG (Eppig et al., 1987). However, Downs 
et al. (2001) considered that in vitro conditions, including choice of meiotic inhibitor 
and absence of certain follicular constituents could alter the normal rate of maturation. 
Thus, recent work by Downs et al. (2001), whilst confirming the stimulatory action of 
FF-MAS on hypoxanthine-arrested denuded mouse oocytes as discussed above; fails 
to support a universal meiosis-inducing function for FF-MAS. The reduced 
effectiveness of FF-MAS on cumulus-enclosed oocytes compared to denuded oocytes 
was explained by Downs et al. (2001) to be due in part to its sequestration by cumulus 
cells. The lower efficiency of FF-MAS in cumulus-enclosed oocytes when compared 
to denuded oocytes was also considered by Grondahl et al. (1998), and attributed to 
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either release by the cumulus cells of inhibitory factors that may negate the 
stimulatory action of FF-MAS or to a loss of sterol accessibility to the oocyte 
potentially via steroid conversions occurring in the cumulus cells (Downs et ai., 
2(01). 
This chapter presents the first study of FF-MAS effects on human oocyte maturation 
in vitro. The results were published (Cavilla et al., 2001) and the published article is 
presented as appendix II. 
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5.2 Aims 
To perform a log dose assessment of the effects of FF-MAS exposure during in vitro 
culture of human oocytes upon their maturation, fertilization and early embryonic 
development. To compare the results of FF-MAS exposure in immature oocytes 
originating from two different patient groups: unstimulated patients with or without 
polycystic ovaries and patients undergoing a fully stimulated cycle of ICSI treatment. 
5.3 Patients and oocytes 
5.3.1 Patients 
For this study, a total of 128 viable immature oocytes were collected from 19 PCO 
patients with unstimulated ovaries and 72 immature oocytes were donated by 28 ICSI 
patients. Clinical details of the patient groups are presented in Tables 3.2 and 3.3 
(chapter 3). 
5.3.2 Oocytes 
The immature oocytes collected were randomly allocated to the three groups: 0 
(control, including the vehicle EtOH, at the same concentration as the FF-MAS 
treatment groups), 10 and 30J,1g/ml FF-MAS for a period of up to 48 hrs. Oocytes 
were considered mature if a polar body was visible by Hoffman microscopy. All 
mature oocytes were subjected to ICSI with donor sperm. 
5.4 Effect of MAS on survival and maturation. 
Figure 5.1 shows the results of FF-MAS exposure of oocytes obtained from PCO 
patients, in terms of oocyte survival and maturation, according to the concentration of 
FF-MAS present in the culture medium during the period of maturation culture. FF-
MAS at a concentration of 30J,1g/ml significantly increased oocyte survival (P< 0.025, 
pxq X2 test, Campbell, 1989) resulting in 88% survival in 30Ilg/ml compared with 
63% and 60% for 101lg/ml and control respectively. The increased survival of oocytes 
in 30Ilg/ml FF-MAS was not associated with an alteration in the proportion of 
surviving oocytes, which matured which was 42%, 37% and 48% in 30llg/ml, 
101lg/ml FF-MAS and control respectively. 
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Figure 5.1 In-vitro maturation of immature oocytes (n=128) collected from 
patients (n=19) with polycystic ovaries and cultured with or without meiosis 
activating sterol (FF -MAS). 
Bars with different letters are significantly different (P < 0.025). 
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Figure 5.2 shows the results of FF-MAS exposure of immature oocytes from ICSI 
patients. Oocyte survival was >90% in all groups, regardless of FF-MAS 
concentration. However, in this patient group, the presence of MAS at 10 or 30!Jg/ml 
significantly increased the proportion of oocytes maturing in vitro (P< 0.05, pxq X2 
test, Campbell, 1989). 
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Figure 5.2 In-vitro maturation of immature oocytes (n=72) donated by patients 
undergoing intracytoplasmic sperm injection (ICSI) (n=28) and cultured with or 
without meiosis activating sterol (FF -MAS). 
Bars with different letters are significantly different (P < 0.05). 
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Figure 5.3 shows the stage of maturity of the oocytes collected from the two patient 
groups, patients with PCO and patients undergoing ICSI treatment. Significantly more 
immature oocytes per patient were obtained from PCO patients in comparison with 
ICSI patients (p< 0.01) as would be expected, but surprisingly there was no 
significant difference in the proportion of immature oocytes that had undergone 
GYBD at the time of oocyte collection between the PCO and ICSI patient groups. 
Oocytes in which the nuclear status was obscured by the tight covering of cumulus 
cells were assumed to be at the GV stage, and identified separately on the graph. 
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Figure 5.3 Maturity at collection of oocytes recovered from pOlycystic ovaries 
(PCO) and intracytoplasmic sperm injection (ICSI) patients, 
GY=germinal vesicle; CE=cumulus enclosed (OY assumed, but not visible): 
GVBD=germinal vesicle breakdown. 
Results are expressed as mean ± SEM, a significantly different (P< 0.01). 
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Figures 5.4 (a) and (b) show the extent of maturation in vitro of oocytes collected at 
the GV and GVBD stages for both patient groups. In peo patients Figure 5.4 (a), the 
proportion of oocytes in both categories reaching MIl was highly variable. Cultured 
immature oocytes (either GV or GVBD at collection) from ICSI patients had a low 
maturation rate but the maturation rate of GVBD oocytes was significantly improved 
by addition of FF-MAS (p< 0.025, X2 test), as shown in Figure 5.4 (b). For the oocytes 
that failed to mature in the ICSI group, approximately equal numbers arrested at or 
after the GV stage. 
Figure 5.5 shows the incidence of atresia occurring in vitro after collection of 
apparently viable oocytes. Especially high levels of atresia were noted in GVBD 
oocytes from PCO patients. Overall the PCO oocytes appeared more susceptible than 
ICSI oocytes. In the ICSI group, atresia was confined to oocytes collected at the GV 
stage. 
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Figure 5.4 Maturation of germinal vesicle (G V) and germinal vesicle breakdown 
(GVBD) oocytes from (a) patients with polycystic ovaries (PCO) and (b) patients 
undergoing intracytoplasmic sperm injection (ICSI) in the presence or absence 
of meiosis activating sterol (FF -MAS). 
n= number of oocytes in each group 
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Figure 5.5 Proportions of germinal vesicle (GV) and germinal vesicle breakdown 
(GVBD) oocytes becoming atretic in vitro after collection from polycystic ovaries 
(PCO) or intracytoplasmic sperm injection (ICSI) patients. 
n= number of oocyte. in each group 
110 
The time course of oocyte maturation differed between the two patient groups. Of 
those oocytes maturing to MIl in vitro, 50% in the ICSI group had reached MIl by 23-
24 hr compared with <5% for PCO patients as shown in Figure 5.6. The majority 
(89.2%) of PCO oocytes that matured to MIl did so on the second day of rVM culture. 
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Figure 5.6 Cumulative time course of maturation in vitro for maturing oocytes 
from polycystic ovaries (PCO) and intracytoplasmic sperm injection (ICSI) 
patients. 
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5.5 Effects of FF -MAS on fertilization and embryo development 
The proportions of in-vitro matured oocytes fertilized by ICSI and subsequently 
cleaving in either PCO or ICSI patient groups are presented in Tables 5.1 and 5.2. The 
fertilization rate was defined as the number of 2PN oocytes as a proportion of the 
oocytes surviving ICSI. Cleavage rate was defined as the number of cleaving embryos 
as a proportion of the 2PN oocytes. The fertilization rates achieved were broadly 
similar in the two patient groups. 
In both patient groups, oocytes cultured with FF-MAS showed a tendency towards 
improved subsequent development, however these data were not tested statistically in 
view of the low numbers of oocytes reaching this stage. No blastocysts were formed 
and the most advanced embryos arrested at the 3rd cleavage division. The stages of 
arrest are indicated in parentheses in table 5.2. 
------------- -
Table 5.1 Fertilization rates of in-vitro matured oocytes arising from patients i 
with polycystic ovaries (PCO) or those being treated with intracytoplasmic I 
sperm injection (ICSI). 
I FF-Meiosis activating sterol (/lg/ml) i 
I 0 10 ____ _ 30 I 
L PCO 4110 (40%) 219 (22%) 7112 (58%) III ICSI 215 (40%) 6111 (55%) 6110 (60%) 
I Table S.2 Cleavage rates of in-vitro matured oocytes arising from patients -with 
I polycystic ovaries (PCO) or those being treated with intracytoplasmic sperm 
injection (ICSI). 
PCO 
ICSI 
FF-Meiosis activating sterol (/lg/ml) 
o 10 ~ 
214 
(3c,4c) 
0/2 
212 
(3c,6c) 
3/6 
(2c, 3c, 5c) 
517 
(2x3c, 2x4c, 5c) 
5/6 
(2c,3c,4c,5c,6c) 
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Table 5.3 shows the stage and grade of embryos arising from the fertilization of in-
vitro matured oocytes retrieved from patients with polycystic ovaries (peO) and from 
patients undergoing ICSI treatment. Oocytes were graded according to the grading 
system devised by Veeck (1990) (Chapter 2, section 2.5.2) with grade 1 representing 
ideal morphology. Embryos resulting from the fertilization of in vitro matured oocytes 
retrieved from patients with PCO and those undergoing ICSI were on average grade 3. 
Oocytes matured in 30J.1g/ml FF-MAS in both patient groups appeared to result in 
embryos of a better quality (ranging from grade 2+ - 3), although this was not a 
significant finding, possibly in view of the limited numbers of embryos for analysis. 
Table 5.3 Stage and grade of embryos arising from fertilization of in-vitro 
matured oocytes retrieved from patients with polycystic ovaries (PCO) or those 
being treated with intracytoplasmic sperm injection (ICSI). 
FF-Meiosis activating sterol (J.1g/ml) 
0 10 30 
3c (4) 3c (2) 3c (3) 
4c (3) 6c (4) 3c (3+) 
PCO 4c (3+) 
4c (3) 
5c (3) 
2c (4) 2c (3) 
3c (3) 3c (3) 
ICSI 5c (4) 4c (2) 
5c (3) 
6c (2+) 
Grade of embryo indicated in parentheses 
Of the nine cleavage stage embryos arising from fertilization of in vitro matured 
oocytes obtained from patients with PCO, one was damaged during the staining 
procedure. Of the remaining eight embryos, six had one nucleus per cell as would be 
expected for normal development. One 3-cell embryo had only two nuclei, and one 5-
113 
cell embryo had only four nuclei, indicating the occurrence of cell di vision without 
nuclear division. 
Of the eight cleavage stage embryos arising from fertilization of in vitro matured 
oocytes obtained from patients undergoing IeSI treatment, six had one nucleus per 
cell. One 5-cell embryo had only 3 nucleate cells and the 6-cell embryo had five 
nuclei, with two of the nuclei in one cell, therefore two cells were anucleate. 
Once oocytes had matured, there were some visible differences in polar body (pb) size 
and shape within each patient group (table 5.4 and table 5.5). 
Two cases of abnormal fertilization were observed in oocytes obtained from patients 
with peo cultured in control and lOflglml FF-MAS: four pronuclei were seen after 
IeSI in an oocyte matured in control conditions and three pronuclei were seen after 
IeSI in an oocyte matured in lOflglml FF-MAS. Both of these oocytes had only one 
pb (indicating digyny), and small pronuclei. An inverse correlation between 
pronuclear number and size is documented (Veeck, 1999) and pronuclear 
fragmentation may also have occurred. The 4PN zygote had a first pb of normal 
appearance, but the 3PN zygote had a flattened, fragmented pb. The majority of 
oocytes with normal polar bodies fertilized normally or failed to fertilize, however, no 
oocytes with either small or large first pbs fertilized. 
A total of nine oocytes had fragmented first pbs, these arose in all culture groups, 
although over half (56%) had matured in lOJlglml FF-MAS; interestingly this 
corresponded with the lower fertilization score (22%) out of the three culture 
conditions for the peo patient group, however it is unclear whether this association is 
causative. In the peo patient group, 16.7% of oocytes that matured without FF-MAS 
(control) underwent atresia after IeSI compared to 15.4% in the combined FF-MAS 
culture groups. This was not significantly different. 
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Table 5.4 Polar body types observed in mature oocytes obtained from patients 
with PCO, cultured with or without FF-MAS 
Outcome of ICSI 
Polar body 2 pn >2pn Unfertilized Atretic 
Normal 10 1 10 2 
Small 2 1 
Large 2 
Fragmented 3 I 5 
Flattened 1 
Among oocytes from ICSI patients, one case of abnormal fertilization was observed 
in an oocyte matured in IOIlg/ml FF-MAS, where four small pronuclei and two pbs 
were observed. This zygote did not develop any further. Around half of the oocytes 
with normal pbs (arising from maturation in all culture groups) failed to fertilize. Five 
of the nine unfertilized oocytes had no membrane resistance when injecting sperm. A 
total of seven oocytes had fragmented first pbs and these arose from all culture 
groups; however only one oocyte was matured in control conditions and this had a 
slightly fragmented pb. Four of these oocytes fertilized normally and three of the 
resulting embryos cleaved. Two oocytes matured in FF-MAS had flattened pbs, but 
fertilized after ICSI. 
In this series of oocytes from ICSI patients, 16.6% that had matured without FF-MAS 
(control) underwent atresia after ICSI compared to 20% in the combined FF-MAS 
culture groups. This was not significantly different. 
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Table S.S Polar body types observed in mature oocytes donated by patients 
undergoing ICSI treatment, cultured with or without FF -MAS 
Outcome of ICSI 
Polar body 2 pn >2pn Unfertilized Atretic 
Normal 8 1 9 5 
Small 
Large 
Fragmented 4 1 2 
Flattened 2 1 
In both patient groups, the incidence of atresia after ICSI was apparently higher than 
the normal -10% atresia level expected with fresh oocytes in ICSI treatment. This is 
probably due to fragility of the oocytes, possibly cause by prolonged NM culture, 
however three injections resulting in atresia of the oocyte were definitely due to poor 
injections. 
In the ICSI patients, 33% of oocytes that matured early (23-24 hr) and were therefore 
injected with sperm after 24 hr (rather than being aged a further day) fertilized after 
ICSI compared with 44% of oocytes maturing after 40-48 hr culture. This was not a 
significant difference. Of the oocytes that matured early, 61 % were cultured in 
lO/lglml FF-MAS; the highest proportion (44%) maturing in the 40-48 hr culture time 
was cultured in 30/lglml MAS. When comparing the early (23-24 hr) and the 40-48 hr 
culture periods, there were no significant differences between the numbers failing to 
fertilize and becoming atretic. 
S.6 Effect of cumulus cells on oocyte development 
Table 5.6 shows the extent of oocyte maturation according to the amount of cumulus 
cell cover at oocyte recovery. In all culture conditions, the maturation rate was 
approximately doubled in oocytes with cumulus cover compared to nude oocytes 
(p< 0.025) and atresia appeared less likely in those with cumulus cover 
(approximately halved) than in those without, in all culture conditions. Statistical 
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analysis was not performed on the latter comparison since the presence of a zero in 
the data set did not meet the conditions for contingency tests. 
Table 5.6 Effects of cumulus presence at collection (day-2) of oocytes recovered 
from patients with polycystic ovaries (PCO) and cultured in 30Jlglml FF -MAS, 
10Jlglml FF - MAS or control. 
Culture Cumulus Mature Immature Atretic grade 
0 19% 19% 62% (4/21) (4/21) (13/21) Control 38% 43% 19% 1-3 (8/21) (9/21) (4/21) 
0 17% 35% 48% IOflglml (4/23) (8/23) (11123) 
FF-MAS 1-3 30% 45% 25% (6/20) (9/20) (5/20) 
0 24% 52% 24% 30flglmI (5/21) (11/21) (5/21) 
FF-MAS 1-3 50% 50% 0 (11122) (11/22) 
o = devoid of any cumulus! no more than 10 scattered cells; 1 = partial cover; 
2 = complete cover; 3 = substantial multilayered cover. 
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5.7 Discussion 
My results demonstrate significant effects of FF-MAS on in vitro survival and 
maturation of human oocytes. Immature oocytes collected from two different patient 
groups, unstimulated PCO patients and stimulated ICSI patients, have been shown to 
differ in terms of oocyte function in vitro, including the proportions maturing and the 
speed of maturation in vitro. These differences may reflect patient-related differences 
in the origin of the oocytes, including the stage of follicular development at oocyte 
retrieval, the endocrine status or atresia of the follicles and the presence or absence of 
supporting cumulus cells. These results will be important for the future application of 
IVM as a potential treatment for certain forms of infertility. While IVM has been used 
with varying degrees of success in Australia, USA and Scandinavia, it has only 
recently been considered by the HFEA as a potential treatment and the first UK 
treatment licenses are yet to be approved. This study was specifically required by the 
HFEA to focus upon data collection on research embryos as a pilot study of this 
nature was essential before any treatment licence application would be considered. 
FF-MAS significantly (P< 0.025) improved the survival of immature oocytes 
collected from unstimulated women with PCO. This is in contrast with the results 
obtained culturing immature oocytes from stimulated ICSI patients, in whom FF-
MAS did not affect oocyte survival (which was >90% in this patient group), but 
maturation in vitro was significantly increased (P< 0.05). The variations in embryo 
development in both patient groups with FF-MAS supplementation of IVM media are 
also interesting, particularly in view of the compromised developmental competence 
which is widely believed to be associated with immature oocytes collected from PCO 
patients (Almahbobi et 01., 1996). Although statistical analysis of developmental 
outcome in vitro was precluded by the limited numbers of oocytes reaching the later 
stages in this study. The limited availability of human oocytes for research is widely 
known, and hence this study describes one of the largest data sets available, 
conducted purely for research. 
FF-MAS is present in human pre-ovulatory follicular fluid at a concentration of 
-1.3pM. In this study supraphysiological concentrations of FF-MAS were employed 
in vitro, 3pglml (7.3pM) and 30pglml (73.2pM). These higher concentrations of FF-
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MAS were used for IVM because it is not known how much steroid actually reaches 
the oocyte in vitro or the route by which it travels (Downs et al., 2(01). The 
concentration of FF-MAS in the IVM medium may be much reduced, for example by 
steroid adhesion to the plastic culture vessel or by sequestration into the cumulus 
cells. 
FF-MAS is also produced in cumulus cells, which are steroidogenically competent, in 
common with other somatic cell components of the follicle (Leonardsen et aL., 2(00). 
Its effects are likely to be mediated via mechanisms employed by other follicular 
steroids, perhaps in a manner similar to progesterone stimulation of meiosis in 
Xenopus oocytes (where progesterone acts through a membrane-bound receptor) 
(Byskov et al., 1998). The FF-MAS receptor and the signalling pathways for FF-MAS 
during resumption of oocyte meiosis have not yet been clarified. However, Janowski 
et al. (1996) observed FF-MAS to be a ligand for the orphan nuclear receptor LXR-a, 
and Grondahl et al. (2000) suggested that a putative nuclear MAS receptor could have 
similarities at least in the ligand-binding domain to LXR-a. 
The steroid environment of follicles in peo is disturbed (e.g. Almahbobi and 
Trounson, 1996; Pierro et al., 1997), and so the influence of FF-MAS in this 
environment might differ from other circumstances. Such as, for example, after 
ovarian stimulation with gonadotrophins, which would support several follicles 
concurrently in a non-atretic state. 
Oocytes with cumulus cells attached, retrieved from patients with peo exhibited a 
significantly higher maturation rate than oocytes with no cumulus cells in all culture 
conditions, (l test, p< 0.025). An increased likelihood of maturation in the presence 
of cumulus cover confirms findings by Wynn et ai, (1988). However, others (Barnes 
et ai, 1996; Russell, 1998) have found similar rates of maturation and fertilization in 
compact cumulus enclosed oocytes and nude oocytes, although Russell (1998) 
reported a higher cleavage rate in oocytes with compact cumulus cover. Downs et al. 
(2001) suggested that FF-MAS was not as effective in cumulus-enclosed mouse 
oocytes as it was in denuded oocytes, possibly due to cumulus cells suppressing the 
uptake of sterol intermediates by the oocyte, or converting FF-MAS to another 
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steroid, however, FF-MAS appeared more effective on the cumulus-enclosed oocytes 
in my study. The differences between mouse and human oocyte maturation may be 
one factor contributing to this observation. Immature oocytes retrieved from 
unstimulated PCO patients mayor may not have cumulus cells covering them. The 
presence or absence of cumulus cells provides some indication of the follicle from 
which the oocyte originated, denuded oocytes being more likely to have arisen from 
follicles becoming atretic. The known roles of cumulus cells include supporting 
oocyte growth and maintaining meiotic arrest throughout all immature stages of 
oocyte development. They are steroidogenically active and also produce hyaluronic 
acid during cumulus expansion to facilitate the approach of spermatozoa to the zona 
pellucida at fertilization. The somatic cells may also offer some non-specific support 
e.g. potentially buffering against sub-optimal culture media or osmotic shock. 
Oocytes surrounded by cumulus cells may therefore be at an advantage during IVM 
culture. 
Most enclosed oocytes had compact corona cells and contained a GV, and many of 
those without corona cells had progressed to GVBD, probably as a result of incipient 
atresia in the follicle (Gougeon and Testart, 1986; Anderson et al., 1997). 
Surprisingly, similar proportions of oocytes from PCO and ICSI patients had a GV or 
had undergone GVBD; however, these oocytes differed in their tendency towards 
atresia and their ability to mature to MIl suggesting that those undergoing GVBD in 
the two groups were not similar populations. In addition, the removal of cumulus cells 
from immature oocytes collected from ICSI cycles might have affected some aspects 
of their development. 
Several studies have shown that aspirated oocytes may be in various stages of 
maturation (Veeck et al., 1983; De Vos et al., 1999). Oocytes that remain immature 
having failed to respond to ovarian stimulation in vivo (such as those derived from 
patients undergoing ICSI treatment in this study) may be of inherently reduced 
quality, possibly derived from small follicles with reduced gonadotrophin sensitivity 
or having never reached meiotic competence. Alternatively, they may have arisen 
from otherwise normal follicles, which did not receive the same hormonal stimulus as 
others, perhaps due to their relative position in the ovary or limited blood supply (Van 
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Blerkom et al., 1997). Moreover, the artificial conditions of gonadotrophin 
stimulation may have affected some aspects of their metabolism or development 
(Johnson et al., 1991). Nevertheless, it has been reported that these oocytes are 
capable of maturing in vitro, fertilizing and developing normally (Cha and Chian, 
1998). My results demonstrate their responsiveness to stimulation with FF-MAS, 
despite the absence of cumulus cells and their prior exposure to ovarian stimulation. 
The importance of the endocrine environment in ensuring normal cytoplasmic 
maturation and subsequent fertilization is well known from work in animals (Moor 
and Trounson, 1977; Anderiesz and Trounson, 1995). The differing results obtained in 
this study in patients with differing endocrine profiles underlies the potential for IVM 
success rates to be affected by the oocytes' prior exposure to physiological or 
pathological hormonal environments. The lower maturation rate observed in the 
oocytes originating from unstimulated patients with PCO was probably due to 
compromised follicle development as a result of the abnormal endocrine environment, 
which could also account for the higher rate of atresia observed in the GVBD oocytes, 
compared with the ICSI patient group. In PCO patients, GVBD oocytes were 
probably retrieved from partially atretic follicles where granulosa cells have 
dissociated from the oocyte and factors controlling meiotic arrest have been lost. 
Oocytes in atretic follicles may often be found to have progressed further than meiotic 
prophase I (Anderson et al., 1997). 
In vitro, 28-30 hr is required for the maturation of unstimulated human GV oocytes to 
MI and 36-37 hr to MIl (Edwards, 1965a, b). After HCG injection to simulate an LH 
surge, the results are similar, the majority of the oocytes having extruded the first 
polar body by 36 hr after HCG injection (Janssenswillen et al., 1995). One group, 
(Jamieson et al., 1991) reported significantly lower IVF and cleavage rates in oocytes 
retrieved <36 hr after the luteinizing stimulus, demonstrating the importance of 
appropriate timing of insemination. Previous studies have shown that immature 
oocytes obtained from stimulated cycles are more likely to undergo maturation than 
those from unstimulated cycles and that the time required for their maturation from 
GV to MIl is reduced (Gomez et ai., 1993a; Cha and Chian, 1998). Others have 
shown the relative effects of follicular versus luteal phase retrieval of oocytes (Cha 
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and Chian, 1991; Whitacre et ai., 1998), underlining the importance of the endocrine 
environment. In my study, PCO patients were not given any form of hormonal 
manipulation prior to oocyte retrieval; however it is likely that induction of a 
withdrawal bleed with or without late follicular administration of HCG (Buckett et al., 
1999; Chian et al., 1999) may improve the maturation rates achieved in this study. 
These methods still have the benefit of avoiding the major element of the 
gonadotrophic drugs normally administered for ovarian stimulation. 
Throughout this series, the use of oil as a medium overlay was avoided, as oil would 
have extracted the steroidal FF-MAS. However, the possibility of FF-MAS adhering 
to the plastic culture vessel or being affected by albumin or other constituents in the 
culture medium cannot be excluded. Similarly, the method of dissolving steroids in 
EtOH is widely employed, but recent evidence has demonstrated that even 
concentrations <1 % EtOH can adversely affect bovine IVM and subsequent embryo 
development (Avery and Greve, 2(00). Bovine oocytes contain more lipidic yolk-like 
granules than human oocytes; however it is possible that some of the limited 
development observed in my study may relate to the use of EtOH in the cultures. This 
would not, however affect the validity of the results observed, since EtOH was 
included at a similar concentration in all cultures. Downs et al. (2001) confirmed 
results found in previous studies (Grondahl et a/., 1998; Ruan et ai., 1998; Hegele-
Hartung et al., 1999) that concentrations of EtOH present in the active FF-MAS 
preparations (0.05-0.5%) had no significant impact on meiotic maturation, however 
higher concentrations stimulated GVBD in hypoxanthine-arrested denuded mouse 
oocytes. Downs et al. (2001) concluded that the meiosis-inducing action of FF-MAS 
is a specific one and is not likely to be due to an EtOH effect, although they 
recommended that caution be exercised when using EtOH as a vehicle in oocyte 
maturation experiments, particularly those using denuded oocytes in view of the 
studies on bovine oocytes (Avery et al., 1999; Avery and Greve, 2(00). An alternative 
method for solubilization of MAS, using several I-min sonication pulses (Byskov et 
al., 1995; Leonardsen et aI., 2(00) is referred to by Downs et al. (2001), however they 
conclude that the effects, if any, of the sonication procedure on the other constituents 
in the maturation medium remain to be determined. 
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IVM, when applied as a treatment for infertility can result in pregnancy (Cha et al., 
1991; Trounson et al., 1994; Barnes et al., 1995; Russell et al., 1998; Jaroudi et al., 
1999;) but success rates remain lower than those of in-vivo stimulated cycles, 
indicating that optimization of IVM remains a challenge (Goud, et al., 1998). The 
primary problem in oocytes matured in vitro is reduced developmental competence, 
particularly cleavage and development beyond the 4- cell stage (Trounson et al., 
1994). This was apparent in my study, the most advanced embryo observed reached 6 
cells with most embryos arresting around the second cleavage division (3-4 cells). 
However, it appears that if the initiation of maturation is triggered in vivo, then 
developmental potential increases (Chian et al., 1999a,b) although the value of 
priming with low-dose FSH remains unclear (Wynn et al., 1998; Mikkelson et al., 
1999). 
In my study, the effects of FF-MAS alone have been studied, although addition of 
FSH to the medium might augment FF-MAS production in the cumulus (Byskov et 
ai, 1997) and the inclusion of FSH, HCG and/or growth factors in vitro has already 
been demonstrated to stimulate IVM by others (Durinzi et al., 1997). It was decided 
to omit these other factors so that the effects of FF-MAS alone could be established in 
the absence of confounding influences. This was deemed to be important, even though 
a higher overall maturation rate might be gained by a combination of supplements in 
the medium. 
Grf,l)ndahl et al. (2000) presented the results of IVM of 81 human oocytes allocated 
into seven groups, with or without synthetic FF-MAS, for histological analysis. These 
data showed a significant (p< 0.05) increase in the proportion of immature oocytes 
completing maturation after 30 hr in vitro in the presence of 20J..lmoVI FF-MAS; 
however, at 22 and 40 hr, the difference was not significant. Grf,l)ndahl's study differed 
from mine in several respects. His patient group had polycystic ovaries, but received 
oral contraception for 2 months, to which was added a gonadotrophin-releasing 
hormone (GnRH) agonist for pituitary down-regulation, followed by recombinant 
FSH for 3 days. Follicles of 8-12mm were aspirated on days 7-9 and all oocytes were 
cumulus-enclosed throughout culture. These patients therefore underwent stimulation 
cycles. Also, half their aspirated oocytes were used for infertility treatment, although 
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HCG was not administered. The medium used by Grj3ndahl et al. for the research 
oocytes was similar to that which I used, being M199 supplemented with 0.29 mmol/l 
pyruvate, antibiotics and 0.8% HSA, with or without FF-MAS which was prepared in 
EtOH. None of their research oocytes was inseminated. It is not yet known whether 
embryos resulting from NM in the presence of FF-MAS have the potential to develop 
further or implant. 
It has been reported that extracytoplasmic anomalies such as first pb morphology at 
time of ICSI are indicative of subsequent fertilization and embryo quality (Xi a 1997; 
Ebner et ai., 2(00). In my study, first pb morphology was variable in the patients with 
PCO and did not relate to the ability of the oocyte to fertilize or embryo quality. 
Oocytes with normal (intact, well-shaped ovoid with smooth surface) or fragmented 
first pbs resulted in average grade 3 embryos (according to Veeck embryo scoring 
method, 1990), and there was no relationship between first pb morphology and 
fertilization rates. In the ICSI patients, oocytes with normal first pbs resulted in 
embryos with an average of grade 2, however oocytes with abnormal fragmented first 
pbs resulted in embryos with an average of grade 4, lending more support to the data 
collected by Ebner et ai. (2000). 
Mikkelson et al. (2001) investigated the morphology of in vitro-matured oocytes and 
impact on fertilization potential and embryo quality, and found an association 
between first pb and embryo quality. A significantly reduced quality of embryos was 
observed when embryos developed from oocytes with one or more anomalies (such as 
fragmented first pb and/or a large perivitelline space) were compared with embryos 
developed from normal oocytes (p=O.OOI). Previously in 1995, Eichenlaub-Ritter et 
al. (1995) suggested that degeneration of the first pb may be due to asynchrony of 
nuclear and cytoplasmic maturation. According to Veeck (1999), oocytes with 
fragmented and/or flattened first polar bodies (pbs) may demonstrate a reduced 
potential for development and are often associated with a higher incidence of 
triploidy. Variation in the size of the first pb (overly large or small) may represent an 
abnormal condition, inward displacement of the spindle results in a pb of atypically 
large size. In this study, among oocytes retrieved from patients with PCO none with 
either small or large first pbs fertilized after ICSI. However, three out of nine (33%) 
124 
oocytes with fragmented first pbs fertilized, which is similar to the fertilization rate of 
43% of oocytes with normal first pbs. Among oocytes retrieved from patients 
undergoing ICSI treatment, four out of seven (57%) oocytes with fragmented first pbs 
fertilized compared to a fertilization rate of 35% in oocytes with normal first pbs. 
Fragmented first pbs did not appear to affect the fertilization rate of oocytes in this 
study. 
Studies on IVM (without FF-MAS) and resulting embryos have shown a higher 
incidence of nuclear abnormalities when compared to those derived from in-vivo 
matured oocytes. DeScisciolo et al. (2000) compared nuclear morphology of embryos 
using FISH for chromosomes X, Yand 18 to compare rates of aneuploidy, mosaicism 
and nuclear abnormalities. Although no difference in the rate of aneuploidy or in 
incidence of mosaicism was demonstrated, significantly fewer embryos (3% vs. 23%) 
arising from IVM oocytes were classified as normal based on nuclear morphology. 
In my study, oocyte maturation with development as far as the second cleavage 
division has been demonstrated. Only one of the eight cleavage stage embryos (6-cell) 
arising from the fertilization of in vitro matured oocytes obtained from patients 
undergoing ICSI treatment, exhibited a multinucleated blastomere. Multinucleation 
occurs both in vivo and in vitro and it may serve as a mechanism for ridding the 
preembryo of defective blastomeres. These cells most likely represent random failures 
of cytokinesis (Veeck, 1999). The converse, cytokinesis without karyokinesis, 
resulting in cells lacking nuclei was also observed in two cleavage stage embryos 
arising from the fertilization of in vitro matured oocytes obtained from patients with 
PCO and in one cleavage stage embryo arising from the fertilization of in vitro 
matured oocytes obtained from patients undergoing ICSI treatment. The size of the 
cells appeared normal for the developmental stage and so these anucleate cells were 
not considered on visual inspection to be fragments. The effects of FF-MAS on 
embryo development could not be analyzed statistically in view of the low numbers of 
embryos generated. 
Evidence is accumulating that FF-MAS is an important endogenous factor involved in 
promoting oocyte maturation. The data presented here show positive effects of FF-
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MAS upon survival and maturation of human immature oocytes collected from 
unstimulated pca patients and stimulated ICSI patients respectively. aocytes derived 
from stimulated ICSI patients and unstimulated pca patients constitute different 
populations, probably due to their differing endocrine and intrafollicular 
environments. FF-MAS exerted positive effects upon different aspects of oocyte 
function in both groups. In view of its role as an intrafollicular steroid, and its ability 
to promote maturation, its potential for further development as an in-vitro meiotic 
stimulant should be evaluated further. 
If MAS is the natural paracrine hormone that triggers the resumption of oocyte 
meiosis or spermatogenesis, treating women and men with either agonists or 
antagonists to MAS could potentially control these processes, thus stimulating or 
blocking MAS action (Byskov et ai., 1998). MAS could potentially be used to 
promote fertility in certain conditions, i.e. men with a low sperm production, could be 
treated with MASIMAS agonists, which might induce a higher number of 
spermatogonia to enter meiosis. Furthermore, if an antifertility drug could be 
developed based on controlling the MAS receptor response, it would be unlikely to 
affect the normal hormonal balance or interfere with normal steroid synthesis, as it 
would not be based on sex steroids (Byskov et ai., 1998). While there is great 
potential for MAS action in fertility, the complexity of the system ensuring that 
reproduction continues involves many parallel and redundant pathways, so the 
efficacy of such an approach would require through evaluation. 
In view of the limited developmental competence of embryos observed, and the 
variable potential for atresia in the oocytes from pca patients, I planned to examine 
the normality of the maturing oocytes by direct means in the next set of experiments. 
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Chapter 6 
Assessments of normality of maturation in vitro: 
metaphase spindles and chromosome assessments 
6.1 Introduction 
The process of maturation encompasses a complex series of molecular and structural 
events, culminating in the arrest of the oocyte with chromosomes on the metaphase II 
spindle in anticipation of sperm penetration and activation for fertilization (Trounson, 
2(01). 
It is well documented that oocytes can spontaneously progress through the nuclear 
changes characteristic of oocyte maturation when liberated from the antral follicle and 
cultured in vitro (Pincus and Enzmann, 1935; Edwards, 1965a,b). However, this 
process may be less physiological than that occurring in follicles receiving 
appropriate signals in vivo. Prior to meiotic maturation the GV or oocyte nucleus is 
large, pale, spherical and contains a single, exocentric nucleolus. According to 
Mattson and Albertini (1990), who studied chromatin and microtubule dynamiCS 
during meiotic prophase in the mouse, there are four patterns of chromatin 
organization in the GV oocyte. This reorganization of GV chromatin occurs during 
the preantral to antral follicle transition, and the sequential alterations (stage I-IV) in 
chromatin reorganization occur sequentially in vitro prior to GVBD and the 
spontaneous resumption of maturation. Similar stages of chromatin development are 
observed in human oocytes, although the timing of their occurrence in relation to 
follicle development has not been documented. Chromatin foci appear at the nucleolar 
periphery (stages I-III), stage IV is when the foci coalesce to envelope the nucleolus. 
• Stage I: 6-10 chromatin foci, homogenous staining throughout nucleoplasm 
• 
• 
• 
Stage II: 2-3 chromatin foci associated with the nucleolar periphery 
Stage III: partial rim of chromatin staining at the nucleolar surface 
Stage IV: complete layer of chromatin staining, enveloping the nucleolus 
The changes in GV morphology coincide with modifications in the organization of 
cytoplasmic microtubules (CMT) (Mattson and Albertini, 1990). 
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• Stage I GV: extensive CMT complex. uniformly distributed throughout the 
ooplasm 
• Stage II GV: CMT at GV margins, extend into subcortical cytoplasm 
• Stage III GV: decreased number of CMT with decreased length. in perinuclear 
position 
• Stage N GV: reduction in number of CMT, localization to perinuclear 
position, associated with the nucleolus, at the edge of oocyte. 
At Diakinesis, few MTs are associated with the chromatin at the borders of the GV, 
followed by the appearance of a microtubule-organizing center (MTOC). with the 
continuing condensation of the chromatin. At prometaphase of meiosis I, many MT's 
are associated with the chromosomes at spindle assembly. Changes in MT 
organization correlate with chromatin alterations during meiotic prophase (1-N) and 
the nuclear events associated with GVBD and meiotic maturation in vitro. The 
acquisition and expression of meiotic competence in culture requires the transition to 
stage III or IV GV (Mattson and Albertini, 1990). 
Data on human oocytes suggests that they may follow the same pattern of centrosome 
(MTOC) recruitment because numerous MT nucleation sites are visible adjacent to 
the GV. Astral arrays of MTs can be observed throughout the cortex and in accord 
with reports of MTOC disposition in animal models (Messinger and Albertini. 1991). 
MTOCs exist in the oocytes cortex during various stages of maturation, but are most 
prevalent during meiotic metaphase (Battaglia et al., 1996b). 
At GVBD, the nuclear membrane breaks down; this is followed by condensation of 
dictyate chromatin into compact bivalents, formation of the first metaphase spindle 
and progression through meiosis I to telophase and first pb extrusion, with subsequent 
immediate arrest at metaphase n, the stage of maturity in human oocytes (Wassarman 
et al., 1976). During this process of maturation, cortical granules (CG) are 
accumulated and migrate to the oocyte periphery, forming a protection mechanism 
against polyspermy; CGs are sparse and discontinuous in immature oocytes (Veeck, 
1991). 
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Chromosomal abnormalities and abnormal embryonic development are the major 
causes of preimplantation embryonic death, implantation failure or spontaneous 
abortions. These abnormalities may arise not only after fertilization but even earlier 
during meiotic maturation of human oocytes (Plachot et aI., 1988). Meiosis occurs in 
two parts; in meiosis I the homologous chromosomes pair in a process of synapsis, 
and exchange of genetic material, known as recombination takes place between the 
homologous pairs. During the separation of the homologous chromosomes, the points 
of interchange remain united and the chromosomal structure locally has then an X 
appearance, known as a chiasma. The bi valents line up on the spindle, and at 
anaphase the two duplicated homologues separate and move to opposite poles. Each 
daughter cell contains two copies of one of the two homologues when the meiotic cell 
divides. This is followed by segregation of the homologues into the daughter cells, 
reducing the number of chromosomes from the diploid (2n) to the haploid (n) number 
(Eppig, 1996). In oocytes, the allocation of cytoplasm is asymmetric, resulting in a 
polar body whose size is a small fraction of that of the oocyte. This occurs because 
the spindle takes a peripheral location. Its positioning is tightly controlled by the 
cytoskeleton. 
Meiotic recombination (crossing over) not only generates genetic variation but also 
ensures the correct segregation (disjunction) of homologous chromosomes at the first 
meiotic division. Important chromosomal abnormalities may arise in oocytes during 
meiosis if abnormal segregation of chromosomes (non-disjunction) or chromosome 
loss (anaphase lag) results in monosomy or trisomy in the zygote (Wramsby, 1988). 
The frequency and distribution of chiasmata are of major importance in the aetiology 
of trisomy formation (Angell, 1995). When the meiotic process occurs abnormally 
and homologues fail to separate at the first or second meiotic division, some of the 
haploid cells produced lack one or more chromosomes, while others have more than 
one copy. Such abnormal gametes form abnormal embryos, most of which are non-
viable. However, a small proportion does survive, for example: an extra copy of 
chromosome 21 as a result of non-disjunction during meiotic division lor II results in 
Downs's syndrome (trisomy 21) in humans (Alberts et al., 1994). Only chromosomes 
13, 18, 21 X and Y aneuploidies can survive to birth and beyond, i.e. the sex 
chromosomes and the three smallest autosomes. Others die at different stages, e.g. 
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early or late miscarriages, pre-implantation and pre-blastocyst embryonic 
development. 
The existence of chiasmata at MI and their location along the chromosomes is 
believed to relate to the process of chromosome disjunction during oocyte maturation. 
Currently, information on female recombination is derived indirectly from genetic 
linkage studies, which have implicated certain crossover configurations as a risk 
factor for maternal chromosome non-disjunction (Hassold and Hunt, 2(01). The 
ability to observe them directly at this stage in in vitro matured oocytes, while 
difficult, would be advantageous for studies on the mechanism of origin of 
aneuploidies. 
Prior to 1966, when Tarkowski developed the classic air-drying method for 
chromosome preparations from mouse oocytes, the squash method was routinely 
employed to study meiotic chromosomes of oocytes from several species (Edwards, 
1962, Jagiello, 1965). However, oocyte squashing does not produce uniform and 
consistently good preparations and optimal spreading of chromosomes does not result 
(Tarkowski, 1966). The air-dry technique for preparing human oocytes for 
chromosomal analysis by light microscopy (Tarkowski, 1966) allows the visualization 
of normal chromosomal configurations and has allowed the identification of oocytes 
that exhibit either degenerate or aberrant meiotic forms (Racowsky et aI., 1992a,b). 
Racowsky et ai. (1992a) studied nuclear degeneration and meiotic aberrations in 
human oocytes matured in vitro. Their findings revealed that the majority of meiotic 
aberrations occurred either at metaphase I or at some stage subsequent to alignment of 
homologues on the first metaphase plate. These aberrations fell into two classes of 
meiotic configuration: the clumped MI, characterized by adhesion of the 
chromosomes into a compacted mass, and the two groups of bivalents. 
At the time of ovulation, mammalian oocytes are arrested at metaphase of the second 
meiotic division (MIn with the spindle composed of MT's to which maternal 
chromosomes are attached by their centromeres. These microtubules are involved in 
the separation of sister chromatids at the second meiotic division (Baka et ai., 1995). 
The MT's and associated kinetochores align the chromosomes along the metaphase 
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plate, and paired kinetochores on each chromosome separate allowing each chromatid 
to be pulled towards opposite spindle poles. The presence of an intact second meiotic 
spindle is a requirement for normal segregation of chromatids during the completion 
of meiosis. In humans, the spindle is orientated perpendicularly to the cell surface 
(Battaglia et ai., 1996a). Human meiotic spindles are symmetrical, barrel-shaped and 
contain anastral broad poles. Microfilament areas overlie the meiotic spindle of the 
human oocyte and are possibly related to normal pb extrusion. Spindle damage, 
caused for example by maternal aging (Battaglia et ai., 1996a), short-term exposure to 
temperatures below 37°C (Pickering et ai., 1990) and cryopreservation (Pickering and 
Johnson, 1987; Sathananthan et al., 1988) can result in non-disjunction of chromatids 
resulting in aneuploidy (Baka et ai., 1995). 
In 1999, Hegele-Hartung et al. investigated the influence of FF-MAS on 
chromosome, microtubule and ultrastructural dynamics in hypoxanthine-arrested 
mouse oocytes in a set of time course experiments. Hypoxanthine is an inhibitor of 
meiotic maturation; Grondahl et al. (1998) suggest that it may inhibit cAMP 
phosphodiesterase, thus maintaining a high intracellular cAMP level. Grondahl et al. 
(1998) demonstrated the ability of synthetic FF-MAS to mediate the resumption of 
meiosis in vitro in a dose dependent manner, in both naked and cumulus-enclosed 
mouse oocytes arrested in meiosis with hypoxanthine, isobutylmethylxanthine 
(ffiMX) or dibutyryl cAMP (dbcAMP). Hegele-Hartung et al. (1999) found FF-MAS 
treated oocytes to behave similarly to spontaneously matured oocytes. Chromosomes 
became aligned, a barrel-shaped spindle formed and overall organelle distribution was 
normal. There were an increased number of small cytoplasmic asters and an increased 
distance between cortical granules (CGs) and the oolemma in FF-MAS treated 
oocytes. The short fertilizable life span of mammalian oocytes, especially in vitro is 
linked with the proper development of COs during meiotic maturation; COs are 
important indicators of cytoplasmic maturation. During meiotic maturation, CGs 
migrate to the periphery of the oocyte and remain under the oolemma until 
fertilization. CO loss starts at MI (-30% loss) and continues at MIl in both in vitro 
and in vivo matured mouse oocytes. FF-MAS leads to a slow movement of CGs 
towards the oolemma as well as to an increase in reuptake of CO material from the 
perivitelline space (Hegele-Hartung et al., 1999), they suggested that FF-MAS can 
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reduce the spontaneous CG release, observed in vitro and in vivo conditions in mouse 
oocytes in the absence of sperm penetration (Okada et al., 1993), thereby preventing 
precocious modification of the zona pellucida, e.g., zona hardening (De Felici and 
Siracusa, 1982). These observations led Hegele-Hartung et al. (1999) to conclude that 
FF-MAS appears to improve mouse IYM oocyte quality by supporting microtubule 
assembly and by delaying spontaneous CG release, which is known to contribute to 
reduced fertilization. 
In 2000, Nogueira et al. analyzed the nuclear status and chromosome composition of 
embryos derived from in vitro matured oocytes, retrieved from stimulated patients 
undergoing lYE They demonstrated a similar fertilization rate of in vitro matured 
oocytes and in vivo matured oocytes, but a higher incidence of non-cleavage in the 
former along with chromosomal anomalies in 78.5% (11/14) this was associated with 
a high proportion of multinucleation. Multinucleation could result from nuclear 
disintegration during interphase or karyokinesis in the absence of cytokinesis. 
Nogueira et al. speculated that the high incidence of genetically abnormal embryos 
(showing aneuploidy and multinucleation) derived from in-vitro matured oocytes was 
due to a deficiency in cytoplasmic maturation that cannot be recovered completely by 
the sperm and probably causes spindle defects at cleavage. 
Reduced competence for the human oocyte has been associated with spindle 
malformations and chromosome malalignment (Battaglia et al., 1996a; Battaglia and 
Miller, 1997; Van Blerkom and Davies, 2(01). The normal assembly of MTs and 
microfilaments in unfertilized oocytes is required for successful fertilization (Kim et 
al., 1997), both are associated with the reconstruction and proper positioning of 
chromatin after GVBD and during meiotic maturation in human oocytes. Defects of 
the microtubular system can probably induce loss or gain of a single or a few 
chromosomes, leading to aneuploidy (Kim et al., 1998). In improperly matured 
oocytes, chromatin is located outside of microfilament-rich areas, which seem to be 
related to abnormal embryonic development following fertilization (Kim et al., 1998). 
Suboptimal culture conditions during maturation may cause insufficient maturation of 
cytoplasmic organelles, such as MTs and microfilaments, resulting in abnormal 
spindles and developmental arrest. Moreover, during IVM, the timing of phases of 
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meiosis might be altered, resulting in MT irregularities and unusual chromosome 
placement. 
Goudet et al. (1997) studied metaphase spindles in equine IVM oocytes and in vi vo 
matured oocytes. They found spindles obtained after IVM to be significantly wider 
and longer than spindles obtained at recovery of in vi vo matured oocytes. A general 
change in the critical concentration of tubulin in the cytoplasm may induce an 
alteration in the size of the spindle (Eichenlaub-Ritter et al., (986). Thus it is possible 
that in vitro culture may allow the same nuclear maturation as in vivo maturation but 
may induce a change in the concentrations of cytoplasmic proteins, such as tubulin, 
and also other factors involved in cell cycle regulation (Goudet et al., (997), which 
might jeopardize the developmental competence of the resulting oocyte. 
Temperature control during IVM is of paramount importance, as spindle MTs are 
highly thermosensitive; even a small change in temperature can disturb the spindle 
structure of the oocyte. In 1990, Pickering et al. observed disassembled spindles in 
50% of oocytes after 10 min at RT and in 100% after 30 min at RT; chromosome 
anomalies resulted. Wang et al. (2001) demonstrated that a reduction in temperature 
to 33°C resulted in the depolymerization of spindles within 10 min. 
In view of the promising results obtained with FF-MAS in promoting the survival and 
maturation of human GV oocytes (Chapter 5) and similar data in animals from other 
groups, the maturing oocytes' chromosomal constitution and spindle appearance was 
studied to determine whether the oocytes in which FF-MAS had stimulated 
maturation were developing normally. This assessment was undertaken in oocytes 
from patients undergoing ICSI treatment only, this being the more readily available 
source of human oocytes, and potentially less likely to have anomalies already present 
than oocytes from patients with PCO whose follicular environment may be 
compromised. 
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6.2 Aims 
To assess the feasibility of studying human oocyte chromosomes and chiasmata at 
metaphase I during IVM. To attempt IVM of oocytes obtained from patients 
undergoing a cycle of ICSI treatment, in conditions including FF-MAS at a 
concentration of 30J.1g/ml or control (no FF-MAS, vehicle only). To compare in vitro 
matured with in vivo matured (IVF failed fertilized) oocytes, in terms of spindle and 
chromatin organization. To observe differences in the cytology and chromatin of 
oocytes maturing or remaining immature under control or FF-MAS conditions. 
6.3 Chromosome assessments of MI oocytes from patients undergoing a cycle of 
ICSI treatment 
6.3.1 Patients 
For this preliminary study, a total of 19 immature oocytes were collected from eight 
patients undergoing cycles of IeSI treatment. Clinical details of the patients are 
presented in table 3.3 (chapter 3). 
6.3.2 Oocytes 
The immature oocytes were cultured with colcemid (lOJ.1g/ml) for 4-6 hr at 37°C, 5% 
CO2 in air before fixing and spreading (Chapter 2, section 2.6). 
6.3.3 Results from chromosome spreading 
Four of the 19 oocytes did not progress beyond the GV stage, 14 displayed no pb and 
were presumed to be in MI and one was in MIl at the time of spreading. Only three 
analysable spreads were obtained from 15 oocytes studied. In one of these, 22 
bivalents and several chiasmata were evident (Figure 6.1). In the MIl oocyte, 14 
chromosomes were observed in the oocyte and five in the pb. In the third preparation, 
only five chromosomes were seen. 
In view of the disappointing results obtained, despite supervision by an experienced 
cytogeneticist, this line of investigation was discontinued. 
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Figure 6.1 Spread of chromosomes from a human oocyte at first meiotic 
metaphase, during maturation in vitro. 
22 chromosomes are evident. One shows signs of three chiasmata (3C), whereas 
several show signs of two chiasmata each (2C) or one chiasma (1 C). Premature 
dissociation of chromosomes pairs in the left hand group is apparent (PO). The 
identification of individual chromosomes is not possible for a spread of this quality. 
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6.4 Effect of FF -MAS on spindle formation in in-vitro maturing oocytes from 
patients undergoing a cycle of ICSI treatment 
6.4.1 Patients 
For this study, a total of 35 immature oocytes were collected from 21 patients 
undergoing cycles of ICSI. Clinical details of the patients are presented in table 3.3 
(chapter 3). 
6.4.2 Oocytes 
The oocytes were cultured with 30J.lg/ml FF-MAS, the concentration shown in 
previous experiments to promote NM in this source of oocytes, or with no FF-MAS 
(control) for 24 hr; spindle analysis as described in section 2.7.1 was then performed 
on mature oocytes. 
Oocytes were considered mature if a polar body was visible by Hoffman microscopy. 
Oocytes failing to mature were stained with Hoechst 33258 to confirm their chromatin 
status as described in 2.5.3. 
6.4.3 Spindle analysis 
The position and shape of the Mll spindle and the normality of chromosomal 
alignment in oocytes were assessed using fluorescence microscopy after preparation 
of oocytes by staining with anti-tubulin antibodies and DAPI, as described in section 
2.7.1 
6.4.3.1 Mouse oocytes 
Preliminary work carried out using mouse oocytes demonstrated the reliability of the 
technique and was used to confirm appropriate antibody concentrations. Figure 6.2 
shows the normal equatorial alignment of chromosomes in a mouse oocyte at MIl 
after staining with antitubulin antibodies and DAPI. The polar body had degenerated. 
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Figure 6.2 Mouse oocyte stained with FITC-labelled anti-tubulin antibodies 
(green) and DAPI (blue). The position of the spindle (intense green) parallel with the 
oocyte surface is characteristic in mice. The chromosomes appear blue and are 
arranged in a compact line across the spindle indicative of the normal arrangement. 
Bar=25~m 
6.4.3.2 Human oocytes 
Human oocytes were randomized to either 30~g/ml FF-MAS or control conditions, 15 
oocytes were cultured in 30fJglmi FF-MAS and 12 were considered to have matured, 
as shown by the presence of a pb. One oocyte arrested at the GV stage, one remained 
immature and one oocyte became atretic in culture. 
20 oocytes were cultured in control conditions, three oocytes matured, five arrested at 
the GV stage, seven remained immature (six oocytes atTested at GYBD and one 
oocyte at MI) and five degenerated in culture. Three oocytes (MIl and GVBD or MI 
in control and MIl in 30fJg/ml FF-MAS) could not be analysed after culture due to 
unforeseen circumstances. The results presented in Table 6.1 confirm those in Chapter 
5, that 30fJglmi FF-MAS significantly promotes maturation of oocytes (from patients 
undergoing rCSI treatment) in vitro (p<O.OOl). 
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Table 6.1 Outcome of in vitro culture with or without FF -MAS of oocytes 
donated by patients under2oin2 ICSI treatment. 
Mature Immature Atretic Total 
Control 3 12 5 20 
FF -MAS (JOpglml) 12 2 1 15 
Oocytes were identified as having nucleolar chromatin condensation corresponding to 
Mattson and Albertini (1990) stages II to IV. Table 6.2 shows the chromatin staging 
of all non-matured oocytes stained with Hoechst 33258. For the oocytes cultured with 
FF-MAS (30I-lg/ml) the oocyte with a GV visible was observed to be at stage III with 
a partial rim of chromatin staining at the nucleolar surface. For the oocytes cultured in 
control, there were five with visible GVs, four of these were stage II GVs and one was 
stage III. For the seven remaining immature oocytes, in which no GV was seen, one 
had stage III chromatin, three had stage IV chromatin, one was at MI and two were 
not examined. Oocytes with a GV visible at the time of staining had stage II or III 
chromatin. 
Table 6.2 Chromatin staging of non-matured oocytes, donated by patients 
undergoin~ ICSI treatment and cultured with or without FF-MAS. 
Non-
GV MI identifiable/not Atretic Total 
examined 
II III IV 
Control 4 2 3 1 2 5 17 
FF-MAS 
1 1 1 3 (JOpglml) 
Figure 6.3a,b and c shows hoechst images of oocytes that arrested at the GV stage 
after culture in control. 
138 
Figure 6.3 Nuclear staining with Hoechst 33258 of human oocytes that arrested 
at the GV stage after culture in control conditions. 
a) Stage II GV, 2-3 chromatin foci associated with the nucleolar periphery (Mattson 
and Albertini , 1990). 
b) Stage III GV. partial rim of chromatin staining associated with the nucleolar 
periphery. 
c) Stage IV GV, complete layer of chromatin staining enveloping the nucleolus 
Bar = SOJ.lm 
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Figures 6.4- 6.6 show the results of spindle staining in human oocytes. When tubulin 
was identified immunocytochemically in oocytes fixed at MIl in combination with 
DAPI staining of chromatin, spindles and chromatin were readily identified in a 
proportion of oocytes. 
No spindles were observed in the two oocytes matured under control conditions, one 
for technical reasons (oocyte damaged during preparation) the other oocyte stained, 
although no spindle was seen. Of the 12 MIl oocytes matured in 30IJg/mi FF-MAS, 
five out of six oocytes stained were observed to have abnormal spindle structures and 
the sixth oocyte was not analysed (see p.136). Figure 6.4 shows a spindle with some 
displacement of chromatids of an oocyte at anaphase of MIl. Figure 6.5 shows 
examples of abnormal spindles. Technical failure affected five oocytes; three oocytes 
failed to stain (nothing seen on slide) and two oocytes crumpled during slide 
preparation making observation impossible. 
Eight in vivo matured oocytes that had failed to fertilize after clinical ICSI were 
stained using the same protocol. in order to act as controls. Two oocytes exhibited 
normal spindle structures (an example is shown in figure 6.6) although poor 
alignment of chromosomes was evident, possibly due to in vitro aging known to occur 
(Asch et al. J 1995). Three oocytes exhibited abnormal spindle structures and the three 
remaining oocytes failed to stain. 
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Figure 6.4 Combined DAPI and FITC fluorescence in a mature human oocyte 
cultured in 30fJglmI FF -MA ,at anaphase of Mil. The spindle can be een, with 
the chromatid. . eparating and moving to opposite poles. Some chromatids are 
di. placed from the , pindle. 
Bar = 50 fJm 
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disorganized spindle with 
chromosome displacement 
Chromosomes in pb 
Spindle in middle of oocyte 
(half of oocyte not stained) 
Chromosomes dispersed 
within the spindle 
Figure 6.S Examples of abnormal spindles in three human oocytes matured in 
vitro in the presence of 30J.lglml FF -MAS. 
a) A dL organized . pindle i present towards the periphery of the oocyte, adjacent to 
the polar body. The chromosomes are not aligned normally on the oocyte spindle. 
Chromosome disorganization within the first polar body is common and does not 
affect the genetic complement of the oocyte. 
b) A di organized . pindle with di persed chromosomes is evident. This was observed 
in the centre of the oocyte. The polar body is not visible in this image. 
Bar = 50 I-Im 
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Pb undergoing division Abnormal spindle 
Figure 6.5 Examples of abnormal spindles in three human oocytes matured in 
vitro in the presence of 30J.1g1ml FF -MAS. 
c) A small spindle is evident towards the periphery of the oocyte with some 
chromosomes aligned at the midpoint and others mal-aligned. The polar body is in the 
process of division. 
Bar = 50IJm 
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Figure 6.6 Example of a normal shaped spindle in an oocyte that failed to 
fertilize. Individual spindle fibres visible and chromosomes in pairs but dispersed on 
the spindle. The other spindle (not in focus, is the polar body), the clear area in the 
centre of the oocyte is a vacuole, sperm and/or degenerating cumulus cells can be 
seen around the edge of the oocyte. Bar = 50l-! m 
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6.S Discussion 
In this chapter, three different approaches have been used to identify whether meiotic 
progression is occurring normally in vitro; chromatin staining in situ, chromosome 
spreads and spindle structure assessments. 
Chromatin staining of oocytes that did not complete maturation in vitro showed a 
range of arrest points, and this was particularly evident in the control group where the 
proportion of maturing oocytes was low. The classical chromatin condensation 
patterns observed by Mattson and Albertini (1990) were evident, and clearly, some of 
the immature oocytes were incompetent to undergo GVBD under control conditions, 
being at stages II and III. Interestingly, the oocytes exposed to FF-MAS had matured 
in a significantly (p<O.OOI) higher proportion, confirming previous data, and they 
appeared to have overcome the GY arrest observed in a proportion of control oocytes, 
potentially suggesting that the FF-MAS can act during the GV stage to promote 
chromatin maturation. This point is worthy of further investigation with larger 
numbers of oocytes, if this can be achieved in humans. 
Colcemid is a microtubule inhibitor, therefore nuclear progression is blocked at MI by 
prevention of the formation of a MI-spindle, however GVBD and chromatin 
condensation take place in an apparently normal manner in the presence of colcemid 
(Wassarman et ai., 1976). In 1995, Angell reported the results of first and second 
meiotic metaphase spreads of human oocytes. While spreads of second meiotic 
metaphase were obtained in some 70% of oocytes that had failed to fertilize or cleave 
during IVF cycles (Angell, 1995), MI oocytes are known to be more difficult to 
prepare. MI oocytes were obtained from volunteer women scheduled for laparoscopic 
sterilization. The MI preparations lacked the clarity of MI preparations from mice and 
accurate chiasma counts could not be made. However, Angell (1995) reported on a 
total of 22 oocytes, of which 18 had 23 bivalents, two had 22 bivalents with one pair 
of homologous univalents, and two at early anaphase, had two pairs of homologous 
univalents. 
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The results of my attempts to obtain interpretable MI spreads were disappointing 
including loss of chromosomes, probably due to excessive spreading. The one useful 
spread showed 22 chromosomes. One chromosome showed signs of three chiasmata 
whereas several showed signs of two chiasmata each or one chiasma. Premature 
dissociation of chromosome pairs in the left hand group was apparent. The 
identification of individual chromosomes was not possible. 
MI occurs during the period of IVM and therefore it was important to this study to 
attempt to visualize chiasmata at MI. As crossing over occurs in fetal life at prophase 
I, long before IVM, observations from in vitro matured oocytes would be unlikely to 
differ from standard maturation, and would add greatly to the currently limited 
knowledge base on this topic. 
An alternative approach to analysing crossing over uses antibody labeling to MLH1, 
the DNA mismatch repair gene. MLH-l forms foci along the axes of paired 
homologous chromosomes in germ cells at prophase I of meiosis. In 1998, Barlow 
and Hult~n analyzed crossing over at pachytene in human spermatocytes with anti-
MLH 1 antibody labeling, as in the mouse the numbers and distributions of MLH 1 foci 
matched those of chiasmata at MI. Had visible spreads been obtained, it had been 
hoped to apply anti MLHI antibody to identify chiasmata. However, a recent study by 
Tease et al. (in press), which detected MLHI foci in human fetal oocytes, showed that 
the foci remained clear on synaptonemal complexes from zygotene to pachytene but 
started to disappear in early diplotene, and so would most probably have been 
undetectable in MI oocytes. This assessment was therefore not undertaken in my 
study. 
Even using the up to date microscopy and cytogenetic technology now available, 
chiasmata remain difficult to visualize. This pilot study has confirmed that the 
spreading technique is technically difficult, in view of the limited supply of human 
oocytes and the lack of analysable results obtained it was decided that an assessment 
of mature oocytes at MIl would be more producti ve. 
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My results (Chapter 5 and Chapter 6) showed significant effects of FF-MAS on 
human oocyte maturation in vitro. However, the manner in which FF-MAS promotes 
maturation is uncertain and the normality of maturation under in vitro conditions 
required further exploration. This would be critical for any future application in 
therapeutic regimes. This preliminary study therefore aimed to examine the spindle 
organization in morphologically normal oocytes, arising after IVM with or without 
culture with FF-MAS. The incidence of maturation in vitro in the presence of FF-
MAS was significantly greater than that in its absence (confirming previous results in 
chapter 5), however, this resulted in a relative shortage of oocytes maturing without 
FF-MAS exposure, limiting the interpretation of the results. However, the data show 
that spindle malformation affected a high proportion of oocytes matured in vitro with 
FF-MAS (30Ilg/ml). Five out of six MIl oocytes with stained spindle structures were 
abnormal. It cannot be determined from the data whether this was due to the 
maturation in vitro or the FF-MAS since control oocytes rarely matured in vitro and 
two of those which appeared to mature were not analysed with the third having no 
spindle structure visible. 
The normal MIl spindle structure is a symmetrical barrel-shaped structure located 
eccentrically, with the 23 chromosomes each with two sister chromatids, aligned on 
the equatorial or metaphase plate. Spindle microtubules attach to the centromeres. The 
chromosomes are divided between the oocyte and the pb (23 chromosomes, 46 
chromatids, 2n DNA in each). The first pb remains connected to the oocyte by a 
cytoplasmic bridge for a while after its formation. The chromosomes within the first 
pb may remain clumped together, undergo a second meiotic division or scatter within 
its cytoplasm (Veeck, 1999). 
In Figure 6.4, the spindle was symmetrical and barrel shaped with correct positioning, 
the oocyte appeared to be at anaphase as the chromatids had split at the centromeres 
and had begun to move to opposite ends of the spindle apparatus. As the oocyte had 
not been fertilized, chemical exposure or environmental trauma may have activated 
the oocyte causing the resumption of meiosis. Some chromatids can be seen detached 
from the spindle apparatus, although scattering throughout the cytoplasm was not 
evident. 
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Figure 6.5 shows oocytes exhibiting spindle defects; these oocytes were also 
characterized by the occurrence of detached chromosomes. In Figure 6.5a, the spindle 
is disorganized, not barrel shaped, rounded instead of pointed at the poles and the 
chromosomes are displaced. In Figure 6.5b, the spindle is not located in an eccentric 
position and again, the chromosomes are mal-aligned, however they are not scattered 
throughout the cytoplasm. 
Baka et a/. (1995) saw some dispersion of chromosomes throughout the cytoplasm in 
prophase I human oocytes which had matured in vitro, however 83.8% of the oocytes 
showed a normal appearance of the meiotic spindle and chromosomes. Tremoleda et 
at. (2001) studied the organization of the cytoskeleton during IVM of horse oocytes. 
Both the microtubular and microfilament elements of the cytoskeleton were seen to 
reorganize in a fashion that appeared to enable chromosomal alignment and 
segregation. In Figure 6.5c, the spindle is in the correct position located at the 
periphery of the cell and orientated radially with its long axis perpendicular to the 
surface membrane but it is disorganized with chromosome malalignment. 
Similar to the study by Hegele-Hartung et at. (1999) analyzing the effects of FF-MAS 
(lOpglml) on the microtubular cytoskeletal and chromosomal organization in mouse 
oocytes via double-labeling fluorescence; the majority of spindles of MIl oocytes 
were barrel shaped with a dense network of microtubules appearing to fill the region 
between the poles and the chromosomes. However, Hegele-Hartung et a/. (1999) 
observed chromosome alignment in FF-MAS matured oocytes, which was disrupted 
in most of the oocytes maturing in culture with FF-MAS in this study. 
In 1996, Battaglia et at. studied the influence of maternal ageing on meiotic spindle 
assembly in oocytes from naturally cycling women. They found that -80% of oocytes 
aspirated from antral follicles of naturally cycling women between 40-45 years 
contained abnormally organized spindles with malaligned or detached chromosomes 
In contrast, only 17% of oocytes from antral follicles of naturally cycling women 
between 20-25 years exhibited aneuploid conditions (Battaglia et a/., 1996a). 
Battaglia et at. (1996a) studied the various phases of meiosis; they observed 
condensed chromosomes throughout GVBO (as expected), which became organized 
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as meiosis progressed, they were unable to visualize the MI spindle and concluded 
that, similar to animal models, the ftrst metaphase spindle was transient. At MIl, a 
distinct spindle was observed with chromosomes aligned on the metaphase plate. 
Aged oocytes display an increased incidence of disrupted or abnormal cytoskeletal 
organization (Eichenlaub-Ritter et at., 1988; Pickering et at., 1988). Poor alignment of 
chromosomes was evident in oocytes that had failed to fertilize, probably due to in 
vitro ageing (Asch et al., 1995). The patient group used in my study was aged 
between 25-40, with a mean age of 33.8 years; it is therefore unlikely that increased 
maternal age was a major factor for most of the abnormal spindles observed here. 
Microtubules of the metaphase spindle are highly thermo-sensitive. Even a small 
change in temperature can disturb the spindle structure of the oocyte (Munne and 
Cohen, 1998). Human oocytes have exhibited a disassembled spindle in 50% of cases 
after 10 min at room temperature (R T), and in 100% after 30 min at R T accompanied 
by chromosome abnormalities (Pickering et at., 1990). In my study, cooling was not a 
causative agent in the abnormal spindles observed, as all oocytes were ftxed. The ftx 
used was formaldehyde, although this is not a fast fix, the relatively small size of the 
oocyte helps to ensure fast ftxation. 
This preliminary study of spindle normality after IVM of human oocytes with FF-
MAS suggests that there are major abnormalities in the chromosomes distribution 
upon the oocytes' spindles after IVM. The cause of this is uncertain, potentially 
relating to either exposure to FF-MAS, or the IVM process or conditions, but 
difficulties in establishing an adequate control group of oocytes prohibit further 
interpretation. The gross abnormalities in spindle development may be a major 
contribution to the limited developmental potential of oocytes matured in vitro 
observed in this series and reported by several other groups. However, the number of 
studies which have examined this issue remain small and thus conclusions are not yet 
available. It will be crucial to follow up the possibility of abnormal chromosome 
complements in in vitro matured oocytes, since the normality of any offspring as well 
as success rates may depend upon this. However, even when chromosomally normal 
oocytes are formed, the normality of the cytoplasmic component remains uncertain. 
149 
Future work on the genetic results of in vitro matured oocytes in the presence of 
various factors known to stimulate maturation is required, however, there is a major 
need to develop non-invasive measures of developmental competence which could be 
applied in the clinical situation. The next chapter explains some of the measurable 
morphological features which might contribute to the development of such non-
invasive method 
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7.1 Introduction 
Chapter 7 
Image analysis 
Oocyte IVM may result in viable mature oocytes and in some respects may mimic the 
in vivo process (Schroeder and Eppig, 1984). However, all oocytes within the ovary 
are not equally competent to resume meiosis in vitro and reach full maturity. Oocyte 
competence to undergo GVBD and mature to MIl is primarily determined by the 
developmental stage of oocyte, including its volume, reflecting adequate growth, and 
these aspects are closely coordinated and controlled by the follicular environment and 
stage of development (Gilchrist et ai., 1995). As described in the introduction 
(Chapter 1) the human oocyte and the follicle initially grow in parallel in a tightly 
regulated manner, however, beyond the point of antrum formation, oocyte growth 
declines markedly while follicle growth continues apace. However, the somatic and 
germ lines remain closely in contact and their further development is effectively 
symbiotic. 
In 1985, Tsuji et al. examined the relationship between the follicular size in the 
human ovary and the oocytes' capability of resuming meiosis in vitro in each phase of 
the menstrual cycle. In the follicular phase, the percentage of immature oocytes 
resuming meiosis and extruding a polar body in the large-follicle group (9-15mm 
diameter) was significantly higher than that in the small-follicle group (3-4mm 
diameter) (p < 0.05). The capacity for meiotic maturation therefore seemed to increase 
with increasing follicle size. However, in the luteal phase the incidence of maturation 
was fairly constant, irrespective of the follicular size. Based on their results, Tsuji et 
al. suggested that the capacity for human oocyte maturation is closely related to 
follicular status, and the differing hormonal environments in the follicular and luteal 
stages, associated with differing follicular maturity may affect oocyte function. 
Lonergan et ai. (1994) studied the effect of follicle size on bovine oocyte quality and 
developmental competence following maturation, fertilization, and culture in vitro, 
demonstrating that more oocytes with many layers of cumulus (p < 0.01) and a higher 
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proportion of blastocysts (p < 0.01) were obtained from follicles of diameter >6 mm 
compared to 2-6mm follicles. 
In 1989, Eppig and Schroeder isolated oocytes with increasing mean diameters from 
juvenile mice of increasing ages. They found that oocytes from mice 13 days of age or 
younger, whose mean diameter was less than 60J,1m, were able to undergo 
spontaneous GVBD in culture, but an increasing percentage of larger oocytes from 
mice 15 days of age and older was able to undergo maturation in culture. With 
increasing age and mean oocyte diameter, more oocytes progressed to Mil. In mice, 
competence to undergo GVBD was normally achieved when oocytes reached -60J,1 m 
in diameter, the capacity to progress to Mil being acquired subsequently. Hirao et al. 
(1993) confirmed that this principle of increasing developmental competence with 
increasing size also applied to in vitro grown mouse oocytes, where the threshold 
diameter of 6OJ.! m for GVBD remained the same. 
The capacity to cleave after maturation and insemination in vitro is also acquired with 
increasing age and mean oocyte diameter. Bao et al. (2000) demonstrated that the 
ability of mouse oocytes to support development occurs in a stepwise manner as 
oocyte diameter increases from 65-75J.!m. Oocytes with a diameter of 65-75J.!m cleave 
to the two-cell stage at normal rates, but subsequent developmental changes occurring 
in the oocytes during the final stages of the growth phase are critical for full 
developmental competence. Maternal chromatin is first competent to support 
development to term during the latter half of oocyte growth when oocytes are 
6O-69J,1m and 50-59J.!m in diameter in immature and adult female mice, respectively 
(Bao et al., 2000). Thus it appears that epigenetic modifications of maternal 
chromatin necessary for development to term are established earlier in the oocyte 
growth phase in the adult ovary. This distinction between adult and juvenile ovaries is 
important since many studies in mice are performed on immature. relatively 
synchronized cohorts of follicles, not reflecting the physiological situation during 
reproduction. 
Daniel et al. (1989) demonstrated an increased ability to undergo GVBD with 
increasing mean oocyte diameter in a rat model of in vitro follicle growth. At the start 
152 
of follicular growth in vitro, each follicle contained an oocyte in the midgrowth phase, 
with a mean diameter of 40-45jJm, which was incapable of undergoing meiotic 
maturation. Oocytes that grew to full size had a mean diameter of 70-80jJm. Oocytes 
capable of undergoing GVBO after in vitro culture were significantly larger than 
incompetent oocytes. No oocytes less than 55jJm in diameter were GVBO competent. 
This indicates a relationship between oocyte growth and acquisition of meiotic 
competence. However, Canipari et al. (1984) observed mouse oocytes that became 
GVBO competent after being cultured in conditions that did not promote significant 
growth. They reported an inverse relationship between acquisition of meiotic 
competence in vitro and initial size of oocyte at the time of isolation, and that meiotic 
competence corresponded to the timing of the event in vivo. This suggests that the 
events of meiotic resumption and oocyte growth may be separable when non-
physiological conditions are applied in vitro. 
Hirao et al. (1994) studied the in vitro growth and maturation of pig oocytes. 
Progression to metaphase II was observed in 40% of oocytes that were >llOjJm in 
diameter, whereas no oocyte <9OjJm in diameter resumed meiosis. 
Fair et al. (1995) studied bovine oocyte diameter in relation to maturational 
competence and transcriptional activity. Four groups of oocytes based on diameter 
were studied: <100, 100-<110, 110-<120 and >120jJm. The proportions achieving in 
vitro development to MIl were 21.2%, 42.3%, 75.9% and 80.7% respectively for the 
four size groups. Oocytes <110jJm were shown to be actively synthesizing RNA, as 
demonstrated by measuring the degree of 3H-uridine incorporation in vitro and they 
were still in the growth phase of oocyte development. Whereas those which were 
larger, demonstrated a much lower degree of 3H-uridine incorporation. 
The situation in primate oocytes appears to be similar. In 1993, Schramm et al. 
studied the meiotic competence of rhesus monkey oocytes. They demonstrated that 
the oocytes attain maximum size after antrum formation in this species, although at 
this stage MIl competence is still low and increases with follicle diameter while 
oocyte size remains constant. Adachi et al. (1982) reported an increase in meiotic 
maturation of marmoset monkey oocytes with increasing follicular size, although 
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oocyte diameter did not change. In 1995, Gilchrist et al. also studied the meiotic 
competence of marmoset monkey oocytes in relation to follicle size and oocyte-
somatic cell associations. They further demonstrated the sequential acquisition of 
oocyte GVBD and MIl competence with increasing follicular size, however they were 
unable to obtain oocyte diameter data, as they did not disturb the oocyte-somatic cell 
contacts before culture. Equine oocytes seem to behave similarly to those of the 
rhesus monkey in that meiotic competence is not necessarily associated with 
maximum oocyte diameter, and oocytes that appear fully grown may still need to 
undergo cytoplasmic maturation before they are competent for optimal maturation 
(Goudet et al., 1997). There may therefore be species differences in the point at which 
meiotic competence is reached, and its relationship with oocyte and follicle size. 
During this study, longitudinal cultures of up to four days were performed. This 
afforded the opportunity to quantify human oocyte growth under the in vitro 
conditions employed, and to explore the possibility of using a non-invasive measure 
of oocyte development as an indicator of subsequent developmental competence. 
Such studies have not previously been published. 
7.2 Oocytes from peo patients, cultured with or without FF-MAS. 
7.2.1 Oocyte diameter 
The reproducibility of the image analysis measurements was assessed by a series of 
trial measurements performed as described in section 2.8.1. The results are shown in 
Table 7.1. The standard deviations observed were well within 1 % of the mean value 
in 9 out of the 10 oocytes after measuring 10 times each, and all results were within ± 
2~m of the mean, most within ± l~m. The confidence that could be placed in these 
measurements was therefore high with good reproducibility. 
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Table 7.1 Control oocyte measurements 
Oocyte 1 2 3 4 5 6 7 8 9 10 
105 103 104 103 110 107 105 108 106 110 
103 105 103 104 109 107 105 107 107 110 
104 104 105 104 110 105 106 107 105 112 
106 105 105 105 111 106 107 106 106 112 
105 105 105 104 110 106 105 106 106 109 
106 104 105 105 109 106 105 107 108 108 
106 103 104 103 109 107 106 107 106 109 
105 105 105 103 109 106 105 109 107 109 
105 104 105 105 110 107 107 108 105 110 
104 104 104 105 111 107 107 107 106 110 
Mean 104.9 104.2 105.8 104.1 109.8 107.2 105.8 107.2 106.2 109.9 
Std 0.994 0.789 0.771 0.876 0.789 0.699 0.919 0.919 0.699 1.287 
dev 
Sem 0.3 0.2 0.2 0.3 0.2 0.2 0.3 0.3 0.2 0.1 
Range 3 2 2 2 2 2 2 3 3 4 
Table 7.2 presents the number of oocyte measurements available for each parameter 
measured on the day of oocyte collection and on day 0 (day of insemination of mature 
oocytes) for both patient groups. For patients with PCQ, a total of 128 oocytes were 
collected (Chapter 5). Table 7.2 shows that on the day of oocyte collection, the 
measurement of oocyte diameter provided the largest number of measurements, a total 
of 86 oocytes were measured. A total of 42 oocytes were not measured on the day of 
collection, due mostly to a dense surrounding of cumulus cells obscuring the 
oolemma, making measurement impossible or unreliable. In some cases, by 
enhancing the image contrast and converting to grey scale it was possible to visualize 
and measure the oolemma through the attached cumulus cells. Fewer of the other 
measurement types were available because for those involving the zona pellucida, the 
zona required to be completely clear of any cumulus attachments and with clear 
visibility throughout for the measurement to be made, which only occurred for a 
relatively small proportion of oocytes. 
For patients undergoing ICSI treatment, a total of 72 oocytes were donated, 48 oocyte 
diameters were measured on the day of collection and 24 were not measured. Eight 
oocytes were not measured on the day of collection or on day 0 due to camera failure 
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preventing images being taken. The rest were omitted because very faint oolemmas 
made measurement impossible and/or cumulus cells obscured visibility as already 
discussed. The cumulus cover on these immature oocytes was very difficult to remove 
totally using the standard hyaluronidase technique since it is well known that 
immature cumulus is relatively tight and dense compared to a mature expanded 
cumulus mass. 
For all parameters measured, and for both patient groups, the number of oocytes 
measured on day 0 was more than or equal to the number of oocytes on the day of 
collection. This was due to cumulus expansion in vitro and the stripping of cumulus 
cells in preparation for ICSI, which enabled measurements to be made more readily. 
Table 7.2 Total number of oocyte measurements available for each parameter 
measured on the day of oocyte collection and on day 0 (day of insemination of 
mature oocytes) for both patient groups. 
Zona 
Oocyte Oocyte+zona Perivitelline 
Patients Day pellucida 
diameter diameter space (PVS) 
thickness 
Unstimulated Collection 86 48 44 12 
PCO 0 90 48 47 26 
Stimulated Collection 48 46 45 38 
ICSI 0 61 60 59 39 
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Figure 7.1a presents the frequency histogram of the mean diameter of measurable 
viable oocytes collected from patients with peD on the day of collection (day-2). 
These results approximate a normal distribution with a mean diameter of I06Jlm. 
However, the diameters on day-2 of oocytes that went on to mature in vitro 
irrespective of conditions of culture did not follow a normal distribution (Figure 7.1 b). 
The data in Figure 7.1c show that the proportion of oocytes in each size range which 
matured showed a tendency to increase with increasing size, while no oocytes of 
diameter <lOOJlm matured. Within this series, one oocyte with a mean diameter of 
l00Jlm on day-2 reached MIl subsequently, which represents the minimum 
"threshold" observed for maturation. However, the incidence of oocyte maturation in 
this size range may be lower than for larger oocytes. 
157 
--
~ 
= 
'" ~
.... 
.... 
~ 
0 
~ 
a 
25 
20 
15 
10 
b 
25 
20 
,5 15 
~ 
~ 10 
o 
5 
o ~ 
c 
100 
80 
11 
.... 60 \,/ 
0 
0 
.... 40 -0 
~ 
20 
0 
<100 100-102103-105106-108 109-lll 112-114 115-117118- 120 121 -123 124+ 
<100 100-102103-105106-108109-111112-114115-117 118-120121-123 124+ 
D 
<100 100-102 103-105 106-108 109-111 112-114 115-117 118-120 121-123 124+ 
Mean oocyte diameter (J.1m) 
Figure 7.1 Frequency histogram showing mean oocyte diameters on day of 
collection (day-2) of oocytes from unstimulated patients with peo. 
a) Viable oocytes 
b) Oocytes becoming mature in vitro 
c) Oocytes that progressed to maturity expressed as a percentage of viable 
oocytes on day-2 
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Figure 7.2 shows the frequency histogram of oocyte diameter of oocytes from 
unstimulated patients with PCO on day 0 (the day of insemination of mature oocytes) 
according to whether the oocytes matured in vitro. More than half (55%) of the 
oocytes that did not mature (remained immature or became atretic) had a mean 
diameter of 1051lm or below on day 0 (Figure 7.2a). One oocyte that remained 
immature measured 140llm in diameter, this abnormally large oocyte was probably 
diploid. 
For oocytes that did mature, only 18% fell into the same size category on day 0 
(Figure 7.2b). Among the mature oocytes, 43% had a diameter >109llm compared to 
21 % in this size range among those oocytes not maturing. 
Figure 7.2c shows that the threshold for oocyte maturation in this study was 1031lm 
on day 0, as compared with a minimum of l00llm on day-2. However, the majority of 
oocytes (82%) that matured had diameters on day 0 of 106llm or above. Figure 7.2c 
shows that the proportion of oocytes achieving maturity tends to increase with 
increasing diameter on day O. 
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Table 7.3 shows the effects of the levels of cumulus cover on oocytes at collection 
(day-2) recovered from patients with PCO on outcome of in vitro culture. 49% of 
oocytes retrieved from unstimulated ovaries had some cumulus cells attached and this 
was associated with a tendency towards improved maturation. Table 7.4 shows mean 
diameters of oocytes from patients with PCO in relation to the outcome of in vitro 
culture according to cumulus grade at collection (day-2). The diameters of oocytes 
with dense cumulus cover at collection were not significantly different to those with 
less or no cumulus cover, so although -33% of oocytes could not be measured on 
day-2 due to a dense cumulus cover (see table 7.2) those that could (14/128, 11 %) did 
not differ significantly from those with less or no cumulus cover (Table 7.4). 
Table 7.3 Effects of the levels of cumulus cover on oocytes at collection (day-2) 
recovered from patients with PCO on outcome of in vitro culture. 
Cumulus grade Mature Immature Atretic 
0 13 23 29 
1 10 6 1 
2 2 3 0 
3 13 20 8 
Table 7.4 Mean diameters of oocytes from patients with PCO in relation to the 
outcome of in vitro culture according to cumulus grade at collection (day-2) 
Mean oocyte diameter (JIm) 
Cumulus Outcome Day-2 Day-I 0 grade 
0 Mature 107 ± 3.9 107 ± 5.6 108 ± 4.1 
Immature/atretic 106 ± 5.5 106 ± 5.8 104 ± 8.4 
1 Mature 109 ± 3.7 110 ± 3.6 110 ± 5.3 
Immature/atretic 107 ± 2.3 108 ± 0.4 107 ± 2.2 
2 Mature 110 104 
Immature/atretic 97 106 ±6.0 106 ± 2.5 
3 Mature 106 ± 2.7 108 ±4.9 112 ±4.4 
Immature/atretic 103± 4.5 106 ± 4.5 107 ± 12.0 
Mean±SD 
Key for Tables 7.3 and 7.4: 0 = devoid of any cumulusl no more than 10 scattered 
cells; I = partial cover; 2 = complete cover; 3 = substantial multilayered cover. 
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Figure 7.3 shows the relationship between the diameters of in vitro matured oocytes 
from patients with PCO on day 0 and their ability to fertilize and cleave when injected 
with sperm from a fertile donor. The minimum diameter of a mature oocyte in this 
group on day 0 was 1031lm, although only two oocytes were of this size. The median 
oocyte diameter of mature oocytes on day 0 was 1081lm, interquartile ranges = 106-
113, n = 28 and the range = 103-121Ilm. 
The minimum diameter of an oocyte on day 0 which fertilized was 1051lm and the 
median oocyte diameter on day 0 for oocytes that subsequently fertilized was 
112.5Ilm, interquartile ranges = 107.25-116, n = 10 and the range = 105-121Ilm. Of 
the mature oocytes on day 0, only 18% in the smallest diameter group (103-106llm) 
subsequently fertilized after ICSI (Figure 7.3b). Between 103 and 118fJm, there was 
an increasing trend in fertilization with increasing diameter, although the numbers of 
oocytes available at larger diameters were reducing, making statistical analysis 
unreliable. 
Figure 7.3c shows the relationship between the mature oocyte diameter on day 0 and 
the ability of fertilized oocytes to cleave. The smallest oocyte to cleave, following 
fertilization had a diameter of 105fJm on day 0, however the median oocyte diameter 
on day 0 was 112.5fJm, interquartile ranges = 107.75-116.25, n = 8 and the range = 
105-121 fJm. 8/10 oocytes that fertilized subsequently cleaved, although low numbers 
of measurements preclude any further analysis. 
These data suggest the size threshold for oocyte maturation to be a major limiting 
factor. The majority of oocytes that mature in vitro appear not to be limited by their 
size from subsequent development, at least to fertilization and cleavage, although a 
tendency towards increased maturation and fertilization with increasing oocyte 
diameter was apparent. 
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Figure 7.3 Diameters of in vitro matured oocytes on day 0 obtained from 
unstimulated patients with PCO in relation to their competence to fertilize and 
cleave. 
a) Frequency hi togram of diameters of in vitro matured oocytes on day O. 
b) Proportion of mature oocytes fertilizing (2pn) according to their diameter on 
day O. 
c) Frequency histogram of fertilized oocytes undergoing cleavage or arresting at 
the 2pn stage according to the oocyte diameter on day O. 
163 
Figure 7.4 shows the relationship between time and oocyte diameter during in vitro 
culture with and without FF-MAS. The diameter measurements obtained from 
individual oocytes were plotted between days-2 and 0 according to the outcome of 
culture and the conditions to which they were exposed (0, 10,30 /Jg/ml FF-MAS). 
Similar graphs were obtained using full measurement sets only (Le. three 
measurements, day-2, -I and 0 for each oocyte) or if incomplete data sets were 
included. 
Different growth patterns in the mean diameters of oocytes were apparent according 
to whether they became mature, remained immature or underwent atresia. A similar 
pattern was observed in all culture conditions (Figure 7.4). The oocytes that matured 
in each culture condition were the largest oocytes by day 0 and the oocytes that 
became atretic in all culture conditions decreased in size from day-2 to day 0 to 
become the smallest oocytes on day O. The reducing diameters of oocytes that became 
atretic in culture was significantly different between day-2 and day 0 for those 
cultured in lO/Jglml FF-MAS only (p < 0.05), although a similar trend was evident in 
all conditions. 
In both FF-MAS culture conditions (30 and lO/Jg!ml) the mean oocyte diameters of 
mature, immature and atretic oocytes on day 0 (Figure 7.4b and c) were significantly 
different (p < 0.05) despite their diameters on day-2 being similar. Interestingly, this 
difference did not occur in oocytes cultured in control conditions (Figure 7.4a). 
Oocyte growth during culture (from day-2 to day 0) for those oocytes that matured 
was tested for statistical significance using the non-parametric sign test according to 
the conditions of culture to which oocytes were exposed, revealing that the extent of 
growth over the two-day period was not significantly different among the three 
culture conditions. The difference in growth between oocytes maturing in 30/Jg!ml 
FF-MAS and in control conditions was also assessed using a two-sample t-test. No 
significant difference was found, although the t-value of 1.806 lies between the 5-10% 
probability range, indicating a trend towards increased growth between day-2 and day 
o in 30/J glml FF-MAS compared to control. 
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Figure 7.4 Relationship between time and oocyte diameter during 
in vitro culture in a) control, b) lOJ1g1ml FF-MAS and c) 30J1g1mJ 
FF-MAS. These oocytes were collected on day-2 from unstimulated 
patients with peo. Results are expressed as mean ± SEM. 
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7.2.2 Oocyte + zona diameter 
The majority (79%) of measurements of viable oocytes had mean diameters 
(including zona) in the 146-163J.lm range on day-2 (Figure 7.5a). Figure 7.5b shows 
the measurements including zona, on day-2 of oocytes that subsequently matured in 
vitro, 70% of these were in the 152-163J.lm range. 
The most common size range for immature/atretic oocytes on day 0 was 152-157J.lm 
with 34% of oocyte diameters (including zona) falling in the size range (Figure 7.6a). 
One abnonnally large oocyte measuring 192J.lm on day 0 was probably diploid. The 
majority of oocytes + zonas that matured on day 0 were larger than those remaining 
immature or undergoing atresia, 46% of oocytes + zonas had diameters in the 158-
163J.lm size range, and 62% of mature oocytes had diameters over 158J.lm on day 0 
(Figure 7.6b). Figure 7.7 shows the relationship between the oocyte (including zona) 
diameter and the ability to fertilize and cleave. The smallest oocyte (including zona) 
which matured had a diameter on d 0 of 145J.lm, 46% of oocytes had diameters in the 
158-163J.lm size range, and 62% were over 158J.lm (Figure 7.6b). Of the oocytes in 
the 158-163J.lm size range 50% fertilized. The one oocyte with a diameter of 170jlm 
that matured subsequently fertilized and cleaved. Low numbers of measurements of 
this type preclude any further analysis. 
There was no significant difference between the mean diameter of oocyte + zona 
between day-2 and day 0 within each culture group. The oocyte + zona data on day-2 
and day 0 did not reveal significant differences between oocytes (including zona) 
measuring 140-151J.lm and those measuring 152-175J.lm and the ability of the oocyte 
to mature in vitro. However, on day 0, there was a significant difference (p < 0.05) 
between oocytes (including zona) measuring 140-157J.lm and those measuring 158-
175J.lm in the oocyte's maturity. This significant difference was not due to the 
presence or absence ofFF MAS during culture (Figure 7.8). 
Therefore, while there exist several similarities in the results of oocyte diameter and 
oocyte including zona measurements, the dimensions of the oocyte itself appear to 
have a greater discriminatory ability than the combined oocyte including zona 
measurement. 
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Figure 7.8 Relationship between time and oocyte + zona diameter during in 
vitro culture in a) control, b) lOJ.lglm1 FF-MAS and c) 30J.lglm1 FF-MAS. 
These oocytes were collected on day-2 from unstimulated patients with peo. 
Results are expressed as mean ± SEM. 
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7.2.3 Zona pellucida thickness 
Figure 7.9a presents the frequency distribution of the mean zona pellucida thickness 
of viable oocytes collected from unstimulated patients with pca on day-2. This 
distribution was approximately normal. The most common size range was 21-22~m 
(34%) and the majority (77%; 34/44) of oocytes collected had a mean zona pellucida 
thickness of between 19-24~m on the day of collection. 
The measurements of zona pellucida thickness on day-2 of oocytes that subsequently 
matured in vitro showed that 60% measured between 21-221..lm (Figure 7.9b) although 
numbers were low. 
Figure 7.10 shows the measurements on day 0 of mean zona pellucida thickness of 
oocytes that failed to mature or underwent atresia compared to those, which matured. 
There was no significant difference in the distribution of zona pellucida thickness 
between these two groups. Interestingly, the broad distribution on day 0 was 
noticeably different to that observed at collection on day-2 (compare with Figure 7.9) 
suggesting some modification in thickness of the zona pellucida in culture. 
Figure 7.11 shows the relationship between time and zona pellucida thickness during 
in vitro culture with and without FF-MAS. Changes in zona pellucida thickness were 
not related to the presence or absence of FF-MAS. 
Table 7.5 shows the zona pellucida thickness on day + 1 (day after insemination) of 
oocytes that fertilized and those that failed to fertilize or became atretic and on day+2 
of embryos or oocytes that failed to fertilize or became atretic after ICSI insemination 
on day+ 1. There was little change in zona pellucida thickness between day + 1 and 
day+2 in either group, however, the fertilized oocytes tended towards significantly 
thicker zonas (p<O.05). 
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Figure 7.11 Relationship between time and zona peUucida thickness 
during in vitro culture in a) control, b) IOJ.1g1m1 FF-MAS and c) 
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174 
Table 7.S Zona pellucida thickness on day+l and day+2 of oocytes collected from 
patients with PCO that fertilized after ICSI insemination on day+ 1 and those 
that failed to fertilize or became atretic 
Mean zona pellucida thickness (JJm) 
Day+l Day+2 
Fertilized 21.8 ± 1.9 20.1 ± 1.9 
Range 19.8-24.2 15.5-24.2 
Unfertilized/atretic 16.9 ± 2.7 17.2±3,4 
Range 11.6-21.5 12.5-22.0 
Mean ± SD 
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7.2.4 Perivitelline space (PVS) 
Figure 7.12a presents the frequency histogram of the mean PVS of viable oocytes 
collected from unstimulated patients with PCO on the day of collection (day-2). The 
most common size range was 3-4Jlm. The measurements of mean PVS of oocytes that 
became mature in vitro were spread out between 1-6Jlm (Figure 7.12b). 
Figure 7.13 shows the frequency histogram of the mean PVS of oocytes from 
unstimulated patients with PCO on day 0 (the day of ICSI of mature oocytes) 
according to whether the oocytes matured in vitro. 50% of oocytes that remained 
immature or became atretic had a mean PVS of 3-4/Jm; there was a broad distribution 
ofPVS in oocytes that matured in vitro (Figure7.13b). 
Figures 7.14 shows the relationship between time and mean PVS during in vitro 
culture with and without FF-MAS. The data do not indicate any consistent 
relationship between PVS and oocyte maturation in vitro, furthermore FF-MAS does 
not appear to relate to this measurement. There were no significant differences 
between the groups. 
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Figure 7.12 Frequency histogram showing mean perivitelline space on day of 
collection (day-2) of oocytes from unstimulated patients with PCO. 
a) Viable oocytes 
b) Oocytes becoming mature in vitro 
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Figure 7.13 Frequency histogram showing mean perivitelline space on day 0 (day 
of ICSI for mature oocytes) of oocytes from unstimulated patients with PCO. 
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Figure 7.14 Relationship between time and mean perivitelline space (PVS) 
during in vitro culture in a) control, b) lOJlglml FF-MAS and c) 30Jlglml FF-
MAS collected on day-2 from patients with pea. 
Re ults are expressed as mean ± SEM. 
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7.3 Oocytes from patients undergoing ICSI treatment, cultured with or without 
MAS 
7.3.1 Oocyte diameter 
Figure 7.15a presents the distribution of the mean diameter of viable immature 
oocytes donated by patients undergoing ICSI treatment on the day of oocyte recovery 
(day-2). The distribution is approximately normal; the most common size range was 
109-11IJlm (36% of oocytes). The measurements of those that went on to mature in 
vitro did not follow a normal distribution (Figure 7.15b); all except one had mean 
diameters of >106Jlm on the day of collection (day-2). 
In this study, the smallest oocyte that matured had an initial diameter of 99Jlm on day-
2, whereas the majority of oocytes maturing had diameters of at least 106Jlm. 
Interestingly, none of the seven oocytes with initial diameters of 2: 1151lm matured. 
Comparison of Figure 7.15 with 7.1 shows that the oocytes donated by ICSI patients 
were Significantly larger at the time of collection than those from PCD ovaries 
(p<O.OOl). 
Figure 7.16 shows the diameters of oocytes on day 0 according to whether they 
matured in vitro. Comparison with Figure 7.15 shows that many oocytes had grown in 
vitro during the culture period resulting in a modal diameter of 112-114Jlm in both 
mature oocytes and those that remained immature. There was no significant difference 
in size between the two groups of mature and immature/atretic oocytes (Figure 7.16). 
There was no apparent relationship between mean oocyte diameter and the likelihood 
of maturation in these oocytes derived from ICSI patients in contrast to those derived 
from patients with PCD (Figure 7.2). The small number of oocytes of a small size 
precludes any comment on a threshold size for maturation in oocytes from this source. 
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Figure 7.15 Frequency histogram showing mean oocyte diameters on day of 
collection of immature oocytes from patients undergoing ICSI treatment. 
a) Viable oocytes 
b) Oocytes becoming mature in vitro 
c) Oocytes that progressed to maturity expressed as a percentage of viable 
oocytes on day of collection. 
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oocytes on day O. 
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Figure 7.17 shows the relationship between the diameters of in vitro matured oocytes 
on day ° and their subsequent fertilization and cleavage. The minimum oocyte 
diameter associated with maturation was 106lJm on day 0, compared with 99IJm on 
day of oocyte collection. Very few oocytes had smaller diameters, so a threshold 
could not be attributed. The median oocyte diameter for mature oocytes on day 0 was 
1141..1 m, interquartile ranges = 110-116, n = 35 and the range = 106-1311..1 m. 
Figure 7.17 c shows all the oocytes that fertilized or both fertilized and cleaved, 
whereas Figure 7.18a and b presents oocytes maturing in 23-24 hr and 46-48 hr 
respectively. The smallest oocyte fertilizing after ICSI had a diameter of 106l..1m on 
day 0, the median oocyte diameter on day 0 for oocytes that were competent to 
fertilize was 113l..1m, interquartile ranges = 109-114, n = 13 and the range = 106-
1251Jm. For competence to cleave after fertilization, the minimum oocyte diameter on 
day 0 was 1071Jm, however the median oocyte diameter on day 0 was 1131Jm, 
interquartile ranges = 111-117, n = 7 and the range = 107-125IJm. 
Figure 7.18 shows the numbers of oocytes fertilizing and cleaving after maturation in 
vitro according to oocyte diameter. Figure 7.18a shows, of oocytes that matured 
within 23-24 hr of in vitro culture, 2/6 (33%) of the fertilized oocytes subsequently 
cleaved. However, of oocytes that matured within 46-48 hr of in vitro culture, 517 
(71 %) fertilized oocytes subsequently cleaved (Figure 7.18b). While this may provide 
some suggestion that a prolonged period of maturation could be associated with 
improved cleavage potential, the numbers of embryos cleaving. and the subsequent 
measurements available were too few for meaningful analysis. 
Among the ICSI patients, 50% of oocytes maturing in vitro had matured by 23-24 h 
(Chapter 5. Figure 5.6). For oocytes maturing in 23-24 hr, the median oocyte diameter 
was 113lJm, interquartile ranges = 110-113.75 and for oocytes maturing in 46-48 hr. 
the median oocyte diameter was 112I..1m. interquartile ranges = 108.5-114.5. There 
was no significant difference in oocyte diameter on day 0 between oocytes maturing 
in 23-24 hr and those in 40-48 hr, within each culture group (control, 101Jg/ml FF-
MAS and 30IJg/ml FF-MAS) or when pooling all the culture groups. 
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Figure 7.17 Diameters of in vitro matured oocytes on day 0 obtained from 
patients undergoing ICSI in relation to their competence to fertilize and cleave. 
a) Frequency hi togram of diameters of in vitro matured oocytes on day O. 
b) Proportion of mature oocytes fertilizing (2pn) according to their diameter on 
day O. 
c) Frequency histogram of fertilized oocytes undergoing cleavage or arresting 
at the 2pn stage according to the oocyte diameter on day O. 
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Figure 7.18 Numbers of oocytes donated by patients undergoing ICSI 
treatment, fertilizing and cleaving after maturation in vitro according to oocyte 
diameter 
a) Oocytes that matured in 23-24 hr 
b) Oocyte that matured in 46-48 hr 
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Figure 7.19 demonstrates the relationship between time and oocyte diameter during in 
vitro culture with and without FF-MAS. The growth patterns in Figure 7.19 were 
compared with those observed in oocytes retrieved from patients with peo (Figure 
7.4), revealing similarity in the patterns of mean oocyte diameter between the 
different subsets of oocytes (mature, immature and atretic) only for the lO~g/ml FF-
MAS groups. 
Oocyte diameter on the day of oocyte collection was compared to that on day 0 within 
each culture group and there were significant differences (p<O.05) in the diameters of 
oocytes on the day of collection and day 0 cultured in both 30~glml FF-MAS and 
lO~glml FF-MAS; however there was no significant difference for those oocytes 
cultured in control conditions. No significant difference was found within each culture 
group, when oocyte diameters on day 0 were compared in oocytes that matured and 
those that did not mature. 
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Figure 7.19 Relationship between time and oocyte diameter during in vitro 
culture in a) control, b) 10J.1g1ml FF-MAS and c) 30J.1.g1ml FF-MAS. These 
oocytes were collected on day-2 from patients undergoing ICSI treatment Results 
are expressed as mean ±SEM. 
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7.3.2 Oocyte + zona diameter 
Figure 7.20 shows the frequency histogram of oocyte diameters on day of collection, 
giving an approximately normal distribution. The majority (80%) of viable oocytes 
had mean diameters (including zona) in the 152-169Jlm range on the day of 
collection (Figure 7.20a); the most common size range was 158-163Jlm (41 %). 
Figure 7.20b shows the oocyte diameter (including zona) measurements on the day 
of collection of oocytes that subsequently matured in vitro, the majority being in the 
152-1691.lm range. 
Comparison of Figure 7.20 with Figure 7.5 shows that the oocytes (including zonas) 
donated by ICSI patients were significantly larger at the time of collection than 
those from polycystic ovaries (p<O.OOI). 
Figure 7.21 shows the frequency histogram of oocyte diameters on day O. The most 
common size range for immature and atretic oocytes on day 0 was 158-1631.lm with 
41 % of oocyte diameters (including zona) falling in this size range. The majority 
(52%) of oocytes that matured were in the same size category on day o. There was 
no significant difference between the mean diameters of oocyte + zona between the 
day of collection and day 0 despite the extensive enlargement of oocyte cytoplasm 
that occurred over the same period (Figures 7.15 and 7.16). 
The oocyte + zona data on the day of collection and day 0 did not reveal significant 
associations between oocyte (including zona) measurements and oocyte maturation 
in vitro. 
Figure 7.22 shows the relationship between the oocyte (including zona) diameter 
and the ability to fertilize and cleave. Figure 7.22a shows that 2/6 (33%) of oocytes 
that matured after 23-24 hr of in vitro culture cleaved following fertilization, 
whereas 5/6 (83%) of oocytes maturing after 46-48 hr cleaved following fertilization 
(Figure 7.22b). The smallest oocyte to cleave following fertilization had a diameter 
(including zona) of 1521.lm on day 0, however the median oocyte diameter 
(including zona) on day 0 for oocytes that fertilized and cleaved was 1611.lm, 
interquartile ranges = 157.7-162, n = 12, range = 152-174. 
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Figure 7.22 Frequency histogram of fertilized oocytes obtained from patients 
undergoing ICSI treatment, undergoing cleavage or arresting at the 2pn stage 
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b) Oocytes that matured in 46-48 hr 
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to mature in vitro 
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7.3.3 Zona peUucida thickness 
Figure 7.23a shows that the mean zona pellucida thickness on the day of collection 
of viable oocytes donated by patients undergoing ICSI treatment was not normally 
distributed, in contrast to similar data obtained for oocytes derived from PCD 
patients (Figure 7.9). The most common size range was 21-22j.1m (27%). Similar 
proportions of oocytes having different zona pellucida thickness measurements 
matured in vitro; hence there was no apparent relationship between zona pellucida 
thickness on day of collection and the subsequent maturation of the oocyte. The 
median and range values of zona pellucida thickness were similar for oocytes from 
patients with PCD and those undergoing ICSI treatment on the day of collection. 
Figure 7.24 shows the frequency histogram of zona pellucida thickness of oocytes 
on day 0 according to whether they matured in vitro. Between the day of collection 
(Figure 7.23) and day 0 (Figure 7.24) slight alterations in the distribution of zona 
pellucida thickness were evident. However, there was no relationship evident 
between zona pellucida thickness on day 0 and oocyte maturation in vitro (Figure 
7.24). 
Figure 7.25 shows the relationship between time and zona pellucida thickness during 
in vitro culture with and without FF-MAS. Changes in zona pellucida thickness 
were not related to the presence or absence of FF-MAS. However, the zona 
pellucida thickness appeared to be more consistent in oocytes obtained from patients 
undergoing ICSI (Figure 7.25) compared to oocytes obtained from patients with 
PCD (Figure 7.11). The oocytes obtained from patients with PCD were smaller than 
those obtained from patients undergoing ICSI treatment on the day of collection and 
so it may be that the zona pellucidas on the smaller oocytes from patients with PCD 
were still forming or growing and changing in vitro. 
Table 7.6 shows the zona pellucida thickness on day +1 and day +2 of oocytes 
collected from patients undergoing ICSI treatment, that fertilized and those that 
failed to fertilize or became atretic. There was no significant difference in zona 
pellucida thickness between day + 1 and day +2 in either group, nor between the 
groups of oocytes that did or did not fertilize. This is in contrast to the data in table 
7.5, which shows that the fertilized oocytes arising from in vitro matured oocytes, 
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collected from patients with pea tended towards significantly thicker zonas 
(p<O.05). 
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Figure 7.23 Frequency histogram showing mean zona pellucida thickness on day 
of collection of oocytes from patients undergoing ICSI treatment 
a) Viable oocytes 
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Table 7.6 Zona pellucida thickness on day+l and day+2 of oocytes collected from 
patients undergoing ICSI treatment, according to whether they fertilized or 
failed to fertilize/became atretic 
Mean zona pellucida thickness (JIm) 
Day+l Day+2 
Fertilized 20.5 ±0.8 21.2 ± 0.9 
Range 17.8-25.1 18.1-24.6 
Unfertilized/atretic 20.3 ± 0.6 19.3±0.5 
Range 17.9-22.0 18.9-19.8 
Mean±SD 
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7.3.4 Perivitelline space (PVS) 
Figure 7.26a presents the frequency histogram of the mean PYS of viable oocytes 
collected from patients undergoing ICSI treatment. The majority of oocytes (82%) 
had a mean PVS between 3-6~m on the day of collection. Most measurements on the 
day of collection, of oocytes that became mature in vitro were also between 3-6~ m 
(Figure 7.26b). 
Figure 7.27 shows the frequency histogram of the mean PVS of oocytes from patients 
undergoing ICSI treatment on day 0 (the day of ICSI of mature oocytes) according to 
whether the oocytes matured in vitro. The distribution of PVS was similar in oocytes 
that matured in vitro and in those that remained immature or became atretic. 
Figure 7.28 shows the relationship between time and mean PYS during in vitro 
culture with and without FF-MAS. The data do not indicate any relationship 
between PYS and oocyte maturation in vitro, and the inclusion of FF-MAS in the 
media seems unrelated to this measurement. There was no significant variation with 
time, of the PYS thickness of mature and immature oocytes throughout the culture 
period. 
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7.4 Discussion 
Oocyte development incorporates two major activities: growth and maturation. 
Throughout the growth phase, the oocyte is arrested in prophase of the first meiotic 
division but increases in diameter from -30J.lm to -120J.lm, which is associated with a 
470-fold increase in volume. The duration of the growth phase of the human oocyte is 
estimated to be -8-12 weeks (Gougeon, 1986) compared to three weeks in the mouse 
(Carroll, 1996). 
The diameter of the mature human oocyte excluding the zona pellucida is normally 
approximately 110-120J.lm; the zona pellucida is normally approximately 15-20J.lm 
thick and becomes slightly thinner after fertilization, although zona pellucida 
anomalies including excessive thickness are quite commonly noted in IVF and may be 
patient or maturity related. Including the zona pellucida and perivitelline space, the 
pre-ovulatory oocyte commonly has a diameter of approximately 150J.l m (Veeck, 
1999). Oocytes that are much larger than normal, sometimes up to twice the volume 
of normal oocytes, are presumed to have arisen through failure of cytoplasmic 
division of oogonia. Most of these oocytes possess diploid amounts of DNA and some 
are binucleate. After penetration of a binucleate oocyte by a single spermatozoon, two 
maternal pronuclei and one paternal pronucleus may be formed, resulting in triploidy 
(Veeck,1999). 
My project is the first to monitor the growth of human oocytes during in vitro 
maturation, and has produced some interesting results showing that measurable 
oocyte growth may continue in vitro and may relate to the eventual outcome of 
maturation and insemination in vitro. Moreover, the starting material obtained from 
the two different patient populations was significantly different in oocyte diameter, 
which may help to explain observations on the different results observed in this study 
(Chapter 5) and by previous authors, according to the origins of the oocytes. 
Durinzi et al. (1995) examined the relationship between oocyte size and maturati on in 
vitro in unstimulated human oocytes. They set out to determine if the size of human 
oocytes at collection is related to their ability to resume meiosis and undergo 
maturation in vitro. They observed a significant difference in oocytes measuring 86-
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105J.1m versus those measuring 106-125J.1m, leading to the conclusion that, in 
common with other species (see introduction, 7.1) the unstimulated human oocyte has 
a size-dependent ability to resume meiosis and complete maturation. The following 
oocyte diameter thresholds in relation to meiotic potential were deduced: oocyte 
diameter ~ I05J.1m: GV; oocyte diameter> 105J.1m < 115J.1m: GVBD -+ MI; oocyte 
diameter> 115J.1m: GVBD -+ MIl. My data for oocytes retrieved from patients with 
PCO produced a threshold of -1 03J.1m for maturation in vitro, similar to Durinzi et al. 
(1995), however oocytes were observed to have reached meiotic maturity in vitro with 
an oocyte diameter considerably less than I 15J.1m. However, interestingly, none of the 
oocytes from stimulated patients undergoing ICSI treatment, and having initial 
diameters of 2:1 15J.1m matured in vitro. In my study, measurements of oocyte diameter 
on the day of oocyte recovery and the day of insemination for mature oocytes both 
demonstrated size dependent maturation, as well as the capacity for oocyte growth 
within this time frame. 
In 1977, Moor and Trounson analysed the developmental potential of fully grown 
ovine oocytes retrieved from antral follicles of known sizes, it was established that 
follicles had to be >2-3mm diameter to confer developmental competence on ovine 
oocytes, these results have been confirmed in a variety of species by showing that 
oocytes become competent only when follicles reach diameters ranging from -500J.1m 
in mice to 3-4mm in cattle (Eppig et al., 1992; Pavlock et al., 1992; Lonergan et al., 
1994; Blondin and Sinard, 1995). Dubey et al. (1995) suggested that competence in 
human oocytes may normally be conferred relatively late; perhaps only when follicles 
have reached diameters of > lOmm, although occasional pregnancies have resulted 
from NM of oocytes from smaller follicles (Trounson et al., 1994). The percentage of 
maturing human oocytes from non-stimulated ovaries increases with follicular size (3-
15mm) during the follicular phase but appears to remain constant during the luteal 
phase, irrespective of follicle size (Tsuji et al., 1985). In the follicular phase, the 
proportion of oocytes maturing in the large follicle group (9-15mm diameter; 34.5%) 
was significantly (p < 0.05) higher than that in the small follicle group (3-4mm; 
8.8%). 
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In my study, oocytes from patients with peo were retrieved from antral follicles 
approximately 10mm diameter or less, whilst oocytes donated by patients undergoing 
lesl were retrieved from larger follicles >lOmm diameter, although other differences 
may have contributed, as well as follicle size. Oocytes retrieved from patients 
undergoing lesl were significantly larger at collection (mean oocyte diameter 
111/lm) than oocytes retrieved from patients with pea (l06/lm), which may have 
been partially due to the larger size of follicles in patients undergoing leSI. It was 
more difficult to measure oocyte diameter for those where a substantial covering of 
cumulus obscured the oolemma, so it is possible that oocytes with a dense cumulus 
cover were a different size to those with less cumulus. However, those oocytes with a 
dense cumulus cover that could be measured (Table 7.4) were not significantly larger 
than those with less or no cumulus cover, so it is probable that these results can be 
generalised. 
Mature, immature and atretic oocytes from patients with peo cultured in FF-MAS 
culture conditions (10 or 30/lglml) but not those cultured in control conditions were 
significantly different in terms of diameter on day 0 (p < 0.05), though not on day-2. 
Similar results did not occur for oocytes donated by patients undergoing leSI 
treatment. The reason for this is not clear. However in the oocytes from patients 
undergoing leSI, there was a significant enlargement of oocyte diameter between the 
day of collection and day 0 in both FF-MAS culture conditions, although not in 
control, indicating significant growth of oocytes in vitro with FF-MAS. Therefore, a 
response to FF-MAS in terms of oocyte growth, a quantifiable, non-invasive 
parameter, was evident in immature oocytes from both sources of patients. As oocytes 
from both patient groups have grown in vitro, it is clear that the growth phase has not 
been completed in vivo, or that it may be resumed under certain conditions. In 1998, 
Moor et al. suggested that the reduced developmental potential in human oocytes 
matured in vitro might be attributable to incomplete oocyte growth, however, no data 
were presented on human oocytes to illustrate this suggestion. 
Karnikova et al. (1998) suggested that a critical nucleocytoplasmic volume ratio is 
necessary for normal maturation in mammalian oocytes. They demonstrated that a 
reduction in cytoplasmic volume before culture of fully-grown mouse oocytes isolated 
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from large antral follicles and cultured in vitro, resulted in a decrease in the 
proportion of oocytes completing maturation and extruding a pb. The time course of 
GVBD was also delayed in relation to the decreased cytoplasmic volume. However, 
there may be many reasons for this, such as a reduced number of cytoplasmic 
organelles, or a reduced surface area for metabolic exchange. 
In my study, among oocytes that matured in culture from patients with PCO, 43% had 
a diameter > I 091l m on day 0 compared to 21 % in this size range among those not 
maturing, which was significantly different (p<O.05), therefore oocytes with a smaller 
diameter appear to be less likely to mature, however the same was not true for oocytes 
retrieved from patients undergoing ICSI. The reason for this discrepancy might relate 
to the prior exposure of oocytes to ovarian stimulation, which may have supported 
their growth in vitro while not facilitating their meiotic maturation. Clearly, then, in 
some respects oocytes from patients with PCO and those undergoing ICSI are 
behaving differently under similar conditions, (e.g. growth) whereas in other respects, 
they are different populations (e.g. size dependence). For both patient groups, and in 
all culture conditions the diameter of oocytes that underwent atresia in culture 
decreased during the culture period. This is likely to be attributed to oocyte shrinkage 
commonly associated with atresia. The differences in oocyte diameter after IVM may 
be linked to changes in osmolarity of the cytoplasm, potentially linked to membrane 
properties or some other factor. In this study, control experiments, (Chapter 2, section 
2.2.1.1) demonstrated that the osmolarity of cultures without an oil overlay 
maintained in a humidified incubator (37°C, 5% C02 in air) varied by <I % after 24 
hr. However, both increases (maturing) and decreases (atresia) in oocyte diameter 
were observed under similar conditions in the same culture preparations in these 
experiments, discounting alterations in media osmolarity as the mechanism by which 
oocyte size changes occurred. 
FF-MAS is a steroid related to cholesterol, and cholesterol is known to influence 
membrane fluidity. It is possible that FF-MAS, or another steroid component of the 
system associated with oocyte maturity may have a direct effect upon membrane 
fluidity or function, which might contribute to the effects observed in these 
experiments. 
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The perivitelline space (PVS) is the area between the inner surface of the zona 
pellucida and the oolemma. The polar bodies are released from the oocyte into the 
PVS, as are the contents of the cortical granules in the zona reaction. This study has 
demonstrated a variation in thickness of the PVS of oocytes after IVM; however there 
did not appear to be a pattern of shrinkage or growth of the PVS during in vitro 
culture with or without MAS, or in association with the maturation of the oocyte. 
Oocyte shrinkage is associated with atresia and this might be expected to enlarge the 
PVS (Hyttel et al., 1986), however this did not occur in a consistent fashion in this 
study. Overall, the PVS measurements were variable and inconsistent. This could be a 
result of single plane measurements on spherical objects, as well as the low proportion 
of reliable measurements of this feature that could be achieved in this study. 
The zona pellucida is a structure that is crucial to fertilization and early development. 
It is synthesized by the oocyte and secreted to form an extracellular protein matrix 
that surrounds the growing oocyte, ovulated oocyte and preimplantation embryo 
(Dean, 1991). According to Bertrand et al. (1995), human zona pellucida thickness 
varies from 10-31Jlm, with a mean of 17.5Jlm. A zona pellucida thickness of >25Jlm 
or <lOJlm is rarely observed. The zona pellucida thickness is a feature of individual 
oocytes that influences sperm penetration (Bertrand et al., 1995,1996), and ICSI is 
recommended in order to encourage fertilization of oocytes with particularly thick 
zonas. In this study, on day 0 all mature oocytes had a zona thickness measurement of 
between 15-24Jlm, which is within the expected range. Zona measurements were 
normally distributed but appeared not to be related to maturity. 
In 1996, Bertrand et al. studied the zona pellucida thickness of 827 human oocytes 
16-20 hr after in vitro insemination. The zona pellucida of fertilized oocytes (16.6 ± 
3.2Jlm) was significantly thinner than that of unfertilized oocytes (18.9 ± 4.0Jlm; p< 
0.(01), but this was not related to ooplasm diameter. Thinning of the zona pellucida is 
believed to continue during the first and second cleavages (Veeck, 1999). However, 
my data do not follow the same pattern. 
The increased size of oocytes + zona for patients undergoing ICSI treatment on day of 
collection is consistent with the larger oocyte diameter at collection for this patient 
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group. The oocyte plus zona measurements did not offer any additional information to 
oocyte diameter for either patient groups, and may have reduced the discriminatory 
potential of oolemma measurements. The zona pellucida would not be expected to 
change size greatly during a short period of culture, however, clearly changes in size 
and/or thickness have to be accommodated during the oocyte's growth phase. 
It has been suggested that zona hardening may occur during maturation in vitro 
(Barnes et aI., 1996; Cha and Chian, 1998) and ICSI has been shown to increase 
fertilization rates of in vitro matured oocytes from 30% for routine insemination by 
sperm incubation in vitro to 50% (Trounson et al., 1996). 
Garside et al. (1997) suggested that zona pellucida measurements should be included 
in the overall assessment of human embryo quality, as it may be useful in the 
selection of optimal embryos for transfer. They used an ocular micrometer to measure 
zona pellucida thickness in zygotes and cleavage stage embryos daily during in vitro 
culture. They found that the average zona thickness decreased during culture after 
fertilization, from 17.7 ± 0.14 jJ m on day 1 of in vitro culture to 16.3 ± 0.14 jJ m on 
day 2 and 14.9 ± 0.14jJm on day 3 (p < 0.0001). Embryos transferred and resulting in 
a successful pregnancy cycle had significantly thinner zona pellucidas (p < 0.000 1) 
when compared to embryos that were not transferred or from non-conception cycles. 
They also demonstrated a decrease in average zona thickness with age, most apparent 
after 35 years. Loret De Mola et al. (1997) analyzed the thickness of the human zona 
pellucida during culture, and also suggested that zona pellucida thickness be 
considered as part of the embryo quality evaluation prior to transfer or when assessing 
the possibility of using assisted hatching. They hypothesized that zona pellucida 
thickness is influenced by the preovulatory hormonal environment and infertility 
diagnosis. 
Cohen et al. (1989) and Gabrielsen et al. (2000) studied the influence of zona 
pellucida thickness of human embryos on clinical pregnancy outcome following IVF 
treatment. Cohen et al. (1989) concluded that an increased variation of zona pellucida 
thickness was the most important prognostic factor for fresh embryo implantation. 
When the "best" embryo had> 25% zona pellucida thickness variation (ZPTV), 40 % 
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(24/60) resulted in pregnancy, however when the "best" embryo had <10 % ZPTV 
pregnancies were not induced (0/21). Gabrielsen et al. (2000) observed a highly 
significant correlation between ZPTV of transferred embryos and the IVF outcome, 
with 84% of the clinical pregnancies resulting from transferred embryos with ZPTV 
values greater than 25%. The mean ZPTV values for 70 conception cycles and 62 
nonconception cycles were 28 ± 6.4 and 17.8 ± 8.1 respectively. They suggest that 
ZPTV could be used as a criterion for embryo selection during clinical transfers. 
The measurements of zona thickness of fertilized oocytes on day+ I from both patient 
groups in this study appeared significantly larger than the data (measurements of in 
vivo matured oocytes) of Garside et al. (1997). On day + 1, fertilized oocytes obtained 
from patients with peo and patients undergoing lesl treatment had mean zona 
pellucida thickness measurements of 21.8 ± 1.9fJm and 20.5 ± 0.8fJm respectively, 
compared to 16.4 ± 3.lfJm (Bertrand et al., 1996) and 17.7 ± 0.14fJm (Garside et aI., 
1997). On day +2, fertilized oocytes obtained from patients with peo and patients 
undergoing lesl treatment had mean zona peUucida thickness measurements of 20.1 
± 2.9fJm and 21.2 ± 0.9J.1m respectively, compared to 16.3 ± 0.14fJm (Garside et al., 
1997). Zona pellucida thickness appeared to change to some extent during culture in 
my study. The reasons for this difference are unclear but could relate to differences in 
methodology and/or starting material, including the origin of the oocytes. In addition, 
some effect of IVM cannot be ruled out at this stage. 
Overall, this novel study has provided the first quantitative non-invasive analysis of 
human oocyte growth during maturation under various conditions in vitro. It has laid 
the foundations for the application of a non-invasive assessment of oocyte 
maturation potential in vitro, which will be an advantage for the future clinical use 
of NM where selection of the two embryos with the greatest potential for 
development is the key to a successful outcome. This is particularly true of in vitro 
matured oocytes, where developmental potential is known to be a limiting factor. 
Such quantitative methods could also be applied in other areas such as zygote 
analysis and assessment of the regularity of early cleavage, where eventually, their 
incorporation into an automated system of oocyte and embryo monitoring might be 
feasible. 
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Chapter 8 
General Conclusions 
The aim of this project was to assess specific factors affecting IVM of human oocytes 
in relation to the developmental competence of the resulting embryos. This task was 
undertaken using a variety of approaches, to study immature oocytes arising from two 
patient groups, those with unstimulated PCO undergoing treatments which required a 
laparoscopy; and those undergoing ICSI treatment, which included ovarian 
stimulation according to a standard 'long' pituitary down-regulation protocol. As well 
as providing original information on oocyte responses to supplementation of 
maturation medium in vitro, this project has provided an opportunity to develop 
technical expertise, which will be essential to the eventual clinical application of IVM 
in this country. 
Chapter 3 presented the characteristics of patients donating oocytes to this study, in 
order to assess whether particular patients or groups might be more or less suitable for 
immature oocyte collection and IVM. Clear differences between the patient groups 
were noted, as expected, and this allowed the subsequent experiments to be conducted 
on oocytes originating from contrasting endocrine environments. While differences 
between the two patient groups were evident, both later demonstrated positive effects 
of manipulation of the IVM procedure, suggesting that clinical IVM might potentially 
be applicable to both types of patients. 
Two factors were investigated for their effects upon IVM and subsequent 
development of immature oocytes. These were selected based upon previous work 
suggesting their potential to promote embryonic development through effects 
mediated during oocyte maturation. The effect of supplementation of the IVM culture 
medium with EGF was investigated in human immature oocytes obtained from 
unstimulated ovaries from women with PCO. The EGF concentrations used (0.1-10 
nglml) were similar to those shown to be effective in previous studies (Das et al., 
1991; Gomez et al., 1993; Goud et al., 1998). Any mature oocytes arising from in 
vitro culture were inseminated with known fertile donor sperm using ICSI in order to 
assess any effects of EGF on fertilization, cleavage and embryo development. Data 
presented in Chapter 4 did not generally indicate significant effects of EGF used 
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alone, in the absence of gonadotrophins, on in-vitro survival and maturation of human 
oocytes. This was in contrast to data provided by Das et al. (1991), G6mez et al. 
(1993a), and Goud et al. (1998) who had all reported beneficial effects of EGF in 
human IVM. However, the patient groups and culture conditions varied from those in 
this study. When the developmental competence of the matured oocytes in terms of 
their fertilization and embryo development after maturation with EGF was assessed, 
no significant effect of EGF on fertilization and cleavage was observed possibly due 
to the low numbers of oocytes. However, cleaving embryos were achieved in all 
culture conditions confirming that the oocytes matured in vitro were capable of 
fertilization and the initial stages of embryo development, despite the absence of 
gonadotrophin stimulation in vitro. 
Human oocyte availability is a limiting factor in such research; hence the use of 
EGF for IVM was not studied further. Instead, the more promising results on the use 
of FF-MAS, the putative physiological mediator of oocyte maturation in mice 
(8yskov et al., 1995, 1999; Hegele-Hartung et al., 1999), were pursued with the first 
study of this compound on human oocytes. This was and remains a new and exciting 
area, since no data on this subject had been previously published and there may be 
many benefits of applying the proposed physiological effector rather than highly 
potent purified growth factors, whose unopposed effects might eventually prove 
hazardous for development. To date, little is known about the precise mechanism of 
FF-MAS action in human oocyte maturation in vivo, although it is found in high 
concentrations in follicular fluid just prior to final oocyte maturation and ovulation 
(8yskov et al., 1999; Grondahl et al., 2000). This study has contributed to the 
literature on this topic and presents the largest series studied to date (Cavilla et al., 
2001). 
The study design and results presented in chapter five allowed not only an assessment 
of the effect of FF-MAS exposure during IVM of human oocytes upon their 
maturation, fertilization and early embryonic development, but also enabled a 
comparison of the results of FF-MAS exposure in immature oocytes originating from 
two different patient groups. The data demonstrated that FF-MAS at a concentration 
of 30J.lglml significantly (P < 0.025) increased oocyte survival resulting in 88% 
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survival compared with 63% and 60% for 10Ilglml and control respectively in the 
unstimulated patient group, although the proportion of oocytes completing maturation 
in vitro was not significantly altered. In contrast, for the patients undergoing ICSI 
treatment, oocyte survival was >90% in all groups, regardless of FF-MAS 
concentration. However, in this patient group, the presence of FF-MAS at 10 or 
30}lglml significantly increased the proportion of oocytes maturing (P < 0.05). The 
time course of oocyte maturation differed between the two patient groups, with 
oocytes from patients undergoing ICSI maturing more rapidly in vitro than those from 
patients with PCO, most likely as a result of their differing follicular environments 
prior to oocyte collection. In terms of further development, in both patient groups, 
oocytes cultured with FF-MAS showed a tendency towards improved subsequent 
development, which, though insignificant with the numbers of oocytes and embryos 
available, may be an important observation for future application, since poor 
developmental potential of in vitro matured oocytes currently remains an intractable 
problem. 
Among the oocytes obtained from patients with PCO, those with attached cumulus 
cells had a greater tendency towards survival and maturation in vitro than nude 
oocytes in all culture conditions. Overall, the rates of IVM achieved in this study were 
acceptable, but not outstanding in comparison with publications where oocyte 
maturation was achieved under different conditions. There may be a variety of 
reasons for this. For example, a higher maturation rate may have been gained by a 
combination of supplements in the medium; for example, addition of FSH may have 
augmented FF-MAS production in the cumulus (Byskov et al., 1997) and the 
inclusion of FSH, HCG and/or other growth factors in vitro has previously been 
demonstrated by others to stimulate IVM (Durinzi et al., 1997; Chian et al., 1999a,b). 
However, these factors were omitted here in order that the effects of FF-MAS alone 
could be established in the absence of confounding influences. 
Especially high levels of atresia occurring in vitro after collection of apparently viable 
oocytes were noted in GVBD oocytes from PCD patients. The incidence of atresia 
was significantly higher in GVBD oocytes than GV oocytes collected from PCO 
patients (p < 0.001). Compromised follicle development as a result of the abnormal 
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endocrine environment could account for the higher rate of atresia observed in the 
GVBD oocytes from patients with peo compared with the lesl patient group. In the 
oocytes obtained from patients undergoing lesl treatment, atresia was confined to 
oocytes collected at the GV stage. Overall the oocytes obtained from patients with 
peo appeared more susceptible than oocytes obtained from patients undergoing leSI 
treatment however, patients having peo are amongst those who may gain most from 
the potential clinical application of IVM, yielding a larger cohort of oocytes than non-
peo patients (Trounson et al., 1996) and being the most likely to suffer 
hyperstimulation as a result of gonadotrophic drug exposure in vivo (Rizk and Smitz, 
1992). Hence, continuing research into IVM in this group of patients is of particular 
value. Research in cattle has shown that oocytes arising from follicles in the early 
stages of atresia are as competent, or even more so, to initiate embryonic development 
than oocytes from actively growing follicles (Sirard and Blondin, 1996). Follicles in 
early atresia may contain competent oocytes, whereas oocytes from follicles at 
advanced stages of atresia may contain oocytes less competent to develop into viable 
embryos (Hendriksen et ai., 2000; Mikkelsen, 2001). The endocrine environment of 
follicles in patients with peo may contribute to premature oocyte maturation, 
however appropriate control of this situation in future, perhaps by gonadotrophic 
manipulation following a withdrawal bleed, may offer potential gains for IVM 
application in this group of patients. 
IVM is widely reported to result in embryos of reduced developmental competence 
relative to those undergoing oocyte maturation in vivo. The only true assessment of 
the success of IVM is live birth. This most stringent measure of developmental 
competence of embryos can rarely be applied in human IVM research, in which the 
transfer of embryos subjected to research procedures is potentially risky and is 
constrained by legal and ethical concerns. The transfer of in vitro matured and 
fertilized oocytes is not yet permitted in the UK and the HFEA required that a 
research study, in which embryos are not transferred to patients, must be conducted 
prior to any application for a clinical licence. Hence, it remains unclear whether the 
embryos resulting from in vitro maturation in this study might have had the potential 
for complete developmental competence if transferred to the uterus, however, their in 
vitro development did not progress beyond cleavage. 
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While FF-MAS was shown by my work to have positive effects on maturation in 
vitro, and possibly subsequent development, the normality of the resulting gametes 
had not been assessed directly. This presented some concerns since a large proportion 
(34-50%) of human oocytes are known to be abnormal (Martin et al., 1986; Wramsby 
et al., 1987) and no test for "normality" currently exists. Maturation comprises two 
major aspects, genetic (meiotic) maturation and cytoplasmic maturation (Fulka et al., 
1998). These two areas were tackled and the potential effects of FF-MAS explored in 
so far as was possible, however, the lack of fresh, good quality, in vivo matured 
oocytes as a control group causes difficulties in interpretation, most notably of genetic 
maturation where in vitro ageing of gametes is known to influence competence 
adversely. In Chapter 6, a preliminary study was undertaken to study the maturing 
oocytes' chromosomal constitution. This assessment used oocytes from patients 
undergoing ICSI only, this being the most readily available source of human oocytes 
and less likely to suffer from the unknown effects of the PCO endocrine environment, 
having been exposed to a controlled regime of gonadotrophic stimulation. Based upon 
the rather disappointing results, three analysable spreads from 15 oocytes; this line of 
investigation was discontinued in favour of studying spindle appearance and 
chromosome alignment using fluorescent markers for tubulin and chromatin. 
In 1999, Hegele-Hartung et al. observed the formation of a barrel shaped spindle and 
apparently normal chromosome alignment in FF-MAS treated mouse oocytes. In 
contrast, the findings of my preliminary study of spindle formation during IVM with 
exposure to FF-MAS demonstrated major abnormalities in the chromosome 
distribution upon the oocytes' spindles after IVM and abnormalities in spindle 
development. These may possibly be major contributors to the limited developmental 
potential of oocytes matured in vitro observed in this series and reported by others 
(Barnes et al., 1996; Trounson et al., 1996, Hu et al., 2001). However, the extent to 
which the abnormal spindle formation and chromosome alignment was a reflection of 
IVM or FF-MAS exposure is unclear, because control oocytes rarely matured in the 
absence of FF-MAS. The absence of gonadotrophins in vitro, the natural stimulus for 
meiotic maturation via the midcycle surge in vivo, may also have affected this 
analysis. 
213 
Aberrations in the cytoplasmic maturation of oocytes are more likely to be apparent as 
failure in later stages of development than in failure to reach metaphase II arrest. A 
non-invasive technique for assessing developmental competence is not currently 
available but would be a major advantage in human assisted conception and 
particularly in the application of IVM, where developmental competence is lower than 
for in vivo matured oocytes. In Chapter 7, a large database of images was analysed, 
enabling quantifiable morphological features to be related to the in vitro culture 
conditions employed and/or the subsequent development of the oocyte/embryo. The 
use of image analysis provided a non-invasive technique by which to compare and 
study maturing oocytes and this study, which is in preparation for publication, has laid 
the foundations for a non-invasive assessment of developmental competence during 
maturation in vitro. The presence of residual cumulus cells limited the feasibility of 
taking measurements from the whole image set, however, further refinements of the 
laboratory and imaging techniques could overcome some of these problems in future, 
if this procedure's usefulness in non-invasive assessment is proven clinically. 
Oocyte size is associated with maturation, fertilization and embryo development in 
most species examined and this may indicate that a certain absolute volume is 
necessary to initiate the molecular cascade of normal nuclear and cytoplasmic 
maturation (Trounson et a/., 2001). During preantral follicle growth the diameter of 
the human oocyte increases markedly from approximately 35}lm to 120}lm, 
equivalent to a 470-fold increase in volume, crossing the threshold for meiotic 
competence at about I09}lm diameter (Durinzi et a/., 1995). An increased ability to 
undergo GVBD with increasing mean oocyte diameter has been demonstrated in 
several species (Daniel et a/., 1989; Eppig and Schroeder, 1989; Hirao et al., 1994; 
Bao et al., 2000) although few data are available for humans. 
The findings of Chapter 7 provide data on the growth of human oocytes during IVM 
from two sources, unstimulated women with PCO and those undergoing ICSI 
treatment. Similar to the findings of Durinzi et al. (1995) a threshold of - I03}lm for 
maturation in vitro for oocytes obtained from patients with PCO was observed, 
however in contrast to data obtained by Durinzi et al. (1995), oocytes were observed 
to reach meiotic maturity in vitro with an oocyte diameter considerably less than 
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115~m. Furthennore, none of the oocytes from stimulated patients undergoing ICSI 
and having initial diameters of ~115~m matured in vitro. Measurements of oocyte 
diameter indicated that detectable oocyte growth continues in vitro, which is a new 
observation not previously reported, and maturation of oocytes on both the day of 
oocyte recovery and the day of insemination of mature oocytes was related to oocyte 
diameter. Oocyte diameter (within the oolemma) proved the most useful and reliable 
measure, superior to measurement of total oocyte + zona diameter, zona pellucida 
thickness and PVS, in tenns of its relationship with subsequent oocyte behaviour in 
vitro. A response to FF-MAS in tenns of oocyte growth was evident in immature 
oocytes from both sources of patients. Mature, immature and atretic oocytes from 
patients with PCO cultured in FF-MAS (10 or 3011g/ml) became significantly 
different in vitro in tenns of oocyte diameter. This was not true of oocytes cultured in 
control conditions, or those obtained from patients undergoing ICSI treatment. 
However, significant growth of oocytes obtained from patients undergoing ICSI was 
indicated by enlargement of oocyte diameter between the day of oocyte recovery and 
the day of insemination when oocytes were cultured in the presence ofFF-MAS. 
These data therefore suggest that FF-MAS may have a positive effect upon oocyte 
size during maturation culture, which may be related to its activity in promoting 
maturation and possibly developmental competence, as demonstrated in Chapter 5. 
This applied to oocytes without cumulus, or with a limited amount, which did not 
preclude visualization of the oolemma, and therefore raises questions about the 
control of oocyte growth, which is generally believed to be controlled substantially by 
cumulus-oocyte interaction. The mechanism of such an effect by FF-MAS is 
uncertain and its elucidation would require further experimentation. 
The work conducted has resulted in a number of original observations. The potential 
of FF-MAS as a natural stimulator of oocyte maturation has been confinned in 
humans, as anticipated from previous studies in mice, and the ongoing growth of 
human oocytes associated with further development during maturation culture has 
been presented and quantified for the first time. The potential of FF-MAS to affect the 
growth of oocytes directly, in both cumulus-enclosed and cumulus free conditions in 
vitro is also a novel finding. However, a number of outstanding questions have arisen 
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from this work, which could be addressed further in future studies. For example, the 
mechanism of action of FF-MAS remains uncertain and hence the molecular signals, 
which may influence the oocyte, require elucidation. FF-MAS appeared not to have 
any discernable effect, within my small cohort of oocytes, upon the structure or 
organization of chromosomes and spindles. However, the lack of normal material for 
comparison requires future study of freshly collected mature oocytes. It would also be 
interesting to test the effects of other factors promoting oocyte maturation, notably 
FSH, upon the non-invasive measure of oocyte diameter to assess whether diameter 
per se is a useful marker of developmental potential. 
Finally, this series of experiments has provided insights into the techniques and 
culture conditions necessary to achieve IVM and to promote developmental 
competence in human embryos. They form a foundation for a future clinical trial of 
IVM and have contributed to our advancing knowledge on the future prospects of this 
promising treatment. 
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Figure At Meiosis and follicular growth in the female 
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Appendix II 
Tables of media compositions 
Table Al Composition of EBSS lOx (Gibco) 
Component ~ 
Inor2anic salts: 
CaCh (anbyd.) 2.00 
KCI 4.00 
MgS04·7H2O 2.00 
NaCI 68.00 
NaH2P04·H20 1.40 
Other components: 
D-Glucose 10.00 
Phenol Red 0.10 
Table A2 Composition of PBS (Gibco) 
Component ~ 
Inorganic salts: 
CaCl·2H2O 0.132 
KC1 0.20 
KH2P04 0.20 
MgCh·6H2O 0.10 
NaCI 8.00 
Na2 HP04 1.15 
Table A3 Composition of Hams FlO (leN Biomedicals) 
Component mg/L 
Inor2anic salts: 
CaCh2H2O 44.00 
CUS04 0.0016 
FeS04·7H2O 0.834 
MgS04 74.60 
KCl 285.00 
KH2P04 83.00 
NaCI 7400.00 
Na2HP04 156.20 
ZnS04·7H2O 0.0288 
Other components: 
Dextrose 1100.00 
a2 
HEPES 4770.00 
Hypoxanthine 4.08 
Lipoic Acid 0.206 
Phenol Red Sodium Salt 1.240 
Sodium Pyruvate 110.00 
Thymidine 0.727 
Amino acids: 
L-Alanine 8.910 
L-Arginine·HCI 210.700 
L-Asparagine· H2O 15.010 
L-Aspartic Acid 13.310 
L-Cysteine HCI·H2O 35.130 
L-Glutamic Acid 14.710 
Glycine 7.510 
L-Histidine HCI·H2O 20.960 
L-Isoleucine 2.620 
L-Ieucine 13.120 
L-Lysine·HCI 29.300 
L-Methionine 4.480 
L-Phenylalanine 4.960 
L-Proline 11.510 
L-Serine 10.510 
L-Threonine 3.570 
L-Tryptophan 0.610 
L-Tyrosine 1.810 
L-Valine 3.510 
Vitamins: 
Biotin 0.024 
Choline Chloride 0.698 
D-Calcium Pantothenate 0.715 
Folic acid 1.320 
M yo-Inositol 0.541 
Nicotinamide 0.611 
P~doxine HCI 0.206 
Riboflavin 0.376 
Thiamine HCl 1.012 
Vitamin B12 1.360 
a3 
Table A4 Composition of M199 2x (Gibco) 
Component m2/L 
Inorganic salts: 
CaCh'2H2O 528.00 
Fe(N03)3 '9H2O lAO 
KCI 800.00 
MgS04'7H2O 400.00 
NaCI 13600.00 
NaHC03 2500.00 
NaH2P04'2H20 316.00 
Other components: 
Adenine Sulphate 20.00 
Adenosine-5-tril~hosl~hate 2.00 
Adenosine-5-phosphate 0.40 
Cholesterol 0.40 
2-Deoxy-D-ribose 1.00 
D-Glucose 2000.00 
Glutathione (reduced) 0.10 
Guanine 0.60 
Hypoxanthine 0.60 
Ribose 1.00 
Sodium Acetate'3H2O 166.00 
Thymine 0.60 
Tween 80 40.00 
Uracil 0.60 
Xanthine 0.60 
Amino acids: 
DL-Alanine 100.00 
L-Arginine'HCI 140.00 
DL-Aspartic Acid 120.00 
L-Cysteine HCI 0.22 
L-Cysteine 40.00 
DL-Glutamic Acid 267.32 
L-Glutamine 200.00 
Glycine 100.00 
L-Histidine HCI'H2O 43.76 
L-Hydroxyproline 20.00 
L-Isoleucine 80.00 
DL-Ieucine 240.00 
L-Lysine'HCI 140.00 
DL-Methionine 60.00 
DL-Phenylalanine 100.00 
L-Proline 80.00 
DL-Serine 100.00 
a4 
DL-Threonine 120.00 
L-Tryptophan 20.00 
L-Tyrosine 80.00 
DL-Valine 100.00 
Vitamins: 
Ascorbic acid 0.10 
D-Biotin 0.02 
Calciferol 0.20 
D-Calcium Pantothenate 0.02 
Choline Chloride 1.00 
Folic acid 0.02 
i-Inositol 0.10 
Menadione 0.02 
Nicotinic acid 0.05 
Nicotinamide 0.05 
Para-aminobenzoic acid 0.10 
Pyridoxal HCI 0.05 
Pyridoxine HC} 0.05 
Riboflavin 0.02 
Thiamine HC} 0.02 
Vitamin A (acetate) 0.20 
Table AS Composition of PI medium with gentamycin (Irvine Scientific) 
Component mM 
NaC} 101.6 
KCl 4.69 
MgS04 0.20 
CaCh-2H2O 2.04 
NaHC03 25.0 
Napyruvate 0.33 
Na Lactate 21.4 
Taurine 0.05 
Na Citrate 0.15mglL 
Phenol Red 0.005g!L 
Gentamicin IOJlglml 
as 
Table A6 Composition of Sl and S2 media (Scandinavian IVF Science) 
Sl Medium S2 Medium 
NaCI NaCI EDTA 
KCI KCI Alanine 
KH2P04 KH2P04 Aspara_gine 
MgS04 CaCI·2H2O Aspartic acid 
hSA MgS04 Glutamine 
NaHC03 NaHC03 GlYcine 
NaPyruvate NaP~vate Proline 
Na Lactate Na Lactate Serine 
CaCI·2H2O Taurine Calcium Pantothenate 
Glucose Glucose Choline Chloride 
EDTA Threonine Folic acid 
Alanine Estradiol i-Inositol 
Asparagine Progesterone Nicotinamide 
Aspartic acid Arginine Pyridoxine 
Glutamine Cystine Riboflavin 
Glycine Histidine Thiamine 
Proline Isoleucine Insulin 
Serine Lysine hSA 
Methionine 
a6 
Table A 7 Composition of Gardner's G1.2 and G2.2 sequential media 
(Scandinavian IVF Science) 
Component Gl.2 medium G2.2 medium 
NaCI (mM) 85.16 85.16 
KCI (mMl 5.5 5.5 
NaH2PO-t2H2O (mM) 0.5 0.5 
CaCh2H2O (mMl 1.8 1.8 
MgS04.7H2O (mM) 1.0 1.0 
NaHC03 JmM) 25.0 25.0 
Na lactate (60% syrup) (mM) 21.0 11.74 
(10.5 L-isomer) J5.87 L-isomcrl 
Napyruvate (mM) 0.32 0.10 
Glucose (mM) 0.50 3.15 
Glutamine (mMl 1.0 1.0 
Taurine (mM) 0.1 0.0 
Non-essential amino-acids All All 
Essential amino-acids None All 
Ethylenediaminetetraacetic acid (mM) 0.1 0 
BSA 
_(gill 2.0 2.0 
Penicillin (gil) 0.06 0.06 
Streptomycin (gil) 0.05 0.05 
Phenol red 
_(g/11 0.01 0.01 
Adapted from Barnes et al. (1995) 
a7 
Appendix III 
Figure A2 Representative images of oocytes demonstrating the 
variable extent of cumulus cover 
Figure A2 Representative images of oocytes demonstrating the variable extent 
of cumulus cover. Cumulu was graded subjectively from 0-3. 
a) Grade 0- Oocyte devoid of cumulus 
b) Grade 1- Partiall y covered zona 
c) Grade 2- Completely co ered zona 
d) Grade 3- ub tantial multilayered cumulus cover 
a 
Appendix IV 
Figure A3 Image of oocyte demonstrating the various parameters 
measured using the image analysis package 
Figure A3 Image of oocyte demonstrating the various parameters measured using 
the image analy i package. 
a. Mean diameter of oocyte- final measurement was calculated by measuring the mean 
length of diameter a far as the oolemma at two-degree intervals and passing through 
the object's centroid. 
b. Mean diameter of oocyte + zona- fInal measurement was calculated as for oocyte 
diameter, but extending the diameter measurement to the outer surface of the zona 
pellucida. 
c. Mean zona p Ilucida tbickne s- final measurement was calculated after measuring the 
zona pellucida tbicknes at 2~ intervals. 
d. Perivitelline pace (P S)- final measurement was generated by calculating the 
minimum and the maximum distance between the inner zona and the oolemma and 
calculating a mean PY from this. 
a9 
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The effects of meiosis activating sterol on in-vitro 
maturation and fertilization of human oocytes from 
stimulated and unstimulated ovaries* 
J.L.Cavillal .2, C.R.Kennedyl, M.Baltsen3, L.D.Klentzeris4, A.G.Byskov3 and 
G.M.Hartshornel,2,5 
ICentre for Reproductive Medicine. Walsgrave Hospital. Coventry CV2 2DX, 2Sir Quinton Hazell Molecular Medicine Research 
Centre, Department of Biological Sciences. University of Warwick. Coventry CV4 7 AL, UK, and 3Laboratory of Reproductive 
Biology, Rigshospitalet. Copenhagen. Denmark 
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The object of this study was to assess functional maturation in vitro by obtaining data on the fertilization and 
embryonic competence of human oocytes with or without exposure to meiosis activating sterol (MAS) during 
maturation in vitro. Immature oocytes were either collected from unstimulated patients with polycystic ovaries 
(PCO) during gynaecological surgery, or were donated by patients undergoing a cycle of intracytoplasmic sperm 
injection (lCSI) treatment including ovarian stimulation with gonadotrophins. PCO oocytes had variable cumulus 
cover, which was retained during culture while those from ICSI patients were cultured without cumulus. The study 
included 119 oocytes from PCO patients and 72 from ICSI patients. The oocytes were allowed to mature in vitro 
for up to 46 h in the presence or absence of MAS. Mature oocytes were inseminated by ICSI with fertile donor 
spermatozoa and embryo development was monitored in vitro. MAS (30 J.1.g!ml) significantly increased the survival 
of oocytes from PCO patients (P < 0.01) but did not significantly affect the proportion completing maturation 
in vitro. For the ICSI patients, >90% of oocytes survived in all culture groups, regardless of MAS addition, however 
MAS (10 or 30 J.1.g!ml) significantly increased the proportion of oocytes maturing in vitro (P < 0.05). The apparent 
tendency towards improved subsequent development in vitro will require larger numbers of oocytes for evaluation. 
Oocytes from ICSI patients matured more rapidly in vitro than those from PCO patients. Our results show positive 
effects of MAS on human oocytes, confirming previous data in mice. This work may have implications for the 
future clinical application of IVM. 
Key words: humanlICSlJin-vitro maturation/meiosis activating sterol/oocyte 
Introduction 
The final 36 h of human oocyte formation are critical for the 
nonnal functioning of the resulting gamete. During this time, 
oocytes resume meiosis from their prenatal arrest in diplotene 
and progress to metaphase II (MIl). They also undergo 'cyto-
plasmic maturation', a poorly defined process. in preparation 
for fertilization and early embryo development, which largely 
depends upon oocyte constituents until after embryonic genome 
activation. Prior readiness of the oocyte to progress through 
the final maturation phase and attain its full developmental 
*Presented in part at the British Fertility Society Conference. Sheffield, 
UK, 15-17 April 1998, and at the 15th meeting of the European 
Society of Human Reproduction and Embryology. Tours, France, 27-
30 June 1999. 
~ European Society of Human Reproduction and EmhrWJ/ogy 
potential relies upon an appropriate follicular environment and 
the type of follicle from which the oocyte originates is crucial 
for its subsequent function. It has been known for many years 
that immature human oocytes removed from large follicles 
will mature spontaneously (Edwards, 1965a,b); however, the 
developmental competence of in-vitro matured (lVM) human 
oocytes is low (Veeck et al., 1983; Barnes et al., 1996; Coskun 
et at., 1998), probably due to disruption of the normal 
follicular control mechanisms regulating this important stage 
of development. For this reason, in-vivo maturation has been 
preferred for oocyte preparation for IVF, despite the need for 
large doses of exogenous hormones, with their attendant risks 
and costs (Russell, 1999). This is in contrast to some animal 
species where IVM is commonly used to obtain viable oocytes 
for research or commercial purposes (Trounson et al., 1996). 
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Immature oocyte retrieval combined with IYM could offer 
an alternative to the current ovarian stimulation protocols used 
in lYE however. efficient maturation. fertilization and embryo 
development are needed before IYM can be applied routinely 
in the treatment of human infertility. Recently. several groups 
have reported improved viability of human IVM oocytes using 
various protocols including partiaL minimal or no exogenous 
hormonal stimulation (Wynn. 1.'1 a/., 1998; Chian et aI., 1999; 
Jaroudi I.'t a/ .. 1999). The content of the medium used for IVM 
may also affect the outcome. A key experiment in the I 990s, 
which re-awakened interest in human IVM, used human 
follicular fluid to supplement the culture medium (Cha et aI., 
19(1) but, with the growing preference for defined media, the 
roles of individual factors are now being assessed and the 
inclusion of biological fluids is declining. 
Various hormones included in the culture medium have been 
reported to promote oocyte maturation and subsequent embryo 
devclopment. c.g. epidermal growth factor (EGF; Gomez et al.. 
1993a,b; Goud et al.. 1998) or FSH (Barnes 1.'1 al., 1996; 
Durinzi 1.'1 al .. 1(97) with or without human chorionic gonado-
trophin (HCG; Jaroudi et al .. 1997; Liu et al., 1997). In 
addition, intracytoplasmic sperm injection (ICSI) of IYM 
oocytes has increascd the likelihood of normal fertilization 
(Barnes 1.'1 al., 1996; Cha and Chian, 1998). 
Meiosi~ activating sterols (MAS) have been purified from 
human follicular fluid (FF-MAS: 4,4-dimethyl-5a-cholesta-
8,14,24-trien-313-ol) and bull testicular tissue (T-MAS: 4,4-
dimethyl-5a-cholesta-8,24-dien-313-01) (8altsen and Byskov, 
1999). FF-MAS is present in human pre-ovulatory follicular 
fluid at concentrations of -1.3 J.l.molli. and is an intermediary 
occurring naturally in the biosynthetic pathway between lanos-
terol and cholesterol (Byskov 1.'1 al.. 1995). It activates meiotic 
resumption of both cumulus-enclosed and denuded mouse 
oocytes in vilro (8yskov et al .. 1995, 1999; Hegele-Hartung 
1.'1 (//., 1999). MAS is synthesized by cumulus cells of intact 
oocytc-cumulus-complexes in responsc to FSH stimulation 
(Byskov et a/ .. 1998) and the concentrations of MAS in pre-
ovulatory follicular fluid samples are correlated with the ability 
of the associated oocyte to fertilize and cleave (Byskov et at., 
19(8). A histological study of 81 human oocytes suggested 
that the completion of maturation ill vitro might be promoted 
by FF-MAS (Gno)ndahl et (/1 .• 2000). Our fows has been to 
assess functional maturation by obtaining data on the fertiliza-
tion and embryonic competence of human oocytes after FF-
MAS exposure during IYM. No data on this subject have been 
published previously. 
The prevalcnce of polycystic ovaries (PCO) in 'normal' 
adult women is -209c (Polson et (/1., 1988; Clayton et al., 
1992). PCO may be associated with infertility and such patients 
may be hyper-responsive to the gonadotrophin stimulation 
normally used for IYF. A classical polycystic ovary has several 
antral follicles up to -10 mm diameter around the periphery 
of the ovary. Although these follicles are not actively growing, 
they contain immature oocytes which may be capable of 
further development (Trounson et al., 1994; Chian et a/.. 
19(9). Women with PCO therefore represent a patient group 
most likely to benefit from IVM. 
There may he additional potential benefits from IYM, for 
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Table I. Clinical dctails of patients with polycystic ovaries (PCO) who 
donated immature oocytes 
Patients (II) 
Patient age (years)" 
Menstruation 
Regular (28-35 days) 
Oligomenorrhoeic 
Amenorrhoeic (2°) 
Data not recorded 
No of oocytes collecteda 
Live 
Atretic 
17 
28.1 :!: 3.9 (22-35) 
3 
10 
2 
2 
7.0 :!: 4.1 (1-19) 
4.9 :!: 3.7 W .. 14) 
"Values arc presented as mean :!: SO. with range in parentheses. 
Table II. Clinical details of patients undergoing intracytoplasmic sperm 
injection (lCSI) who donated immature oocytes 
Patients (II) 
Patient age (years)" 
No. of previous ICSI attempts" 
Total no. of oocytes collected" 
Fertilization rate ('if ) (2PN f 
Ongoing pregnancy rate ('it) 
Pregnancy losses 
No. of cleaving embryos frozen 
No. of 2PN frozen 
No. of immature oocytes donated to 
study 
"For one cycle. all embryos frozen. 
hOne sct of twins. 
'Biochemical pregnancy. 
28 
32.4 :!: 3.4 (27--40) 
0.8 :!: 0.9 (0-3) 
16.3 :!: 6.2 (5-27) 
71.5 
10/27"·b (37) 
I ( 
2.6 :!: 2.5 
1.5 :!: 1.7 
2.6 :!: 0.9 (1-6) 
"Data are mean:+: SO. with range in parentheses. 
<Oocytes with two pronUclei (2PN )/oocytes injected. 
example. allowing rapid oocyte collection in women with 
cancer who cannot spend time undergoing a normal IYF cycle 
before sterilizing chemotherapy. The potential of an embryo 
largely reflects the competence of the oocyte and it might 
become possible. in future. to select immature oocytes with 
the greatest potential before fertilization, avoiding some of the 
ethical dilemmas of embryo selection. 
Thesc factors. together with the developing knowledge on 
mechanisms controlling follicle and oocyte growth and early 
embryology suggest that the time is right for IVM to be 
applied with caution in patient treatment. We have performed 
this preclinical research study to assess the effects of meiosis 
activating sterol (FF-MAS), a naturally occurring stimulator 
of meiosis. upon the maturation and preimplantation develop-
ment of immature human oocytes from two different sources: 
(i) unstimulated patients with PCO and (ii) patients undergoing 
a fully stimulated cycle of lCSI treatment. 
Materials and methods 
Oocytes from two groups of patients were studied: ti) those with 
unstimulated PCO and (ii) those undergoing ICSI treatment, which 
included ovarian stimulation according to a standard 'long' down· 
regulation protocol. Information on the patient groups is presented in 
Tables I and II. This study was approved by Coventry Research 
Ethics Committee and licensed hv the Human Fertilisation and 
Embryology Authority. . 
Unstimulated PCO patients 
These patients were attending gynaecology or infenility clinics at the 
Walsgrave Hospital. Coventry. Patients having symptoms of PCO 
(Adams et al., 1986) and who were undergoing treatment. including 
laparoscopy, were invited to panicipate in the study. 
Inclusion criteria were: (i) PCO. diagnosed primarily by the 
ultrasound appearance of the ovaries. but additionally by a history of 
oligomenorrhoea or amenorrhoea. and blood hormone measurements; 
(ii) no drug therapy for infenility in the 4 months before surgery; 
and (iii) requiring diagnostic laparoscopy and/or laser drilling of the 
ovaries. Patients wishing to panicipate provided written consent. 
Laparoscopy was scheduled irrespective of the stage of the men-
strual cycle. 
Retrieval of immature oocWes 
Oocyte retrieval procedu;es were carried out in the afternoon in 
theatres on the same site but separate from the main embryology 
laboratory. A previously described technique (Trounson et al .. 1994) 
was followed using a purpose-designed 17 gauge needle (Cook IVF. 
Letchwonh, UK) and a laparoscopic approach. All visible follicles 
were punctured and aspirated using 80-100 mmHg suction. Measure-
ment of follicular diameter was not possible by direct laparoscopic 
inspection since the follicles were relatively small « 10 mm) and 
the stroma was dense. The fluid was collected into 10 ml sterile 
plastic tubes (Fahrenheit Laboratory Supplies. Milton Keynes. UK) 
containing 2 ml pre-warmed. heparinized (3 IV/ml; Leo Laboratories 
Ltd, Buckinghamshire. UK) Ham's FlO medium (ICN Pharmaceut-
icals Ltd, Thame, UK) buffered with 20 mmol/I HEPES and supple-
mented with 0.5% human serum albumin (HSA; Immuno Ltd. Dunton 
Green, UK). The aspirates were maintained at 37DC in a thermostatic 
hot-block (Grant. Cambridge. UK) and transponed to the embryology 
laboratory in a ponable incubator (Cell Trans 4016 Transport Incub-
ator; Labotech). The oocyte aspiration procedure took -40 min and 
the journey < 10 min. 
Follicular aspirates were placed into an Em-Con filter of 75 11m 
pore size (Immuno Systems. Spring Valley, WI. USA) which had 
been pre-rinsed with warmed heparinized Ham's FlO medium as 
above. The aspirates were flushed with 250 ml of the same medium 
to remove contaminating blood cells and the filter retentate was 
transferred to sterile dishes (Falcon. Fahrenheit>. 
Oocyte-cumulus masses and free oocytes were identified using a 
dissecting microscope (Leica Microsystems. Milton Keynes, UK). 
equipped with a heated stage. and transferred to tissue culture dishes 
(Nunclon; Gibeo. Life Technologies. Paisley. UK) containing 2 ml 
IVM medium. IVM medium comprised Medium 199 (Gibco) supple-
mented with 0.23 mmol/I sodium pyruvate (Sigma. Poole. UK). 50 
IVlml penicillin G and 50 I1g/ml streptomycin (Gibco). The IVM 
medium was prepared on the morning of oocyte retrieval and dishes 
of medium were pre-equilibrated in a humidified incubator at 37"C. 
containing 5% CO2 in air. The preparation of MAS-containing IVM 
medium is explained below. 
The level of cumulus cover surrounding the oocyte was graded 
subjectively from 0-3, where 0 = devoid of cumulus; I = panially 
covered zona; 2 = completely covered zona: and 3 = substantial 
multi-layered cumulus cover. Individual viable oocytes were randomly 
allocated to one of three concentrations of MAS using tables of 
random numbers. 
An oocyte was considered to be viable if it had an intact oolemma. 
a light coloured cytoplasm and a regular-appearing spherical shape. 
In previous experiments using the fluorescent vital stains. carboxy-
fluorescein diacetate (CFDA) and pmpidium iodide (PI). these features 
had been confirmed as identifying viable oocytes. Where possible. it 
was recorded whether a germinal vesicle (GY) was present in the 
EtTects of MAS on IVM and fertilization 
ooplasm. and any other features of oocyte morphology. Oocytes 
obscured by tightly surrounding cumulus cells (cumulus enclosed: 
CE) were presumed to contain a GY. The initial assessment of 
maturity was performed -2 h after oocyte retrieval. 
Images of oocytes were collected daily via a video link on an 
invened high power microscope (Olympus IX 70) employing Hoffman 
optics and Image Pro-plus software. Oocytes which were clearly 
atretic on collection, e.g. dark cytoplasm and irregular shape. were 
noted before discarding. 
ICSI patients 
Immature oocytes were donated by women undergoing rcsr at the 
Centre for Reproductive Medicine. Walsgrave Hospital. Women 
wishing to participate gave written consent prior to the oocyte 
retrieval. Patient preparation. oocyte retrieval and embryological 
procedures were performed using the centre's standard proto;.:ols 
(Garello et aI., 1999). Any immature oocytes identified when oocytes 
were stripped of cumulus in preparation for ICSI were randomly 
allocated to MAS treatment groups using random number tables: 
thereafter. they were treated identically to oocytes from PCO patients. 
Oocytes were considered immature if they contained a GY or had 
undergone germinal vesicle breakdown (GYBD) but had not released ' 
a polar body. 
Meiosis actil'atinK sterol (FF-MASJ 
FF-MAS was purified from human follicular fluid as described 
(Byskov et al., 1995; Baltsen and Byskov, 19(9). MAS was stored ' 
at _20DC in n-heptane under N2 in glass vials. Before use. a stream 
of nitrogen gas was used to evaporate the heptane from a known 
quantity of MAS which was dissolved in a known small volume of 
absolute ethanol (EtOH) and added to the preparcd rYM media in 
glass tubes to final concentrations of 10 and 30 ~g/ml (24.4 and 
73.2 11M). EtOH alone, treated in the same manner, was added to 
controls. All wells contained a final concentration of 0.5% EtOH. 
MASlEtOH was added to the cultures -I h before oocyte retrieval. 
Volumes of 100 ~I IVM medium containing the various concentra-
tions of MAS were set up in a sterile 96-well plate (Nunclon) which 
also contained medium in the surrounding wells to increase humidity 
and reduce evaporation. Cultures were housed in a humidified 
incubator (37°C, 5% CO2 in air). An oil overlay was not used. 
thus avoiding oil phase extraction of MAS. Control experiments 
demonstrated that the osmolarity of cultures maintained under these 
conditions varied by < I % after 24 h. 
Up to four oocytes were co-incubated in each well. The oocytes 
were examined after 23-24 h and their maturational stage recorded. 
Oocytes which had extruded a polar body were considered mature 
and removed for ICSI. 40-48 h after initiation of culture, any 
remaining cumulus cells were removed by pipetting and all oocytes 
were assessed microscopically. Mature oocytes were injected with 
known fenile donor spermatozoa according to the Centre's established 
ICSI protocol (Garello et al., 1999). Frozen stored spermatozoa from 
two fenile donors were used for the entire study. 
After injection. oocytes were transferred individually to S I or G I 
medium (Scandinavian IVF Science, Sweden) in I 00 ~I drops under 
oil (Ovoil: Scandinavian IYF Science). Dishes were pre-equilibrated 
at 37°C in an atmosphere of 5% CO2 in air for I day before use. The 
oocytes were checked for fertilization 14-18 h post-injection using 
standard procedures of pronuclear assessment. Zygotes and cleaving 
embryos were observed and moved to fresh drops daily. Computerized 
photographic images were collected each day until the embryo 
arrested or degenerated. 
Statistical analyses 
The proportions of oocytes in groups exposed to different concentra-
tions of MAS were compared using p x q xl test (Campbell. 1989). 
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Figure 1. In-vitro maturation of immature oocytes (/I = 119) 
collected from patients (/I = 17) with polycystic ovarie and 
cultured with or without meiosis acti vating sterol (MAS). Bars wi th 
different letter are signifi cantly di fferent (P < 0.0 I). 
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Figure 2. In-vitro matura tion (IYM) of immature oocyte (n = 72) 
donated by patient · undergoing intracytoplasmic perm injection 
(ICS I) (n = 28) and cultured with or without meiosis acti vating 
terol (MAS). Bars with different letters are significantly di fferent 
(P < 0.05). 
Scatter plots were as essed for correlation usi ng regression analysis. 
P < 0.05 was considered to be stati stically igni ficanl. Student 's 
I-te t was used to compare the numbers of viable oocytes in the two 
patient group . 
Results 
A total of 11 9 viable immature oocytes were coll ected from 
17 PCO patients with unstimulated ovarie and 72 immature 
oocytes were donated by 28 ICSI patients. C linical detai ls of 
the pati ent groups are presented in Tables I and ll . 
Figure l how the result of MAS expo ure of oocyte 
obtained from PCO pati ents. MAS at a concentrati on of 
30 flg/ml significantl y increased oocyte survival (P < 0.0 I, 
P X q X2 test, Campbell , J 989); 90% survival in 30 Ilg/ml 
compared with 62 and 63% fo r 10 flg/ml and contro l respect-
ively. The increased surviva l of oocytes in 30 Ilg/ml MAS 
550 
Table Uf. Fenili,Galion rates (no. of two pronuclear oocylcs/oocyte 
surviv ing ICSI) for in-vitro matu red oocyles arising from polycystic ovaries 
(P 0) or intracytoplasmic sperm injecli n (lCSI) patients. Values in 
parentheses are percentages 
PCO 
ICSI 
Meiosis activati ng sterol (~glml) 
o 
4110 (40) 
2/5 (40) 
10 
219 (22) 
611 I (55) 
30 
711 I (64) 
611 0 (60) 
Table IV. Cleavage rates (no. of cleaving embryos/two pronuclear oocyte) 
for in-vitro matured oocytes arising from polycystic ovaries (peO) or 
intracytopla mic sperm injection (lCSI) patients 
Meio is activati ng sterol (~glml ) 
0 10 30 
PCO 214 212 5n 
I SI 0/2 3/6 5/6 
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Figure 3. Matu ri ty at collection of oocytes recovered from 
polycystic ovarie (PCO) and intracy10plasmic sperm injection 
(JCSI) patient . GY = germinal ve icle; GYBD = germinal ve icle 
breakdown; CE = cumulu enclo ed (GY a umed, but not visible). 
"Signi fican tly different (P < 0.0 1). 
was not associated with an alteration in the proportion of 
surviving oocyte which matured, which remained at -45 %. 
Figure 2 show the res ul t of MAS expo ure of immature 
oocytes from ICSI patient. Oocyte urvi val wa > 90% in all 
groups. regard le of MAS concentration. However, in thi 
patient group, the presence of MAS at 10 or 30 flg/ml 
signi ficantl y increased the proportion of oocytes maturing 
(P < 0.05). 
The proport ion of maturing oocytes fertilized by ICSI and 
ubsequentl y cleaving in e ither PCO or rCSI groups are 
pre ented in Tables III and IV, but the apparent difference 
were not tested stati tic ally in view of the low nu mbers of 
oocyte reaching thj stage. 
Figure 3 how that signi fica ntl y more immature oocyte 
per patient were obta ined fro m PCO patjent in com pari on 
% Mil 
60 -r-----------, 
40 
20 
o 
n 23 15 24 16 
o 10 
MAS J1g1ml 
29 12 
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IOGV I 
DOYB 
Figure 4. Maturation of germinal ve icle (GY) and germinal 
vesicle breakdown (GVBD) oocyte from patient wi th polycystic 
ovaries (PeO) in the presence or ab ence of meio i activating 
sterol (MAS). n = number of oocytes in each group. 
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Figure 5. Maturation of germinal ve icle CGV) and germinal 
vesicle breakdown CGVBD) oocytes from patients undergoing 
intracytoplasmic sperm injection (ICS l) in the presence or absence 
of meiosis activating sterol (MAS). Il = nu mber of oocytes in each 
group. 
with res I patients (P < 0.01 ), but surprisingly, there was no 
significant difference in the proportion of oocytes that had 
undergone GYBO between the peo and re SI patient groups. 
Figures 4 and 5 show the maturation in vitro to Mil of 
Oocytes collected at the GY and GYBO tages for both patient 
groups. In pe o patients (Figure 4), the proportion of oocytes 
in both categories reaching Mil was highly variable. Cultured 
immature oocytes from Ie SI patients had a low maturati on 
rate (either GY or GYBO at collection) but this wa improved 
by addition of MAS, a hown in Figure 5. For the oocytes 
that failed to mature in the Ie Sr group, approx imately equal 
numbers arrested at or after the OY stage. 
Figure 6 hows the rates o f alre ia occurring in vitro after 
collection of apparentl y viable oocytes. E pecial ly high levels 
of atresia were noted in GYBO oocyte fro m peo patients. 
Overal l the peo oocyte appeared more u ceptible than le SI 
E ffects of M AS 011 I VM IIlId fcrtiliza tiun 
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.... l;V ~ 1..0 40 .... 
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Figure 6. Proportions of germinal vesicle CGV) and germinal 
vesicle breakdown (GVBD) oocytes becoming atre ti c ill villv arter 
collection fro m polycys tic ovaries (peO) or intracytoplasmic sperm 
injection (lCSI) patients. 
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Figure 7. Cumulati ve time course of maturation in vitro for oocytes 
fro m polycystic ovaries (PCO) and intracytoplasmic sperm injection 
(lCSI) patients. 
oocytes. In the leSI group. atresia was confined to oocytes 
collected at the GY stage. 
The time course of oocyte maturation was di fferent in the 
peo and reSI groups. Of those oocytes maturing to M il 
in vitro, 50% in the ]eSI group had reached Mil by 23- 24 h 
compared wi th < 5% for peo patients (Figure 7). The majori ty 
(89%) of PCO oocyte that matured to Mil, did so on the 
second day of IVM culture. 
There was no significant relati onship between the num bers 
of viable or atretic oocytes collected and pat ient age in pe o 
patients (r = 0.141 and 0.268 respecti vely), as shown in Figure 
8. Similarly, there was no relati onship between the numbe r of 
viable oocytes and the number of days s ince the las t me nstrual 
period (r = 0.040) or patient weight (r = 0 .264) in the P 0 
patients (data not shown). 
Discussion 
Our results demonstrate, for [he first time, the s ignificant 
effects of MAS on in-v itro surviva l and maturation of human 
oocytes . immature oocytes co llected fro m two different patient 
groups, unstimulated pe o patients and stimulated IeSJ 
patients, have been shown to di ffer in terms of oocyte function 
in vitro, inc luding the proporti ons maturing and the speed of 
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Figure 8. Scatterplot of the number of \iah!.: lal and atretic (hi 
(lOC·~ te, retrie\cd \\ ith age of p()l~ c~ -tl( mane' (peo I patieTlt. '\0 
,igniticant corrdalion, "ere rn.~,ent lal,. = O.141.lhl r = O.2hX. 
maturation ill I·itm. These differences may reflect patient~ 
related differences in the origin of the om:ytes. including the 
stage of follicle deYelopment at oocyte retrieval. the endocrine 
~tatu, or atresia of the follicles and the presence or absence 
of ,upporting cumulu~ celk The,e result-. will oe important 
for the future application of IVM a, a potential treatment in 
various clinical situations. 
MAS significantly (p < 0.0 I) improved the ,uni\ al of 
immature oocyte, collected from unstimulated women \\ ith 
PCO. Thi, i, in contrast with the re,ult" ootained culturing 
immature oocyte, from -timulated ICSI patlenh in whom FF~ 
MAS did not affect oocyte ,uni\al (which was >90'·; in 
this patient group). but maturation ill I·itm was significantl~ 
increased (p / (LOS). The \ ariations in emoryo de\elopment 
in both patient groups \\ ith ;\lAS supplementation of IV \1 
media are abo intere,ting. particularly in \iew of the c()mpro!1l~ 
ised de\elopmental competence which is widel~ helined to 
be associated with immature oocytes collected from PCO 
patient-.. although stati,tical analy,is was precluded o~ the 
limited nurnoers of oocyte, reaching the later stagc, III our 
study. 
There are some difficulties of working with ,teroids ill \·ilr(l. 
We amidl.'d the use of oil. which would extract the sterOidal 
\lAS. out we ~'annot exclude the pm,ibility of it adhering to 
the plaqic culture \essel or oeing affected o} aloumin or other 
con,t1tucnls in the culture medium. Similarly. the methllli of 
dissol\ing steroids in EtOH is widely used. hut recent endence 
• 
has shown that e\en concentrations < If:( EtOH can adversely 
affcct bovine IV\1 and subsequent embryo development (Avery 
and Grew. 2(X)O). Bovine oocyte~ contain more lipidic yolk-
like granules than human oocyte~: however. it is possible that 
some of the limited development observed in our study may 
relate to our use of EtOH in the cultures. This would not. 
howewr. affect the validity of the results observed. since 
EtOH was included at a ,imilar concentration in all cultures. 
\1:\5 is produced in cumulus cell, (Leonardsen el al .. 2(00) . 
Its effects are likely to he mediated \ia mechanisms employed 
hy other follicular "teroids. perhaps in a manner similar to 
progesterone ,timulation of meiosis in Xel/opus oocytes 
iByskm 1'1 (/1.. 199K). \lAS re~'eptors have not yet been 
identified: however. \lAS is known to ha\c direct actions 
upon ll1ou,e IJlll:ytes and doe~ not depend upon mediation by 
cumulus cells (Bysko\ ('I til .. 19l}S). unlike. e.g. gonadotro-
phins. The steroid em ironment of follicles in PCO is disturbed 
(e .g. Almahoobi and Trounson. 199(,: Pierro el (/1 .• 1997), and 
so the influence of MAS in this en\irnnment might differ from 
other CirL'lllllstances. 
Immature oocytes retrieved from unstimulated PCO patients 
may or may not have cumulus cells cmering them. The 
presence or ahsence (If cumulus ~'ells provides ,orne indication 
of the follicle from which the oocyte originated. denuded 
oocytes hcing 1l10re likely to ha\ e arisen from atretic follicles. 
The known r(lles of cumulus cells !I1clude supporting oocyte 
grow th and maintaining meiotic arrest throughout all immature 
,tages of OOC) te de\ e1opment. They are steroidogenically 
acti\e and also pnllluce hyalurolllc acid during cumulus 
expansIOn to facilitate the appro~Il'h of <,permatozoa to the 
lona pdlu~'id~1 at fcrtili/atioll. Ooc~ tes surrounded by cumulus 
cells IT1<I) therefore oe at <tn ad\ anlage during IVM culture. 
\lost ellclmed lHlcyte, had ~'ompaL'l corona cell, and contained 
a (,V. and man) of thme without had progres<,ed to GVBD. 
prooaoly as a result of incipient atre'la in the follicle (Gougeon 
and Te'>tart. I t)X(,: :\nderson 1'1 (II.. 19(7). Surprisingly, similar 
prop(lrtion, of oocyte, from PCO alld ICSI patents had a GV 
or had undergone GYRD: hml e\ er. these olll:ytes differed 
suhstalltially in their predispositions toward, atresia and their 
aoilit~ to mature to \111. The rell1o\al of l'llll1ulu,> cells from 
immature l IO~·) tes ~'olleL'lcd !rom ICSI c~ des might have 
affected some aspec'[" of theIr dn elopment. 
The mean nUllloer of \ laole ()( Il:) IL" collected from peo 
patlenl'> \"IS 7.(). whidl was Ill\\er than the means of 13.8 and 
13.1 ohtained from anm ulatory and o\ulatory PCO patients 
re'peL'ti\·ely (Trounson t"I (II .. I t)lJ~ I. hut nlillparable with the 
average of X.I per patiellt reported III a later ,tudy (Coskun 
t'l lIl.. 19YX J. We tlld not lind an~ 'peciti~· ~'haracteristics of 
the PCO patlen\'-. \\ hil'h were predil'll\e of the numbers of 
ooc;.tes rctncled: 'pc:'cllil,;t1ly. patIent age. time since last 
men,truitl penod. <lnd \\ eIght ,h'l\\ nl nl> significant correla-
tions. The nUfllhl'r oj o()C~ tes col1l'cted w llllld he expected to 
reduce as the ll\ <lflall resen e del'illle, with ad,·ancing age 
( C'ha {'/ lIl .. IlJ9 I : Cha and C'h l;lIl. Illt)X: Whitacre t'l (// .. 1998); 
hll\\c\er. thl' \Ia' lIot our l'\Pc:'flC'fKt' In thi, stlld~. One group 
(Barne, ('I (//.. ll)lJh I h<l' prt'\I111hl;. reported the retrieval of 
a larger Ilurnhn 'It 'l( Il·\ tt" tfllm IITc:'gUiarly cycling and 
anll\ ul,ltllry patIent... compared to repllarl;. cycling women 
(16.5 and 4.9 respectively) which relates to the relative ease 
of aspiration from the peripherally located antral follicles in 
PCO. Extremes of weight are known to affect fertility; in 
obese women with PCOS. fertility may be enhanced by a loss 
of weight. In this study. which included a range of obese and 
non-obese women, we observed no association between weight 
and oocyte yield. 
Several studies have shown that oocytes aspirated after 
ovarian stimulation may be in various stages of maturation 
(Veeck et aI., 1983; De Vos et al., 1999). Oocytes that remain 
immature have failed to respond to ovarian stimulation in vim 
and may be of inherently reduced quality. they may have come 
from small follicles with reduced gonadotrophin sensitivity or 
may never have reached meiotic competence. Alternatively, 
they may have arisen from otherwise normal follicles which 
did not receive the same hormonal stimulus as others. perhaps 
due to their relative position in the ovary or limited blood 
supply. Moreover, the artificial conditions of gonadotrophin 
stimulation may have affected some aspects of their metabolism 
or development (Johnson et al.. 1991). Nevertheless, it has 
been reported that these oocytes are capable of maturing 
in vitro, fertilizing and developing normally (Cha and Chian, 
1998). Our results demonstrate their responsiveness to stimula-
tion with MAS, despite the absence of cumulus cells and their 
prior exposure to ovarian stimulation. 
The importance of the endocrine environment in ensuring 
normal cytoplasmic maturation and subsequent fertilization is 
well known from work in animals (Moor and Trounson. 1977; 
Anderiesz and Trounson, 1995). The differing results obtained 
in this study in patients with differing endocrine profiles 
underline the potential for IVM success rates to be affected 
by the ooeytes' prior exposure to physiological or pathological 
hormonal environments. In \'itro. 28-30 h is required for the 
maturation of human oocytes to MI and 36-37 h to MIl 
(Edwards, 1965a.b). After HCG injection to simulate a LH 
surge, the results are similar, the majority of the oocytes having 
extruded the first polar body by 36 h after HCG injection 
(Janssenswillen et al., 1995). One group (Jamieson et al., 
1991) reported significantly lower IVF and cleavage rates 
in oocytes retrieved <36 h after the luteinizing stimulus. 
demonstrating the importance of appropriate timing of insem-
ination. Previous studies have shown that immature oocytes 
obtained from stimulated cycles are more likely to undergo 
maturation than unstimulated oocytes and that the time required 
for their maturation is reduced (Gomez et al., 1993a; Cha and 
Chi an. 1998). Our results concur with these prior observations. 
IVM can result in pregnancy (Cha et al.. 1991; Trounson 
et al., 1994; Barnes et al .. 1995; Russell. 1998: Jaroudi et al .. 
1999) but rates remain lower than those of in-vivo stimulated 
cycles. indicating that optimization of IVM remains a challenge 
(Goud et al .. 1998). The primary problem in oocytes matured 
in vitro is reduced developmental competence. particularly 
cleavage and development beyond the 4-cell stage (Trounson 
et al., 1994). This was apparent in our study: the most advanced 
embryo observed reached 6 cells with most embryos arresting 
around the second cleavage division (3-4 cells). However. it 
appears that if the initiation of maturation is triggered ill vivo, 
then developmental potential increases (Chian et al., 1999) 
Effects of MAS on IVM and ferlilizaliOl 
although the value of priming with low-dose FSH remain~ 
unclear (Wynn et al., 1998; Mikkelsen et al., 1999). Other~ 
have shown the relative effects of follicular versus luteal phas( 
retrieval of oocytes (Cha and Chian, 1998; Whitacre et al. 
1998), underlining the importance of the endocrine environ· 
ment. In our study, PCO patients were not given any form o' 
hormonal manipulation prior to oocyte retrieval; however, i 
is likely that induction of a withdrawal bleed with or withou 
late follicular administration of HCG (Buckett et al .. 1999 
Chian et al .• 1999) may improve the maturation rates achieve( 
in the present study. These methods still have the benefit 0 
avoiding the major element of the drugs normally administere( 
for ovarian stimulation. 
Evidence is accumulating that MAS is an important endogen· 
ous factor involved in promoting oocyte maturation. The dat, 
presented here show positive effects of MAS upon surviva 
and maturation of human immature oocytes collected frorr 
unstimulated PCO patients and stimulated ICSI patient1 
respectively. The limitations of a morphological assessment 0 
viability are acknowledged, but the choice of criteria ww 
supported by earlier experiments using vital stains. Clearly 
the use of an invasive method in this study would havt 
precluded the collection of data on further development. Thi~ 
is an important area since it is not yet known whether embryo: 
resulting from IVM in the presence of MAS have the potentia 
to develop further or implant. ]n mouse cumulus cells. a heat 
stable meiosis activating substance is stimulated by FSl-
(Byskov et al .. 1997; Y ding Andersen et al., 1999) and artificia 
elevation of MAS in cumulus cells using inhibitors of specifi( 
enzymes on the steroid synthesis pathway promotes maturatiOl 
of mouse oocytes ill I'itro (Leonardsen et al.. 2000). MAS wa: 
shown to improve immature oocyte function in mice b~ 
supporting microtubule assembly and delaying the release 0 
cortical granules (Hegele-Hartung et al .. 1999). 
Results were recently presented (Gr0ndahl et (/1., 1999 
2000) of IVM of 81 human oocytes allocated into sever 
groups, with or without MAS. for histological analysis. Thesl 
data showed a significant (P < 0.05) increase in the proportior 
of immature oocytes completing maturation after 30 h ill vitrc 
in the presence of 20 Ilmolll MAS; however. at 22 and 40 h 
the difference was not significant. Gr0ndahl's study differe< 
from ours in several respects. His patient group had polycystil 
ovaries, but received oral contraception for 2 months, to whicl 
was added a gonadotrophin-releasing hormone (GnRH) agonis 
for pituitary down-regulation. followed by recombinant FSl-
for 3 days. Follicles of 8-12 mm were aspirated on days 7-1 
and all oocytes were cumulus-enclosed throughout culture 
These patients therefore underwent stimulation cycles. Also 
half their aspirated oocytes were used for infertility treatment 
although HCG was not administered. The medium used b~ 
Gr0ndahl et al. for the research oocytes was similar 1< 
ours, being M 199 supplemented with 0.29 mmolll pyruvate 
antibiotics and 0.8% HSA. with or without MAS whicl 
was prepared in EtOH. None of their research oocytes wa: 
inseminated. 
In this study. we have demonstrated oocyte maturation witl 
developmental competence as far as the second cleavagl 
division. The effects of MAS on embryo development coult 
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not be analysed statistically in view of the low numbers of 
embryos generated. The lower maturation rate observed in the 
oocytes originating from unstimulated PCO was probably due 
to compromised follicle development as a result of the abnormal 
endocrine environment. which could also account for the 
higher rate of atresia observed in the GYBD oocytes, compared 
with the ICSI patient group. In PCO patients. GVBD oocytes 
were probably retrieved from partially atretic follicles. where 
granulosa cells have dissociated from the oocyte and factors 
controlling meiotic arrest have been lost. Oocytes in atretic 
follicles may often he found to have progressed further than 
meiotic prophase I (Anderson e1 al., 1997). 
In our study, the effects of MAS alone have been studied, 
although addition of FSH to the medium might augment MAS 
production in the cumulus (Byskov e1 al., 1997) and the 
inclusion of FSH, HCG and/or growth factors in vitro has 
already been demonstrated to stimulate IYM by others (Durinzi 
et aI., 1(97). We chose to omit these other factors so that the 
effects of MAS alone could be established in the absence of 
confounding influences. We felt that this was important, even 
though a higher overall maturation rate might be gained by a 
combination of supplements in the medium. 
In conclusion, oocytes derived from stimulated ICSI patients 
and unstimulated PCO patients constitute different populations, 
probably due to their differing endocrine and intrafollicular 
environments. MAS exerts positive effects upon different 
aspects of oocyte function in both groups. In view of its 
role as an intrafollicular steroid, and its ability to promote 
maturation, its potential for further development as an in-vitro 
meiotic stimulant should be evaluated. 
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